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Abstract 
The global cost of health care is increasing year after year, and one of the ways governments and 
health care providers are looking to reduce cost is by reducing the cost of drug products. The 
generic industry is under tremendous pressure to remain competitive in the market place by 
reducing the cost of their product, with the main cost factor being the active pharmaceutical 
ingredient and some of the excipients used in the manufacture of the drug product. These 
companies are expected to follow the required guidelines set out by the international regulatory 
authorities and more specifically of the countries they intent to market their product in if they are 
planning to change the source of the material. These regulatory guidelines are general in nature 
with a focus on safety and efficacy and the evaluation of an alternate source of material by 
pharmaceutical companies varies greatly from company to company. The evaluation is 
conducted mainly on the basis of chemical and physical data from the Certificate of Analysis 
comparing the current and alternate source to determine equivalency. Differences in process and 
critical processing parameters of the material can have significant impact on the behavior of the 
chemical, which may not be detectable through evaluation of the Certificates of Analysis. It is, 
therefore, critical to study properties that are not captured on the Certificate of Analysis, such as 
polymorphism, melting point, solubility, particle shape, packing tendencies among other aspects 
of the material that are important for the performance of the material in the drug product 
formulation and manufacturing process. The differences in these properties can have significant 
impact on the unit operations during the manufacturing process as well as the critical quality 
attributes and the stability of the drug product. The evaluation is conducted by utilizing various 
tools of analytical and process testing to determine the physical performance, physicochemical 
evaluation, chemical evaluation and functional performance evaluation for the active 
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pharmaceutical ingredient and excipient. The evaluation of the Certificate of Analysis will also 
need to be more in depth, and go beyond the alternate source meeting the specifications as there 
can be significant differences with the results obtained even though they meet specification. It is 
important to identify these differences earlier in the evaluation stage and to assess the impact, if 
any, on the manufacturing process and the drug product prior to introducing the change.  
This study was conducted with active pharmaceutical ingredients selected based on the 
processing unit operations, such as direct compression process (metformin HCl), dry compaction 
(gabapentin), and hot-melt process (fenofibrate). The selection of the excipients was based on 
their functional properties, such as binders (copovidone NF/EP) and super disintegrant 
(croscarmellose Sodium NF/EP), allowing for evaluation with respect to differences in 
functionality if any, from the different sources. Additionally, the copovidone NF/EP is the binder 
in the gabapentin USP tablet formulation while the croscarmellose Sodium NF/EP is the super 
disintegrant in the fenofibrate EP/BP tablet formulation.  
An example of this challenge is that the evaluation of Certificate of Analysis for the 
materials supplied from two companies and two sources revealed differences in tests required for 
the two materials and a significant difference in some of the results obtained; however, both 
materials met their respective Certificate of Analysis specifications. Several tests beyond the 
Certificate of Analysis were performed and significant differences were also observed in many 
of these as well.  The two sources were evaluated with respect to the compression process and 
the alternate source of material did show significant challenges during the tablet compression 
process and did not meet some of the in-process critical quality attributes test.  The in-vitro 
performance for both sources were comparable, however, the recommendation will be not to 
proceed with the alternate source. There were many differences between the sources of all the 
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materials evaluated including differences in particle size, morphology, moisture, manufacturing 
process and residual solvents among others. The impact on the manufacturing unit operation 
varies from no impact for the fenofibrate EP/BP materials, to not meeting the critical quality 
attributes for metformin HCl tablets with the new source of the active pharmaceutical 
ingredients. 
This study indicates the importance of a systematic evaluation of a material from an 
alternate source with respect to the performance of the manufacturing process, drug product, and 
their critical quality attributes; understanding the impact of these changes to the material and 
having the ability to correlate these to potential issues with the manufacturing process and drug 
product critical quality attributes prior to introducing an alternate source of material is critical. 
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    Chapter – 1: Introduction 
1.1 - Market Overview  
The global pharmaceutical industry is worth close to $1 trillion dollars today, with the 
generic industry representing approximately one third, or $350 billion. Over the next five years 
the industry is expected to grow by an additional $200 - $250 billion with most of the growth 
coming from the generic industry. In addition the value of the drug products with their patent 
expiring over the next several years is over $100 billion
1
. This, combined with the double digit 
growth in the industry itself, presents significant opportunity for the generic industry over the 
next several years. There are other major drivers for the generics industry, these include the 
efforts of government and health care providers around the globe to substitute brand product with 
generic product, continued price pressures, too few products expiring for too many generic 
companies, and emerging possibilities for bio-generics
2
.  
There is significant pressure from governments and health care providers globally to try 
to reduce the mounting cost of health care by reducing the cost of generic drugs in addition to 
generic substitution of the branded product. The Ontario government went as far as to introduce 
a law to cap the price government will pay for a generic equivalent of a drug at 50% of the brand 
price if there are two competitors on the market. As one of the largest customers of the generic 
industry in Canada, this puts significant pressure on the industry to be cost competitive. In many 
drugs the Active Pharmaceutical Ingredients (API) is the largest contributor to the cost per 
dosage, representing between 50 – 90 % of that cost. It is therefore no surprise that one of the 
main drivers to reducing the cost per dosage is to find less costly sources of the API. Different 
companies take different approaches, or a combination of approaches, to achieve a reduction in 
the cost of the API. Many of the larger pharmaceutical companies such as Teva, Mylan, and 
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Sandoz are vertically integrated and therefore have the ability to control their cost internally. A 
vertically integrated company is one that has developed the capability to manufacture most of its 
API required for drug product manufacturing internally. Some companies look to their sources of 
the API to reduce the cost, while others look at a combination of the two approaches. Regardless 
of the approach used, one element that is common in all cases is the need to reduce the cost of 
the API over the life cycle of the product. There are significant advantages for a generic 
company to be the first on the market at patent expiry, and companies are usually aggressively 
pursuing the development and approval of their products such that they can be the first to market. 
This also means that they will likely develop the drug product using a single source of API and 
will pay for the opportunity to be the first to market. However, it typically takes less than a year 
for a product to have 80% market penetration and to reach marginal cost after patent expiry
3 
due 
to generic competition. The need for cheaper API means that companies, regardless of if they are 
vertically integrated or not, look to their process to eliminate waste and to reduce cost as much as 
possible soon after they launch the product to the market for them to remain competitive in the 
market place. One way this is achieved is to change the manufacturing process and/or the 
intermediates used in the manufacture of the API. This is usually achieved by going to another 
(cheaper) source, which today is mostly from South Asia; namely India and China.  
There are several guidelines that specify the various requirements for an API 
manufacturer to comply with; however, the guideline to change a source or process is vague in 
terms of the physiochemical properties of the API. Materials may vary as to the legal definition 
of an API depending on the different jurisdictions across the world. When a material is classified 
as an API in the region or country in which it is manufactured or used in a drug product, it 
  
3 
 
should be manufactured according to the guidelines laid by the appropriate regulatory 
authorities
4
.   
1.2 - Regulatory Guidelines 
The United States Pharmacopeia initiated a program referred to as the “USP Drug Substance 
Verification Program” or “Program” to several public health industries5. The participation of the 
API manufacturers in this program is voluntary, but is open to all manufacturing units making 
APIs for use in pharmaceutical products
5
.  The program covers drug substances used in the 
manufacture of pharmaceutical products and it includes: 
 Evaluation of participants’ quality systems through an audit of each manufacturing site 
for compliance with current Good Manufacturing Practices (e.g., ICH Q7 current Good 
Manufacturing Practice Guide for Active Pharmaceutical Ingredients)
6
, 
 Review of the manufacturing and quality control documents for each drug substance 
submitted for verification, including review of the characterization, stability, and release 
data for compliance. The review also includes labelling of the product, Certificate of 
Analysis (C of A) claims as well as compliance with USP-NF or any other monographs 
as applicable, 
 Laboratory testing for drug substance samples from selected lots for compliance with 
labeling and/or C of A claims and program requirements,  
 The Certification Mark is only granted upon full adherence and confirmation that all of 
the Program requirements are met, 
 Post-verification surveillance testing of drug substances bearing the Certification Mark, 
 Post-verification audits, 
 Periodic re-validation of the manufacturing process, 
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 Reporting by participants of any major changes to the manufacturing or testing of drug 
substances bearing the Certification Mark. 
The use of the distinctive Certification Mark is granted for API manufacturers that successfully 
meet the Program requirements. This mark indicates that verification of the API quality and the 
adequacy of the participant’s quality systems and controls by a trusted and established authority 
are completed and it will provide the assurance that: 
 The participant has established and is following a quality system that helps to ensure that 
the drug substance evaluated meets it’s labeling or C of A claim for identification, strength, 
purity, and quality, and is consistent in quality from batch to batch, 
 The participant follows accepted manufacturing practices in producing the subject drug 
substance, 
 The tested drug substance samples meet requirements for acceptable limits of 
contamination and impurities. 
The extension of current Good Manufacturing Practices (cGMP) to API manufacturing has 
increasingly been recognized as a necessary element in ensuring the overall quality and 
consistency of marketed drug products
6, 7
. This requirement resulted in the formation of a 
working group in 1997 to develop cGMP guidance for API manufacturing. This group (and their 
resulting guidance document) is referred to as the International Conference on Harmonization 
(ICH). This document also includes the Canadian requirements, which were finalized and signed 
by the ICH Steering Committee in November, 2000. Health Canada (HC), like its other 
counterparts around the world is charged with implementing and enforcing regulation governing 
drug products adopted by the ICH Q7 guidance initially on a voluntary basis.  It (HC) has now 
implemented internationally aligned regulatory cGMP requirements for APIs destined for human 
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use
8
.
 
To encourage the use of alternative sources for the API in the manufacture of Drug 
Products, the World Health Organization (WHO) developed guidelines for the submission of 
applications for prequalification of the Multi-source (Generic) Finished Pharmaceutical Products 
(FPPs) for the treatment of HIV/AIDS, Malaria and Tuberculosis. The guidelines were 
developed based on WHO document WHO/DMP/RGS/98.5 “Marketing Authorization of 
Pharmaceutical Products with special Reference to Multisource (Generic) Products: a Manual for 
a Drug Regulatory Authority (DRA)
 9” and on the International Conference on Harmonization 
(ICH) guideline “The Common Technical Document for the Registration of Pharmaceuticals for 
Human Use: M4Q: Quality; Module 2: Quality Overall Summary (QOS); Module 3: Quality
7
. 
The use of alternative source of APIs to manufacture a drug product at a lower cost is 
welcome by the generic drug manufacturing organizations as a way to keep pace with increasing 
demand to lower the cost of treatment by various Governments and health care providers around 
the world. In an effort to make the process more effective and efficient, and to ensure that the 
end product using an alternate source of API is of the same Quality, Efficacy and Safety, there is 
now a guidance document issued by the Food and Drug Administration (FDA). This guidance is 
intended to describe the Office of Generic Drugs’ (OGD) policy on the use of alternative sources 
of the API in an unapproved abbreviated new drug application (ANDA). This guidance describes 
the circumstances under which an alternative source can be used prior to the approval of an 
abbreviated new drug application.  This guidance is intended to decrease the regulatory burden 
on industry and the regulatory body, and to provide a more consistent approach to pre- and post-
approval changes in API sources
10
. 
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1.3 - Product Development  
Drug substances, also known as Active Pharmaceutical Ingredients (APIs), generally exist as 
crystalline powders, amorphous powders or as viscous liquids.  Historically in pharmacy practice 
drug substances were dispensed as such in powder or mixtures of powders to the patient. This 
practice is virtually unknown in the pharmacy world today with the advent of modern technology 
to present drug substances to patients in the form of drug products. These drug products can exist 
in several dosage forms such as oral, parenteral, topical, etc. There are significant advantages to 
presenting a drug substance in specific dosage forms; these include patient compliance, taste 
masking, varying release profiles, different route of administrations, etc. While the advantages 
are numerous, the actual performance of the drugs in clinical practice is known to be greatly 
affected by the method of presentation of the drug to the patient. Several factors that impact the 
most appropriate from of presentation include
11
: 
 the portal of drug entry, 
 the physical form of the drug product, 
 the design and formulation of the product, 
 the method of manufacture of the drug product, 
 various physicochemical properties of the API and excipients used in the 
manufacture of the drug product, 
 physicochemical properties of the drug product, 
 control and maintenance of the location of the drug product at the absorption 
site(s), 
 control of the release rate of the drug substance from the drug product. 
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New drug molecules are marketed in various dosage forms suitable for patients to ingest with 
ease. The most common dosage forms developed for use are tablets, capsules, oral liquid or oral 
suspensions, while some of them are also marketed as injections. The intravenous route of 
administration is generally required during the toxicity, metabolic, bioavailability and clinical 
studies to provide precise drug and dose disposition. The development of a drug product starts 
and ends with the API. The major challenge for API development is the design of the appropriate 
physiochemical properties with regards to the route of administration.
  
The process of developing 
an API is a long and challenging one and starts long before the drug product is first tested in 
humans. The goal for the First in Human milestone of a drug product is to “deliver a safe, 
scalable, reproducible and robust protocol for API manufacturing” 12, 13. 
The development of the API over the life cycle of the drug product development will 
continue to evolve
14
 and at the end of the drug product development cycle the physicochemical 
properties are expected to be fully characterized. However, at this stage neither the API nor the 
drug product is commercially viable and both require scale up to meet the commercial demand. 
As the development of an API moves from pilot scale to large scale manufacturing it becomes 
more challenging to maintain the physicochemical properties
15
. There are several factors that can 
contribute to this including changes in the batch size and/or equipment during scale up resulting 
in changes to the processing parameters. There could also be changes to the synthetic route to 
improve the purity and yield of the batch as the drug product development move through the 
different stages. The impacts of some of these changes are discussed in detail in section 1.4 of 
this chapter. Once the API is available it is then required to be formulated into a desire dosage 
form(s) for use by patients. There are several challenges associated with the development of a 
drug product, including stability, compatibility, and the manufacturing process. 
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The innovator company usually has several patents covering both API and the resulting drug 
product, and is very protective of its Intellectual Property. The patents not only cover the drug 
substances and drug products but in most cases also extend to the manufacturing process, 
intermediate material, formulations, etc. The Innovator and Generic companies usually develop a 
drug product using API from a single source which can either be supplied from internal 
synthesis, or from an external source. The material available for development is usually from the 
small scale manufacturing plant of the API source. The process characterization and Critical 
Quality Attributes (CQAs) of the API and the drug product are then established as part of the 
development process. At the time of submission for approval the brand companies will have 
carried out API and process characterization of their scale up material, although not at their 
second generation scale, which is equivalent to the generic scale. As can be seen below (Scheme 
1.1), there are several stages in the development of an API during the innovators development 
process; as the drug product moves through different phases of its development so does the API. 
As a result the physical and chemical characteristics of the API are evolving at the same time as 
the formulation and process development of the drug product is evolving. This provides 
significant advantages to the innovator as the CQAs of the API are well known and characterized 
at the time of launch. As a result of the time and money invested, the brand company does not 
disclose any of the CQAs or any unique characteristics of its API so as to maintain their 
competitive advantage. The generic industry operates on a significantly different model, both in 
terms of cost and time. The cost of developing a generic equivalent of an innovator product is 
approximately $2 - $3 Million, which is less than 1% of the estimated $868 million to develop a 
new drug product
3
. 
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Scheme 1.1: The API – life cycle, illustrating the approximate volume of material at the 
different stages of the API and drug product development process
14 
 
The search for a generic equivalent source of API starts years before a brand patent is due 
to expire and the length of time the generic product is kept on the market is dependent on the 
number of competitors and if the generic company can remain competitive. In most cases that 
competitive advantage is dependent on a generic company finding a much cheaper source of an 
API, or if vertically integrated, a cheaper way to make it. There are over 340 experienced API 
manufactures of which approximately half are vertically integrated into a finished dose
2
. As a 
result there are a significant number of source changes and process changes for API 
manufacturers as both API manufacturers and drug product manufacturers look at ways to reduce 
cost. 
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The API is the main ingredient of any drug product; however, most APIs lack the physical 
and chemical properties to form a drug product on their own. As a result many pharmaceutical 
ingredients are available or are being developed to facilitate the product and process 
development to transform the drug substance into the desired finished drug product. Excipients 
play a critical role in the performance of a drug product, roles that include (but are not limited to) 
enhancing solubility, bioavailability, stability, maintaining pH, release profile etc.
16
 , and any 
change to their physical and/or chemical properties can have as a significant impact on the 
product and/or process as would a change in the API. While the API cost of any formulation is 
the most significant contribution to product cost, another substantial contribution can arise from 
the excipients used in the formulation of the drug product. As drug product manufactures look 
beyond API to reduce cost, excipients are starting to gain focus. While traditionally excipients 
have not been a major driver to reduce cost, excipients are becoming a more common approach 
to cost reduction today. There are two approaches used; one is to maximize the utilization of 
excipients that are already in use as this will give the manufacturing companies buying power 
and therefore the ability to reduce price and the other is to procure excipients from new and 
cheaper sources
17 - 20
. 
 
As stated above, one of the main drivers to reduce the cost of a generic 
product is to source cheaper APIs from sources such as those found in India and China. The 
lower cost of the API is not only associated with lower labor costs, but also to changes in the 
manufacturing process that can contribute significantly to the lower cost. In addition to cost there 
are other factors that may influence a company to change the current source of their material. 
These include  
- Having multiple sources,  
- Intellectual Properties,  
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- Quality of current supplier. 
 There are several guidelines that deal with the change of sources, FDA, EMA, TGA, TPD, and 
ICH among others.  The primary criteria of all of these guidelines are the assumption that if the 
product meets the monograph then it can be considered like for like and therefore can be 
substituted. The regulatory requirements also vary greatly from a submission of comparable C of 
A, to the requirement to have six months of stability data on drug product manufacture with the 
new source of API. The change in source or process for an excipient is even less stringent and 
does not require any form of stability or notification to the regulatory bodies. Again the 
assumption is that if all of the C of A specifications are met then the API and excipient are 
assumed to be equivalent. In order to assess the impact of any change in the manufacturing 
process to the resulting material it is first important to understand the process by which the 
material is manufactured. There are two types of material, crystalline and amorphous, and the 
differences in the manufacturing process and materials are discussed further in the next section.                        
1.4 - Active Pharmaceutical Ingredients  
1.4.1 - Crystalline Material  
The brand and generic industry can both point to numerous instances where a change in 
API or excipient source or process has had a negative impact on their drug product, although the 
opposite is also true
21 - 23
. The impact can vary significantly in how it propagates itself and can be 
observed as early as during the powder dispensing process, in-vitro testing, or worse during the 
long term stability studies of the drug product. One of the main reasons for recall of drug product 
from the market is due to failures on stability. Most stability programs are initiated due to 
changes made to the drug product, including changes made to the manufacturing process, 
specifications, API or excipient sources, or significant changes made to the manufacturing 
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process of the API or excipient. The starting material for the API is also an important 
consideration as this can also go through changes to process or source affecting the physical and 
chemical properties of the API 
24
. New drug molecules are more potent today and with complex 
physical properties changes are much more difficult to characterize.  
Pharmaceutical materials exist mainly in two forms, either as crystalline or as amorphous 
particles. Crystalline material can exist in three forms; polymorphs, solvates, and hydrates and 
co-crystals. The crystalline material has a more definite shape, while amorphous material is more 
random. Amorphous material also differs from crystalline material in that they do not have 
precise melting points. Some material can exist in more than one crystalline form (different 
crystal structure) although they are chemically identical
25, 26
. These different structures are 
referred to as polymorphs and can result from differences in temperature, pressure, moisture, 
salts and/or solvent used in the synthetic process. The different polymorphs can have significant 
impact on the physico – chemical properties as well as the stability of the API and subsequent 
drug product. Polymorphs can differ significantly in crystal properties that include solubility, 
dissolution, melting point, density, hardness and stability. From a clinical perspective these 
differences can potentially lead to a difference in the bioavailability of the drug and therefore can 
have an impact on the safety and efficacy of the drug product 
13, 25, 26
.  As an example 
phenobarbital, primarily used as a treatment for seizures is known to have 11 different 
polymorphs, each with a different melting point ranging from 112°C to 176°C
26.  
They
 
can each 
exhibit different physicochemical properties at given conditions, with Form A reported being the 
stable form and is present in the drug product
26, 27
. However, over time the unstable polymorphs, 
referred to as metastable polymorphs, will convert to the stable form. The amorphous and 
metastable polymorphs are usually more soluble than the stable polymorphs.   This is important 
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in the pharmaceutical industry as polymorphisms have been the source of numerous litigations 
and patents. It is also important to understand the crystalline form that you are working with to 
ensure that conversion from a metastable polymorph to the stable polymorph does not occur over 
time in your manufacturing process, storage or during drug product stability.  There are several 
challenges associated with inadequate characterization of the crystal properties of an API. These 
include unexplained challenges during the manufacturing process, precipitation in liquid 
formulations, poor stability, and poor in vivo and in vitro performance
13
.  There are several 
methods used to evaluate the physical and chemical properties of an API including dissolution, 
X-Ray Diffraction, Infrared Analysis, Thermal Analysis, Hot – Stage Microscopy and Scanning 
Electron Microscopy
13, 28
. There is no one method that is superior or more reliable in identifying 
the crystalline form of a material and it advisable to use a combination of methods during 
evaluation. Typically X-Ray diffraction is used in the pharmaceutical industry to identify if 
different crystalline forms exist within a sample of material or between two different samples. 
This is a critical test during the evaluation of a different source of material as the material can be 
chemically identical; however, they can be different polymorphs.  
There are several properties that can impact the performance of the drug substance, drug 
product or the manufacturing process. These properties, however, rarely have an impact based on 
a single factor. What are obvious from the physical and chemical characteristics described are 
the interdependencies of these properties with each other. As a result a change to one of these 
characteristics can impact one or several other properties; these can be either positive or 
negative
25
. While there is no requirement to test for all of these physical properties, it is 
important to assess which is critical and which is not so that an evaluation can be done prior to 
the introduction of an alternate API or excipient. 
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The primary method of producing APIs is solvent based crystallization and 
recrystallization; however, new methods are being developed with the goal of identifying all 
possible solid states of a molecule. These include: laser induced crystallization, capillary 
crystallization, sonocrystallization, non-solvent based recrystallization and recrystallization 
through solid state transitions and transformation of polymorphs
25
. There are several factors that 
can impact the properties of an API during the API manufacturing process. The impact can vary 
significantly and can impact purity, polymorphism, particle size and the physical properties of 
the crystals.  The particle size and crystal properties are more likely to impact the manufacturing 
process and performance of the drug product while the purity and polymorphism are more likely 
to impact the stability and physicochemical properties of the API and drug product
25, 26
. 
1.4.1.1 – Impact of crystallization process and parameters on the material     
The crystallization process is a long and complex one that involves many steps as described 
in figure 1.1
29
; however, the three main process steps that control the properties of the crystal are 
supersaturation, nucleation and crystal growth
25, 26
. There are several factors that can effect 
nucleation and crystal growth
 
such as concentration, temperature, solvent, agitation, interfaces, 
surfaces, impurities etc
25
.  Changes to the crystallization method can influence the shape and size 
of the resulting crystals; a few examples are described below: 
 Degree of supersaturation: Greater saturation produces needle shaped crystals due to more 
growth in one direction. This is due to significant solute – solvent interaction resulting in the 
rate of nuclei formation being greater than crystal growth which causes more growth in one 
direction. Lower saturation produces plate-like crystals due to insignificant solute – solvent 
interaction
25, 26
, 
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 Nature of crystalizing solvent: A solvent having higher affinity for the crystallizing solute 
results in symmetric crystals as nuclei formation is delayed. Interactions of certain functional 
groups between solute and solvent can impact the crystal growth at the crystal surface and to 
produce well shaped crystals requires a high ratio of crystalizing solute and solvent. The 
opposite is true when the solvent has less affinity for the crystallizing solute, where crystal 
growth is rapid as nuclei is formed immediately and produces larger crystals. Also, it requires 
low ratio of crystalizing solute and solvent to produce well shaped crystals
25, 26
, 
 Temperature of crystallizing solvent: At high temperatures nuclei formation is delayed 
resulting in fine symmetric crystals. At low temperature irregular shaped crystals are 
produced due to rapid nucleation resulting from spontaneous decrease in saturation level. 
Temperature also has other secondary but inter related impacts such as on solubility and 
therefore on supersaturation
25, 26
, 
 Agitation/mixing: At high agitation the crystallizing solid is distributed more evenly on the 
nuclei and produces elongated crystals with small particle size. At low or zero agitation the 
crystallizing solid is deposited on selected crystal face resulting in large platy crystals. 
Stirring can also impact the chiral symmetry of the molecule
25, 26, 29
, 
 Rate of cooling: Symmetric crystals are produced from slow cooling due to a decrease in the 
rate of crystal growth while rapid cooling results in asymmetric thin plate – like crystals due 
to the rapid crystal growth 
25, 26
, 
 Crystallization equipment: There are generally three type of reactors used in the 
crystallization process, glass line reactor, alloy reactor or glass lined metal reactor
30 - 32
. 
There are also three types of agitators used: 
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1) Three blade retreat curve agitator with a glass line reactor where the agitation speed is 
moderate to high, 
2) Anchor agitator with a glass plus metal line reactor, where agitation speed is slow, 
3) Turbine agitator with an alloy reactor can also be used with glass line reactor where 
agitation speed is high.  
The type of reactor used generally does not impact the drug substance properties; however, a 
change in agitator can impact the drug substance physical properties. As discussed earlier, this is 
due to variation in agitator speed
25, 33 - 35
.  
There are other factors such as pressure, moisture, humidity, additives and impurities which can 
have differing impact and can either inhibit or cause excessive growth of certain crystal faces
25, 
26, 36
.  
The possible changes in the crystallization process or process parameters can impact the 
crystals in many ways such as different polymorphic forms, impurity levels and in the physical 
attributes such as particle size, particle shape, surface morphology, surface area and porosity. 
These differences can in turn have an impact on both the drug product and the manufacturing 
process of the drug product. These include bulk flow properties, compressibility, dissolution rate 
and stability. Reactive impurities such as iron and peroxide can impact the stability of the drug 
product resulting in failures over time and may not appear for months or years. Nonvolatile 
impurities with low melting point may influence sticking/picking, during the compression stage 
of the drug product manufacturing, based on drug content in the formulation, formulation 
composition and drug product manufacturing process
25, 26
.  
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Figure 1.1: A process flow diagram depicting a typical equipment layout for a crystallization 
process use in the manufacture of APIs and Excipients.
29 
 
1.4.2 – Amorphous Material  
Amorphous solids are described as any non-crystalline solid in which the atoms and 
molecules are not organized in a definite lattice pattern; examples of amorphous solids include 
glass, plastic, and gel
37
. The crystalline state of material has historically been the desired state for 
pharmaceutical materials due to the low free energy of this state when compare to amorphous 
material. This desire was due mainly to the fact that crystalline materials are more stable under a 
given set of conditions; also when there are multiple polymorphs, it is known that the one with 
the least energy will be the most stable and over time other polymorphs will transform to the 
lowest energy form
26
.  Amorphous material is known to contain more free energy and is 
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therefore less stable than crystalline material and will convert to the more stable crystalline form 
during storage and handling. The difference in free energy can also lead to differences in the 
physicochemical properties of the material such as stability, solubility, dissolution and impact on 
the drug product manufacturing process
26, 38, 39
. The amorphous form of an API typically has 
higher solubility and using the amorphous form of an API is increasingly seen as a method to 
overcome low bioavailability of many poorly soluble and permeable drugs. While enhanced 
physicochemical properties is the main driver for the use of amorphous form of a drug and 
pharmaceutical materials, there are other consideration that can also play a role such as patent 
and commercial reasons
26, 40 - 42
. 
 Potentially any material can be made amorphous if the rate at which the material 
solidifies is faster than the rate at which they can align into a crystal lattice structure
26
. There are 
several methods and techniques used in the manufacturing of amorphous material, which can be 
classified into two general categories, solution based or solid state methods
43
. The solution based 
method can be further divided into three different methods; vapor condensation, super cooling of 
melt, and precipitation from solution
38
. The solid state techniques include melt quenching, ball 
milling, cryogrinding, lyophilization, spray drying, super cooling, dehydration, etc. of which the 
most common is lyophilization (freeze drying) 
43 - 45
. The amorphous material is characterized by 
the glass transition temperature (Tg) as they do not have distinct melting points
26
. At 
temperatures below Tg the material remains brittle while at temperatures above Tg the material 
becomes moist, sticky, and cold to the touch.  The technique used to prepare an amorphous 
material will depend on the physical properties of the molecules; melt quenching will be 
appropriate for heat stable molecules, grinding or milling will be appropriate for physically 
stable molecules, spray drying will be appropriate for organic solvent soluble molecules, and 
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freeze drying for water soluble molecules. Many of these techniques (such as ball milling) are 
rarely used commercially to manufacture materials; however, when used can impact the drug 
molecule and ultimately the drug product 
39 - 42
. There is also evidence to show that amorphous 
material of the same molecule prepared by different techniques will exhibit different physical 
properties and chemical stability
43
.  
1.4.2.1 – Impact of manufacturing process and parameters on the material  
The amorphous state of a molecule is thermodynamically metastable; as a result, the focus 
must be to prevent conversion and/or degradation of the drug substance to the 
thermodynamically stable form. Therefore, it is critical to control the manufacturing process of 
the amorphous solids as any changes in the manufacturing process may impact the characteristics 
of amorphous powder. Each amorphization technique has its own set of critical processing 
parameters, with the main goals of preventing the formation of crystalline material and 
maintaining the stability of both the amorphous material and the resulting drug product over its 
shelf life. Changes to the amorphization process can influence the properties of the resulting 
material; a few examples are described below: 
 Rate of Cooling: One of the common parameters that could result in the formation of 
crystals during solution based method of amorphization is the rate of cooling, if it is too 
slow then crystalline material can form
43
, 
 Temperature: The transition glass temperature (Tg) is critical to the amorphous material 
and can result in significant challenges. If the Tg is below the processing temperature then 
the probability of crystals forming is increased
46
. Tg can impact the manufacturing 
process of the material, as well as any subsequent processing to convert the material into 
the desire drug product. The rubbery nature of the material at temperatures above Tg can 
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affect flow properties, handling, and cleaning of the material
43
. Temperature has also 
been shown to influence the material properties during milling. Milling above Tg results 
in different polymorphs while milling at temperatures below Tg results in the creation of 
amorphous material
43
, 
 Degree of supersaturation: The viscosity, solubility, solvent, and solute are all inter 
related and can all impact the degree of amorphization. It has been shown that some 
materials become stronger as solute concentration decreases, while in other cases they 
become more fragile
38
. As an example, high viscosity combined with low temperature is 
used to prevent crystal formation in sugars. These factors can also impact process 
parameters such as spray rate and atomization, which can also impact the properties of 
the resulting material
46
, 
 Time: As stated above the amorphous state is known to be thermodynamically metastable 
and has a tendency to revert to its more stable crystalline form. It has been shown that 
this conversion can occur at temperatures above and below the Tg, although it is expected 
that the rate will be much faster at temperatures above Tg
47
. Time is also a significant 
factor in the milling process technique of making amorphous material. Milling is 
generally used for size reduction purposes which require milling for a short period of 
time. The conversion of crystals to amorphous material, however, requires several hours 
of intense milling resulting in the continuing buildup of crystalline defects
43
, 
 Milling: Milling is one of the techniques used to produce amorphous material; however, 
factors such as time of milling, co-milling with excipients, and temperature are known to 
impact the rate and extent of amorphization
43
. Milling can also impact the particle size, 
particle shape, Tg, and the chemical stability of the material
43
.The manufacturing process 
  
21 
 
utilized in the production of a drug product often also includes milling of the materials; 
however, due to the relatively small time involved, this is not expected to have any 
noticeable conversion to amorphous material. Where milling can have a significant 
impact is if amorphous material is able to absorb water that can then act as a plasticizer. 
This can also lead to increased degradation to levels that can be detected and quantified 
as impurities
38
,  
 Impurities: Impurities such as degradation products, residual solvent, and moisture can 
act as plasticizers, thereby lowering Tg, resulting in some of the challenges described 
above. Increases in moisture have also been shown to increase the rate at which a 
material converts to the crystalline form. In some cases, for example polymer coating, a 
lower Tg is usually desirable to facilitate the effective layering of the polymer
43, 46, 47
. 
 There are other factors such as solubility, viscosity, pressure etc. that can impact the 
process. It was noted that process temperature and pressure have little or no effect on 
particle size, morphology, or water content of the material
38, 43, 46, 48
.  
The possible changes in the amorphization process, much like the crystallization process, can 
impact the material in many ways such as extent of amorphous material, impurity levels and in 
the physical attributes such as particle size, particle shape, surface morphology, surface area and 
porosity. These differences can in turn have an impact on both the drug product and the 
manufacturing process of the drug product
49, 50
.  The processes described above are mainly in 
relation to APIs; however, excipients can also be produced in a similar way as they can be 
crystalline, amorphous, partially amorphous, or partially crystalline. The role of the excipient and 
its impact on the manufacturing process and drug product are discussed in the following section. 
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1.5 – Excipients 
Drug products are made up of the API and excipients, where the type and number of 
excipients present is typically dependent on the dosage form. While, the therapeutic effect of the 
drug product is delivered by the API, the excipients play many critical roles in the design of the 
drug product formulation. These include
51, 52
: 
- support a consistent and robust manufacturing process resulting in physically stable 
product over time,  
- administration by intended route to patient,  
- improve patient compliance,  
- enable/enhance bioavailability and stability,  
- control drug delivery, etc. 
There are several types of excipients use in the manufacture of an oral solid drug product; some 
of the common ones are diluents, binders, disintegrants, glidants, lubricants, coating agents and 
coloring agents
51, 53
. Ideally excipients should have no pharmacological activity and should not 
react chemically, physically or biologically with the API. These excipients can be functional, for 
example as antioxidants and plasticizers, or non-functional, such as diluents and glidants. Table 
1.1 provides a list of typical excipient types along with examples
51, 53
. The list in table 1.1 is not 
exhaustive, and represents excipients commonly used in the manufacture of solid oral dosage 
forms. There are numerous other classes of excipients, used in the preparation of other dosage 
forms (liquids, ointments, etc., and in some cases also solid oral) such as suspending agents, 
viscosity increasing agents, antimicrobials, complexing agents
54, 55
, and solubilizers
55 - 59
.  Newer 
APIs are generally less soluble and less permeable with less than 10 % classified as high 
solubility and high permeability
55
 and many functional excipients such as cyclodextrins
50
, 
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plasma protein
56
, lipids
57 
and surfactants
58, 59
 are used to enhance their solubility, permeability 
and bioavailability
54, 60 - 62
. It is worth noting that not all inactive ingredients are completely 
inactive and patients can have allergic reactions or other adverse effects to these so-called 
“inactive” ingredients.  
Table 1.1: A List of different excipient types and examples use in the Pharmaceutical industry to 
formulate APIs into drug products 
Excipients Type  Examples  
Diluents/Fillers  Lactose, microcrystalline cellulose, sugars  
Binders  Starch, polyvinylpyrrolidone, methylcellulose 
Disintegrants  Sodium starch glycolate, crospovidone, croscarmellose sodium  
Glidants  Colloidal silicon dioxide, talc 
Lubricants  Magnesium stearate, stearic acid, polyethylene glycol 
Anti-adherents Talc, corn starch, sodium dodecylsulfate 
Film coating agents Hydroxypropyl methylcellulose, hydroxypropyl cellulose 
Modified coating agents Methacrylate polymers, hydroxypropyl ethylcellulose, 
ethylcellulose 
Colorants Iron oxide, natural pigments 
Flavor modifiers  Mannitol, aspartame, vanilla  
Adsorbent  Activated charcoal  
Antioxidant  Ascorbic acid, butylated hydroxyanisole, sulfoxylate 
Plasticizer  Glycerin, tributhylcitrate, diethyl phthalate   
Surfactant  Polysorbate 80, sodium lauryl sulfate, nonoxynol 10 
Polishing agent  Carnauba wax  
 
The regulatory bodies, such as the FDA and EMEA, approve the thousands of excipients 
that are used in the manufacturing of pharmaceutical drug products. The specific function of an 
excipient can vary significantly depending on the formulation and manufacturing process of the 
drug product and therefore it can be very difficult to establish acceptable specifications to cover 
a wide range of potential functions. As a result, the focus of the regulatory bodies and the 
excipient monographs is on purity and safety of the material; meeting the monograph 
requirements does not assure that batches are necessarily equivalent. The source of excipients 
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can include plant, animal or can be synthetic and as a result the individual excipients are 
expected to have variation from batch to batch. There needs to be a clear understanding of how 
this variability will affect the drug product formulation and manufacturing process; such 
understanding will most likely be on a product by product basis
63
. This was demonstrated in 
studies where super-disintegrants from different suppliers were found to have no effect on one 
formulation, while affecting another formulation. A study of five different brands of 
croscarmellose sodium in a placebo tablet containing lactose, dicalcium phosphate and 
magnesium stearate illustrated that two brands were almost identical in the disintegration time 
observed; two had slightly higher disintegration times while one was significantly different with 
a higher disintegration time. In addition three superdisintegrants, Crospovidone, Croscarmellose 
Sodium and Sodium Starch Glycolate, supplied by the brand companies and a generic equivalent 
were evaluated at different concentrations in an orally disintegrating tablet formulation for 
Domperidone containing Pearlitol, Avicel PH 101, Aspartame, Orange flavour, Aerosil and 
Sodium stearyl fumarate. In all three instances the disintegration time of the tablets using the 
branded product were lower than the disintegration times of the tablets using the generic 
equivalent irrespective of the concentration used. In addition both suppliers of Crospovidone 
exhibited significantly lower disintegration times than the suppliers of Croscarmellose Sodium 
and Sodium Starch Glycolate
64 - 66
. This problem could extend further if there is a change to the 
manufacturing process or source of the material resulting in a change in the physical or chemical 
properties of the excipient. 
The drug product is made up of the API and at least one excipient, but typically a tablet 
formulation will consist of a diluent, binder, disintegrant and a lubricant. The excipients can 
sometimes make up to 99.9 % of the drug product; however, on average they account for 
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approximately 90% of the drug product
51
. Excipients are generally amorphous in nature and 
many exist as fully amorphous (such as amino acids) or partially amorphous material (such as 
spray dried lactose and microcrystalline cellulose)
 38
. As a result the excipients, like the API, can 
have a significant impact on the physical and chemical properties of the drug product.  The 
mechanical properties of both the API and excipients are critical in the manufacturing of the drug 
product. The crystalline material is known to be more elastic and brittle when subjected to 
external stress, while the amorphous materials exhibit more viscoelastic properties, depending on 
Tg. These properties are critical during the manufacturing of a drug product as they can induce 
flow and provide mechanical strength to the dosage form
38
.  
1.6 - Drug Product  
The required dosage of a drug substance can range from micrograms (10
-6 
g) to 
approximately one gram, but is typically in the milligram (10
-3 
g) range. The average customer is 
not likely to be in a position to accurately weigh this small quantity of material directly from the 
pure API, as a result dosage forms were developed
67
. The drug product formulation must have 
the desired in vivo and in vitro performance, and must not be impacted by any changes in the 
manufacturing process, API or excipient for the formulation designed
53
. This is a diversified 
process that requires a systematic approach to gather a full and detailed understanding of the 
material properties, formulation, manufacturing process, and their interactions, and to also satisfy 
the regulatory authorities that the drug product is completely understood. The approach must 
provide sufficient justifications and support, based on research and experimentation, to 
ultimately provide a dosage form that is physically, chemically, and therapeutically stable for the 
shelf life of the drug product.  A proper experimental design can define the operating boundaries 
for the materials as well as for the manufacturing processes to ensure the quality of the drug 
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product. Information from various categories such as properties of API and excipients, 
interactions between materials, unit operations, and equipment use are required
68
. Figure 1.2 
illustrates the relationship between the API and the excipients in the formation of a drug 
product.
53
 Figure 1.3 illustrates the complexity of the relationship between material, 
manufacturing process and equipment in the development and understanding of a drug product
68
. 
 
Figure 1.2: A schematic of the relationship between API and excipients which are combined to 
produce a drug product with the desired pharmacological effect in a safe and effective manner
53
.  
Design of Experiment (DoE) and statistical methods are now being used extensively in the 
formulation and process development in pharmaceutical manufacturing, to optimize the 
formulation, manufacturing process, and equipment parameters
69 - 72
. The role of statistical 
analysis also extends into the validation study and subsequently to the Product Life Cycle 
Management. The final drug product and the manufacturing process for that product are required 
to be validated according to the regulatory requirements and guidelines. In general the validation 
process is used to verify the quality attributes of the dosage form, which for tablets would 
include disintegration, dissolution, friability, hardness, weight, assay, blend uniformity, and 
dosage uniformity; however the specific quality attributes can vary depending upon the type of  
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dosage form been manufactured. The validation batches also undergo stability evaluation over 
the drug product shelf life to ensure no effect from the scale up of the process or any other 
changes, including material changes that may have occurred. Any significant change to any of 
the starting materials of the formulation will require revalidation of the product and 
manufacturing process, which is expensive in both cost and time
53
. 
            
 
Figure 1.3: Schematic describing the complexity of the relationship between material, 
manufacturing process and equipment; clearly illustrating that a change in the property of one 
impacts the others
68
. 
There are several dosage forms such as capsules, patches, injections, liquid etc.; however, 
the most common dosage form in the pharmaceutical industry is the tablet. The manufacturing 
process for a tablet most often includes mixing, milling, granulation (dry or wet), and 
compression into a tablet (which can be then followed in some cases by film coating). A tablet is 
formed by eliminating the void spaces in between particles, and reducing the volume of a powder 
mix resulting in the formation of a solid mass
73. The process involves “particle rearrangement, 
elastic, viscoelastic and plastic deformation of particles, fragmentation of particles and formation 
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of inter particulate bonds”; see figure 1.4 as an example73, 74. There are several factors to 
consider leading up to the formation of the final dosage form, the selection of excipients, 
physical and chemical compatibility of drug and excipient, characteristics of the individual 
materials, characteristics of the physical blend and finally the characteristics of the final tablet
53
. 
The selection of the appropriate excipient and their relative concentration in the formulation is 
also critical for the success of the manufacturing process of the dosage form. The selection of an 
appropriate excipient is based on the intended function, drug-excipient compatibility, type of 
dosage form, and the manufacturing process and parameters. Drug-excipient incompatibility, 
whether physical, chemical or therapeutic, is a very important issue before and after dosage form 
preparation with respect to the product stability and the requirement to meet the intended shelf-
life. The incompatibility can be chemical (such as hydrolysis, which is most common), oxidation 
or physical such as cross linking with gelatin
52, 53, 75 - 77
. It is important to understand the 
chemistry of the API so that an appropriate excipient can be selected. It is also critical to 
understand the excipients as many of the incompatibilities do not result directly with the 
excipient but with the impurities present in the excipient material. These impurities, such as 
peroxides and heavy metals, can catalyze many of the reactions leading to the degradation of the 
drug product
53
. Any change to the excipient resulting in an increase in these impurities, while 
within the compendia specification, can ultimately lead to degradation and potential failure of the 
drug product. 
1.6.1 Tablet Manufacturing Process 
The API and excipients are required to be mixed together for a predetermined time to 
produce a blend that meets two main objectives; (1) homogeneity of the materials in the blend, 
and (2) the ability of the blend to flow; both objectives are expected to be maintained for the time 
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of processing to the final drug product. The blend of the drug product formulation contains the 
API and the desired excipients, each having their own physical and chemical characteristics. As a  
 
Figure 1.4:  The various stages of powder compaction during tablet formation on a compression 
machine, indicating a decrease in the powder volume with a corresponding increase in 
pressure
74
. 
 
result this can lead to differences in particle size, particle shape, surface area, flowability, 
density, porosity etc. of each material, and of the resulting blend
53
.The factors that affect the 
desired properties of the blend are generally interdependent; blends that are not homogenous can 
lead to several challenges including segregation of material, non – uniformity of the drug 
substance in the drug product, and erratic flow. There are other factors such as humidity, 
temperature, blender speed and blending time that can also affect the blend 
53, 73
. Any single 
property or a combination of these properties can be impacted by a change in any of the 
individual materials in the blend. The root cause of segregation in a blend is mostly due to 
differences in particle size, shape and density. Materials are milled during processing with the 
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intention of ensuring all agglomerates and particles are reduced to a similar size; however, the 
key is to select excipients with particle sizes that are as close to the same size as possible 
compared to the API particle size. The shape of the particle can also cause segregation as 
spherical particles flow well, while needle - like particles do not. The adhesive forces between 
particles in a given material can affect the flow properties of the blend if the material is present 
in a sufficiently large volume. Materials that are very cohesive do not flow well, affecting both 
blending and discharging of the material in a negative fashion. The opposite is true for low 
cohesive material
73
. Depending on the batch size of the blend it may be subjected to compressive 
forces (due to the overall weight and volume of the blend) that can cause partial rearrangement
78
.  
A common tool used to evaluate changes to the properties of the materials is to measure their 
bulk density (or apparent/pour density) and tapped density (see figure 1.4). The bulk density of 
the blend is related to the cohesiveness of a powder while the bulk density and tapped density 
together can be used to calculate the Housner ratio (a measure of flowability) and the Carr Index 
(a measure of the compressibility) for the blend
53
.  
The powdered blend of API and excipient does not always possess the require properties 
for the direct compression into tablet or capsule dosage form. In some cases it is necessary to 
further process the blend to form denser granules. This can be due to several reasons including 
prevention of segregation, prevention of API migration, or prevention of API loss during 
processing. Granulation is a process where the primary powder particles are made to adhere to 
form larger, multi - particle entities called granules. This process is normally initiated after the 
initial mixing of the necessary powdered ingredients, particularly if they have flow or 
segregation issues or there is a difference in each component particle size granulation. 
Granulation of the mix can be achieved either by wet granulation, by adding liquid binder, or by 
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dry granulation, involving the dry compaction of the blend
79
.  The compaction process for 
granulation, much like the milling process, may change the crystal structure into a different 
polymorphic form. To understand the compaction behavior of a material, it is necessary to be 
able to quantify much of the same properties as with the blend, such as elasticity, plasticity, and 
brittleness.  
A good granulated blend can be converted successfully into a tablet dosage form and to 
perform this various properties should be considered, including drug-excipient compatibility, 
flowability, lubricity, appearance, dissolution, and disintegration.  The compression process is 
made up of four distinct stages; pre-compression, main compression, relaxation and 
ejection80.The pressure or compression force is applied to form a lucid mass and is directly 
interrelated to the resulting tablet hardness and used as a surrogate for the weight of the tablets 
on the completely automated compression machines81. The compression machine does not have 
the capability to weigh every tablet during the compression run but is equipped with a strain 
gauge on each punch that can measure the compression force use to produce each tablet. As a 
result the compression machine monitors the weight of the tablets throughout the compression 
run by monitoring the compression forces at each punch. Compression force is considered one of 
the main critical processing parameters during the manufacturing of a tablet; however, several 
other factors such as press feed system, paddle feeder, fill cam, ejection cam, press speed, dwell 
time, punch depth and the tablet press Operator can all impact the quality of the tablet82. The 
formed tablets must meet the quality attributes according to the monograph and generally the 
weight of the individual tablet, weight variation, dosage uniformity, thickness, hardness, 
friability, disintegration, and dissolution should be the CQAs characterized for the validation of 
the process. The tablet dosage form has to undergo several physical processing unit operations 
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and must maintain product integrity as several physical characteristics are required to be met at 
the end. The mechanical strength of tablets is an important aspect and it is required to be 
controlled in the manufacturing process. This has been described by various terms such as 
friability, hardness, fracture resistance, crushing strength, flexure, or breaking strength
83 - 85
.  
Tablets require a certain amount of strength, or hardness and resistance to mechanical stress, to 
withstand the rigors of handling in manufacture, packaging, and shipping of the drug product. A 
sufficient amount of tablet hardness and resistance to prevent friability is a necessary requisite 
for consumer acceptance, while immediate-release tablets should readily disintegrate in the 
stomach as rapid as possible. This makes the relationship of hardness and disintegration 
important to achieve the required dissolution of the drug.  These factors need to be controlled to 
achieve the CQAs of the drug product in the end
53, 86
.  
1.6.2 - Disintegration  
Once the tablet is taken orally a process that is almost the reverse of that for 
manufacturing the tablet takes place, in order to make the drug substance available to the 
circulation system and tissues. The tablets will have to break down into granules or powder and 
go into solution for absorption and distribution to take place. Figure 1.5
 
illustrates the pathways 
that a drug substance, presented as a solid dosage form can take in order to be absorbed into the 
circulation system and tissues
53
.  If the tablet dosage form is designed to release the drug 
substance immediately after ingestion then the tablet should readily disintegrate in the stomach, 
or in the case of an orally disintegrating tablet, should disintegrate within seconds under the 
tongue in the mouth. As a result the disintegration test is an integral part of the in-process testing 
during the compression process of tablets. There are many mechanisms by which a tablet can 
disintegrate depending on the disintegrant and excipients used. These mechanisms include 
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swelling, porosity and capillary action, deformation, and particle repulsive forces, of which 
swelling is the most common
87
. There are several physical factors that can affect the 
disintegration time including water penetration, disintegrant content in the formulation, 
disintegrating fluid, and compression force. In addition, excipients within the formulation such 
as diluents, binders, surfactants and lubricants can all effect the disintegration time. There is 
some correlation between these factors and any change to any of the material property can 
ultimately have an impact on the disintegration time
88 - 90
.   
 
Figure 1.5: The pathways of a solid dosage form to disintegrate and dissolve for the absorption 
of the drug substance in the body
53 
1.6.3 - Dissolution 
Clinical studies by the Innovator are performed on many batches of product, while the bio – 
equivalency study for the generic product is usually done on a single batch of product. It would 
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be both cost and time prohibitive to perform an in-vivo study on every batch of product in order 
to prove efficacy, and as a result the in-vitro dissolution test is use as a surrogate for in-vivo 
studies, to release each batch of drug product for use by patients. The basic premise of this is that 
there is a correlation between the in-vivo results and the in-vitro result and a passing in-vitro 
result will ensure the bio availability of the drug in the body. The dissolution test is a measure of 
the rate and extent of the release of the API and is a CQA for a number of reasons, including; 
 to evaluate the potential effect of material, formulation and process variables on the 
bioavailability of a drug; 
 to ensure that the drug product complies with product specifications; 
 to indicate the performance of the drug product under in-vivo conditions. 
There are several factors that can affect the dissolution of a drug product including material 
properties, formulation, process parameters, the testing equipment, and the testing parameters. It 
is well documented that lubricants and mixing times can change dissolution behavior and any 
variation of either can lead to variation in the dissolution
91, 92
. The material properties that can 
impact the dissolution have already been introduced, and include particle size, particle shape, 
particle density, surface area, surface tension, polymorphism, amorphous state, wetting, 
humidity, and solubility. Changes to these properties can occur as a result in changes to the raw 
material manufacturing process or the drug product manufacturing process. There is also 
inherent variability with any manufacturing process which can result in batch to batch variability 
of any material. Finally, many of these factors are also interdependent; for example the particle 
size of a material can be changed due to milling in the manufacturing process, leading to a 
change in the surface area of the material. The surface area of the drug substance will likely 
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impact the dissolution and absorption for the drug product with an increase in surface area 
resulting in an increase in dissolution rate
91
.
 
1.6.4 – Impact of particle size on drug product and manufacturing process 
While a number of material properties have been introduced that can have direct or 
indirect impact on the manufacturing process and the resulting properties of the drug product, 
particle size
 
can perhaps have the largest single impact on the CQAs of the material, drug 
product and processing of a drug product
93
. CQAs such as blend uniformity, dosage uniformity, 
dissolution, hardness, bio–availability, etc. can all be impacted, while the impact on process can 
include variations in flow properties, granulation properties, compressibility, etc. The other 
aspect directly related to particle size is that of particle shape, which can similarly have a 
significant impact on the bulk properties of material
53
.  Despite its criticality, the impact of 
particle size on the product and process is not studied extensively during development, or during 
the life cycle of the product. The particle size specification is usually set during the development 
process, as it is a required part of the submission dossier. This is usually done on small scale 
batches with data available only from a small number of batches. Particle size is examined in 
greater detail often only as a result of an abnormal event.  As a result during scale up of the API 
manufacturing process it is usually very difficult to meet these specifications and in many 
instances changes in the particle size specification must be made. The impact of such a change is 
not always adequately evaluated as it is done at or close to the time of launch of the product.   
This can also be a challenge for the drug product manufacturer when the source of the API or 
excipient is changed. The new source may meet the specification requested; however, if they are 
using different test equipment and/or test method, the material can still fail when tested at the 
drug product manufacturer site. Pharmaceutical powders, API and excipients, usually range in 
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size from 0.01 micron to 1000 microns. The majority of APIs typically range in particle size 
from 1 to 100 microns; however, newer molecules have been prepared with particles sizes in the 
nanometer range
94
. There are several challenges associated with particle size testing and the 
results using the same material can vary greatly depending on the method and instrument used to 
perform the test. There are several methods used to test particle size including microscopy, 
sieving, electrical sensing, light scattering, and photon correlation spectroscopy
13
. It is critical to 
establish a correlation between the supplier test and result and that of the drug product 
manufacturer, so that the appropriate specification can be set such that good batches are not 
rejected and bad batches are not accepted.  
The ultimate challenge for the Formulations Development Scientist in the twenty-first 
century is to achieve a true understanding of material properties and material science and the 
impact of any change or variation. Those who can conceive a compatible, functional formulation 
will be irreplaceable as large companies shrink their Research and Development resources and 
the public sector demands better efficiency.  
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Chapter – 2: Hypothesis and Objectives 
 
2.1- Overview of the project  
The objective of this research is to understand how the physical and chemical 
characteristics for APIs and excipients may be critical for the success or failure of alternative 
source/process even though the given molecule is deemed to be equivalent. The main focus of 
most alternate API or excipient source change is on the physical properties that can impact either 
the manufacturing process and/or performance of the drug product (refer to table 2.1). The 
impact will vary depending on the material characteristics, such as attractive forces, particle 
shape, particle size, surface morphology etc. Initially three current sources of API and one 
current source of excipient were selected for a parallel evaluation with an alternate 
source/process of the same material leading to a total of eight batches. During the execution of 
the batches, an additional excipient that is used in one of the API formulations was added, 
bringing the total to ten batches. The C of A for each material was then evaluated and the 
differences were highlighted. Additional tests were performed (beyond the C of A), these include 
DSC, X-ray diffraction, bulk density, tapped density, particle size, volume weighted mean 
diameter, surface weighted mean diameter and specific surface area, where applicable.   
2.2 - Research Question 
Variation of Product Quality and manufacturability generally arises from two sources, 
either the raw material, or processes involved in manufacture of the product
95
. This research 
seeks to understand how the physical and chemical properties of an API and excipient obtained 
from an alternate source/process can impact the material properties, manufacture processing, 
drug product performance and their CQAs. The manufacturing process is known to impact the 
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final quality of any product and the confidence in ensuring that the final product will meet its 
quality attributes is dependent on the robustness of the manufacturing process. While APIs and 
excipients from the currently approved source and from the alternative source appear similar, 
they may exhibit significantly different physical behavior during processing and testing of drug 
product. The extent of this difference is not always adequately captured in the C of A for the API 
or excipient. Chemical differences are often due to the synthetic impurities, related compounds 
and degradation products generated during processing or storage and can all lead to drug 
substance and/or drug product failures. In a similar manner, that it is cost and time prohibitive to 
perform an in-vivo study on every batch of product, the expectation was not to perform all of 
these tests for every lot of APIs or excipients received, however, these tests should form the basis 
of the evaluation to introduce an alternate source of material. 
The tests to be completed as part of the evaluation on the impact on the processing, 
CQAs and drug product performance are described in table 2.1.   
Table 2.1: Tests to be completed for the processing, CQAs and drug product performance to 
evaluate the impact of a source/process change for an API and/or Excipient  
Processing  Critical Quality Attributes (CQAs)  Drug Product performance  
Hausner Ratio Weight  Dissolution  
Carr Index  Hardness  Assay of API content  
Sieve Analysis  Thickness  Dosage Uniformity  
Flow Index  Friability (4 minutes and 20 minutes)  
Bulk Density  Disintegration   
Tapped Density    
Compression force    
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2.3 - Hypothesis  
The comparability of the two C of As of an API or excipient supplied from different 
sources/processes will not demonstrate equivalency in the properties or behaviors of the 
materials. 
2.4 - Specific Objectives 
The specific objectives of this study are: 
1. Determine if the raw materials meet all C of A specifications,  
2.  Determine if the two sources differ with respect to the tested C of A specifications,  
3. Determine if the two sources differ with respect to the tests beyond the C of A, 
4.  Determine if the two sources differ with respect to Process testing (see Table 2.1),  
5.  Determine if the two sources differ with respect to CQA and Drug Product Performance 
(see Table 2.1). 
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Chapter – 3: Materials and Methods 
 
3.1 - Rationale for selection of APIs and Excipients  
All materials used in this thesis were graciously provided by Apotex Inc. (Canada), who also 
provided access to the tablet manufacturing facilities, analytical methods and testing 
equipment’s.   
The experimental plan for this study was based upon an examination of 3 API materials 
(metformin hydrochloride USP, gabapentin USP, and fenofibrate EP/BP), and 2 excipients 
(copovidone NP/EP and croscarmellose sodium NF/EP), with each material being obtained from 
two different sources; an exception was the copovidone experiments, where materials from the 
same supplier but different manufactured batch sizes were examined.  A brief description of the 
formulations and processes used is provided below: 
1. Metformin hydrochloride USP API is supplied as crystalline metformin HCl Form A. 
Metformin HCl tablets are prepared using a direct compaction method, is available from 
an alternate supplier using an alternate manufacture process, and  is present as 84%  w/w 
active concentration in the composition of the drug product; 
2. Gabapentin USP API is supplied as crystalline gabapentin USP Form II. Gabapentin USP  
tablets are manufactured using a dry compaction process, is available from an alternate 
supplier using alternate manufacture process, and is present as 69% w/w active 
concentration in the composition of the drug product;  
3. Fenofibrate EP/BP API is supplied as crystalline Fenofibrate Form I. Fenofibrate EP/BP 
tablets are manufactured using a hot melt technology where the resulting solid mass is 
pulverized using a hammer mill, is available from an alternate supplier using an alternate 
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manufacture process,  and is present as 55% w/w active concentration in the composition 
of the drug product; 
4. Copovidone NF/EP is used as a binder in most formulations and is used in the gabapentin 
USP tablets prepared in this study.  There is no change in supplier or in the manufacture 
process for copovidone; however there is a change in the scale of manufacture and 
manufacturing equipment; 
5. Croscarmellose Sodium NF/EP is the only excipient used in the fenofibrate EP/BP 
formulation other than the API; is present as 45% w/w composition of fenofibrate EP/BP 
tablets, is a super-disintegrant, but is also being used as both a disintegrant and as a 
binder in this formulation and is available from an alternative supplier.  
3.2: The APIs, Excipients and their suppliers used in each batch 
The APIs and excipients tested for each batch are provided in table 3.1, along with the supplier 
information. The actual materials used in the preparation of each batch of tablets, including both 
the test APIs, test excipients, along with any other materials (excipients) required for the tablet 
formulation (held constant across experimental batches) are listed in section 3.3. 
The metformin hydrochloride API for the metformin HCl tablets were supplied by two different 
companies, the API used in batch 1 was supplied by company A while the API used in batch 2 
was supplied by company B.  
The gabapentin USP API for the gabapentin USP tablets were supplied by two different 
companies, the API used in batch 3 and batch 5 was supplied by company X, while the API used 
in batch 4 and batch 6 was supplied by company Y.  
The excipient copovidone for the gabapentin USP tablets was supplied by company D; two 
different materials were supplied based on the scale of the manufacturing equipment used by the 
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supplier. The two materials are identified as copovidone NF/EP 35 which was used in batch 3 
and batch 4, and copovidone NF/EP 20 which was used in batch 5 and batch 6.  
The fenofibrate EP/BP API for the fenofibrate EP/BP tablets were supplied by two different 
companies, the API used in batch 7 and batch 9 was supplied by company J, while the API used 
in batch 8 and batch 10 was supplied by company K. 
The excipient croscarmellose sodium NF/EP for the fenofibrate EP/BP tablets were supplied by 
two different companies, the croscarmellose sodium NF/EP used in batch 7 and batch 8 was 
supplied by company G, while the croscarmellose sodium NF/EP used in batch 9 and batch 10 
was supplied by company H.  
Table 3.1: The batch numbers, materials used and their suppliers for each batch during the 
execution of the batches to test the hypothesis of this research 
Batch # API API tested  Excipient tested 
1 Metformin HCl BP  Company A   N/A 
2 Metformin HCl USP  Company B N/A 
3 Gabapentin USP  Company X  Copovidone NF/EP 35     
4 Gabapentin USP   Company Y   Copovidone NF/EP 35 
5 Gabapentin USP   Company X Copovidone NF/EP 20       
6 Gabapentin USP   Company Y Copovidone NF/EP 20       
7 Fenofibrate EP/BP Company J  Croscarmellose Sodium NF/EP (Company G) 
8 Fenofibrate EP Company K  Croscarmellose Sodium NF/EP )Company G) 
9 Fenofibrate EP/BP Company J Croscarmellose Sodium NF/EP (Company H) 
10 Fenofibrate EP Company K Croscarmellose Sodium NF/EP (Company H) 
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3.3 – Formulation, process maps and target in-process CQAs for each product  
Metformin HCl – Batches 1 and 2 
The specific ingredients used in the formulation of the metformin HCl tablets are listed in table 
3.2.  In addition to the two sources of metformin HCl listed in table 3.1, methylcellulose USP 
A15LV and polyethylene glycol NF 8000 were supplied by The Dow Chemical Company, 
microcrystalline cellulose NF M102 was supplied by Mingtai Chemical Co. LTD., colloidal 
silicon dioxide NF was supplied by Cabot Corporation, and magnesium stearate NF was supplied 
by Peter Graven.  A flow diagram of the process used for the preparation of metformin HCl 
tablets is provided as figure 3.1, below. The targets in process CQAs for the compression process 
are listed in table 3.3.  
Table 3.2: Composition of the metformin HCl tablets listing the API and excipients used in 
batches 1 and 2 
Item # Material Name 
1 Metformin HCl BP/EP 
2 Methylcellulose USP A15LV 
3 Microcrystalline Cellulose NF M102 
4 Polyethylene Glycol NF 8000 
5 Colloidal Silicon Dioxide NF 
6 Magnesium Stearate NF 
 
  
44 
 
 
Figure 3.1: Process flow diagram describing the direct compression process for the preparation 
of metformin HCl tablets in batches 1 and 2. 
 
 
Table 3.3: The target in process CQAs during the compression process for batches 1 and 2 
(metformin HCl tablets). 
Dies: 0.3125” x 0.6145” 
Upper punches: Capsule shaped. Standard cup, unscored, imprinted “APO 
500” 
Lower punches : Capsule shaped. Standard cup, unscored, imprinted “MET” 
Individual core tablet weight: Target: 596mg, Range 566mg to 626mg 
Weight of 10 core tablets: Target: 5.96g, Range 5.78g to 6.14g 
Hardness: Target 7 kp, Range 5 kp to 10 kp 
Thickness: Target 0.216 inch, range 0.209 inch to 0.224 inch 
Friability: NMT 1% after 100 revolutions (4 minutes at 25 rpm) 
Disintegration: NMT 30 minutes (without disc)
* 
Description: White to off-white, capsule shaped, unscored cores 
imprinted “APO 500” on one side and “MET” on the other 
side 
* The total time for the six tablets in the disintegration apparatus to completely disintegrate and 
pass though the mesh screen must not exceed 30 minutes.  
 
 
Dispensing
Pass the following:
Methylcellulose USP A15LV, Microcrystalline Cellulose NF M102, 
Colloidal Silicon Dioxide NF and Metformin Hydrochloride  in the 
order specified through a Quadro Comil equipped with a 0.075R screen 
into a bin
Initial Blending
24.5 minutes @ 10 rpm
Pass the following:
Polyethylene Glycol NF 8000 and Magnesium 
Stearate NF through a 
Quadro Comil equipped with a
 0.032R screen into bin
Final Blending
1.5 minutes @ 10 rpm
Compression
Tablet Press
Metformin Hydrochloride Core TAB 500mg
Film Coating
Coating Pan
Metformin Hydrochloride FCT 500mg
In - Process Testing
Sieve Analysis,
Bulk Density, Tapped
Density, Flow Index In Process Testing
Weight, Hardness,
Thickness, Friability,
Disintegration,
Dosage uniformity,
Assay,
Dissolution
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Gabapentin USP /Copovidone – Batches 3 to 6 
The specific ingredients used in the formulation of the gabapentin USP tablets are listed in table 
3.4.  In addition to the two sources of gabapentin USP (batches 3 and 4) and the two types of 
copovidone (batches 3 and 4 as compared to batches 5 and 6) listed in table 3.1, magnesium 
stearate NF was supplied by Peter Graven.  In all 4 batches executed for gabapentin USP, 
copovidone (copovidone NF/EP 35 and copovidone NF/EP 20) was obtained from Company D.  
A flow diagram of the process used for the preparation of gabapentin USP tablets is provided as 
figure 3.2, below. The targets process parameters and CQAs during the compaction process are 
listed in table 3.5, while the targets in process CQAs for the compression process are listed in 
table 3.6.  
 
Table 3.4: Composition of gabapentin USP tablets listing the API and excipients used in batches 
3 – 6.   
Item # Material Name 
1 Gabapentin USP   
2 Copovidone NF/EP  
3 Magnesium Stearate NF 
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Figure 3.2: Process flow diagram describing the compaction process for the preparation of 
gabapentin USP  tablets in batches 3 –6. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dispensing
Pass the following:
Gabapentin USP  (About Half),  all of Copovidone and 
Gabapentin USP (Remainder)
  in the order specified through a Quadro Comil equipped with a 
0.045"R screen into a bin to make Gabapentin Mix 68.97%
Initial Blending
10 minutes @ 10 rpm
Compaction
Compact Gabapentin Mix 68.97% using 
Compactor to make 
Gabapentin COM 68.97%
Add Magnesium Stearate NF.
Final Blending
Bin
3 minutes @ 10 rpm
Compression
Tablet Press
Gabapentin Core TAB 600mg
Film Coating
Coating Pan
Gabapentin FCT 600mg Tablets
In Process Testing
Sieve Analysis
Bulk Density, Tapped 
Density, Flow Index
In Process Testing
Weight, Hardness,
Thickness, Friability,
Disintegration,
Dosage uniformity,
Assay,
Dissolution
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Table 3.5: The target process parameters and CQAs during the compaction process for batches 3 
– 6 (gabapentin USP tablets) 
Process Parameters Settings Operating Range 
Screen size 1.5 mm 
Granulator Wheel Open-faced angular 
Roller Type Knurled 
Roller Gap Width (mm) 3.3 mm 
Compaction force 9.0 kN/cm 
Compaction Roller Speed 6.0 rpm 
Granulator Speed 75 rpm CW 
 75 rpm CCW 
Granulator Angle 180 CW 
 270 CCW 
Sieve Analysis Operating Range 
20 mesh (12+20 mesh) (%) 11-61 
80 mesh (40+60+80 mesh) (%) 24-46 
Fines (100+200+ Fines mesh) (%) 5-53 
Bulk Density (g/cc) 0.45-0.65 
Tapped Density (g/cc) 0.65-0.85 
 
Table 3.6: The target in process CQAs during the compression process for batches 3 – 6 
(gabapentin USP tablets) 
Dies: 0.3440”x0.6875” Oval 
Upper punches: Modified concave, oval, Embossed “GAB” over Partial  bisect “600” 
Lower punches: Modified concave, oval, Embossed “APO” 
Individual core tablet 
weight: 
Target: 870mg, Range 826mg to 914mg 
Weight of 10 core tablets: Target: 8.70g, Range 8.44g to 8.96g 
Hardness: Target 19 kp, Range 11.5 kp to 26.0 kp 
Thickness: Target: 0.258” (Range 0.240” to0.275”) 
Friability: NTM 0.8% after 100 revolutions (4 minutes at 25 rpm) 
Disintegration: NMT 30 minutes (without disc)
* 
Description: White, oval, biconvex,  tablets, Engraved “GAB” over partial bisect                                                          
“600” on one side, “APO” on the other side 
 
* The total time for the six tablets in the disintegration apparatus to completely disintegrate and 
pass though the mesh screen must not exceed 30 minutes.  
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Fenofibrate/Croscarmellose Sodium – Batches 7 to 10 
The ingredient used in the formulation of the fenofibrate EP/BP tablets is listed in table 3.7.  
Sources of both fenofibrate EP/BP and croscarmellose sodium NF/EP are provided in table 3.1; 
there are no additional excipients in the fenofibrate EP/BP tablet formulation.  A flow diagram of 
the process used for the preparation of fenofibrate EP/BP tablets is provided as figure 3.3, below. 
The targets in process CQAs for the compression process are listed in table 3.8.  
Table 3.7: Composition of the fenofibrate EP/BP tablets listing the API and excipient used in 
batches 7 – 10 
Item # Material Name 
1 FENOFIBRATE EP/BP 
2 CROSCARMELLOSE SODIUM NF/EP 
 
Table 3.8: The target in process CQAs during the compression process for batches 7 – 10 
(fenofibrate EP/BP tablets) 
Dies: 0.2620”  x 0.5020”, modified oval 
Upper punches: Modified oval, concave, unscored, embossed “APO” 
Lower punches: Modified oval, concave, unscored, embossed “FEN160” 
Individual core tablet 
weight: 
Target: 291 mg, range 276 mg to 306 mg  
Weight of 10 core tablets: Target: 2.91 g  (Range: 2.82 g to 3.00 g) 
Hardness: Target: 5.5 kp  (Range: 3.5 kp to 7.5 kp) 
Thickness: Target: 0.171 inch  (Range: 0.167 inch to 0.175 inch) 
Friability: NMT 0.8%, after 100 revolutions (4 minutes @ 25 rpm) 
Disintegration: NMT 15 minutes (without discs)* 
Description: White to off-white, oval, core tablet engraved APO on one side,                   
and FEN160 on and “FEN160” on the other side. 
* The total time for the six tablets in the disintegration apparatus to completely disintegrate and 
pass though the mesh screen must not exceed 30 minutes.  
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Figure 3.3: Process flow diagram describing the hot melt technology process used in the 
preparation of fenofibrate EP/BP tablets in batches 7 –10. Half of the fenofibrate EP/BP is 
charged to the kettle (1) and allow to melt at 90 -95°C before the second half is added (2). Once 
all of the fenofibrate EP/BP is melted the croscarmellose sodium NF/EP is then suspended (3) in 
the molten fenofibrate EP/BP.  
 
3.4 - Material Characterization 
The three APIs and two excipients were tested according to their respective C of As using 
the approved and validated method of analysis and C of A criteria for each material. These 
materials were tested by Apotex and the results were provided to me for use in this thesis. The C 
of A criteria for metformin HCl USP are compared in table 3.9, Gabapentin USP are compared in 
table 3.10, copovidone NF/EP are compared in table 3.11, Fenofibrate EP/BP are compared in 
table  3.12 and croscarmellose sodium NF/EP are compared in table 3.13 for the current and 
alternate sources of each material. The two materials can be described as being comparable if the 
requirements of the C of A met the predetermined specifications; however, it is worth noting that 
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the requirements of the C of A can and is often different for the two sources. If the C of A results 
were determined to be comparable for the two different sources of material, then there will be a 
need to test beyond the C of A to further determine if the materials are truly comparable. There 
were two requirements to determined additional testing requirements; the first is if the test is 
required in the current source C of A but not in the alternate source C of A or if the test is 
required in the alternate source C of A but not in the current source C of A, then the test will be 
performed. This was limited to particle size, bulk density, tapped density, specific surface area, 
surface weighted mean diameter and volume weighted mean diameter. The tests beyond the C of 
A included X-Ray Diffraction, Differential Scanning Calorimetric (DSC), Thermogravimetric 
Analysis (TGA), Image analysis, Fourier Transform Infra-Red (FTIR), Scanning Electron 
Microscope (SEM) and Brunauer, Emmett and Teller Surface Area (BET). With the exception of 
X-Ray Diffraction that was a requirement for the alternate source of metformin HCl, none of 
these tests were required on any of the other C of As.  
There is no one tests beyond the C of A that can determine the equivalency of the two 
sources of material and as a result the tests listed above were performed. These test were selected 
based on the knowledge that they, either individually or in combination with others, can be used 
to differentiate between the same material from two different sources. The X-ray diffraction can 
be used to determine if there is any difference in the polymorphic form of the same APIs from 
different sources. The SEM can be used to determine if there are any morphological differences 
between the same excipients from different sources. The impact of these properties on the drug 
product and manufacturing process are discussed in chapter 1.   
In addition to the C of A testing, the following additional analyses were performed for 
each source of each ingredient: image analysis, particle size by laser diffraction, specific surface 
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area, surface weighted mean diameter, volume weighted mean diameter and DSC. Powder X-
Ray diffraction was performed on the three API’s, and TGA and SEM analysis was performed on 
the two excipients. In addition, for metformin HCl USP only, FT-IR spectroscopic 
characterization, BET surface area and TGA were also performed.  
A brief description of each test is described below96: 
1. Powder X-Ray Diffraction (USP <776>) – approximately 1 gram of sample was weighted 
and grinded. The sample was then loaded into a standard sample holder and placed in 
PANalytical X-Ray diffraction system with a data collector.  
2. Differential Scanning Calorimetric (USP <891>) – approximately 100mg of sample was 
weighed onto a tared zero aluminium pan and covered with the lid. The sample was loaded 
into a TA Instruments Q2000 differential scanning calorimetric unit and thermally 
equilibrated at 25°C. The sample was then heated to 180°C at a rate of 10°C/min; all 
activities were carried out under a nitrogen purge. 
3. Thermogravimetric Analysis (USP <891>) – approximately 100mg of sample was weighed 
onto a platinum pan, with the precise weight recorded on the thermogram. The sample was 
loaded into a TA Instruments Q500 thermogravimetric analyzer and heated from room 
temperature to 200°C at a rate of 10°C/min, using the dynamic high resolution mode. All 
activities were carried out under a nitrogen purge. 
4. Image analysis (USP <776>) – a small sample was spread onto a glass slide and mixed with a 
drop of 0.2% lecithin in mineral oil with a cover slip on top. The sample was then examined 
under polarized light using an Olympus BX61 microscope.  
5. Scanning electron microscope (USP <776>) – a small sample was mounted onto and 
scanning electron microscope stub using carbon conductive tape. The sample was then 
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analyze using a Hitachi TM-3000 microscope under accelerating voltages of 15 Kilo Volts 
and charged up reduced mode.  
6.  Particle size by laser diffraction, specific surface area, surface weighted mean diameter and 
volume weighted mean diameter were all performed using the same method (USP <776>). 
The flow cell was installed and the dispersion unit connected onto the Malvern Mastersizer 
2000 particle size analyser. A 0.04% lecithin in kerosene reagent was added to the dispersion 
unit until detected by the sensor. The system was set at 2500 rpm with no ultrasound and 
approximately 400mg of sample was added directly to the dispersion unit until the 
obscuration value reached between 5 - 20%. The sample was processed under “normal 
sensitivity” with the equivalent diameter distributions calculated on a volume percent and is 
reported as follows; 
D (v,0.1): - meaning that the volume at which 10% of the sample is under the target particle 
size equivalent diameter  
D (v,0.5): - meaning that the volume at which 50% of the sample is under the target particle 
size equivalent diameter  
D (v,0.9): - meaning that the volume at which 90% of the sample is under the target particle 
size equivalent diameter  
The target specification for each fraction, D (v,0.1), D (v,0.5) and D (v,0.9) is either NMT 
(not more than) or NLT (not less than) the target particle size equivalent diameter described 
in the individual specification for each material. 
7.  Fourier Transform Infra-Red (USP <851>) – a small sample was mixed and grounded with 
potassium bromide and made into a pellet by compressing the mixture under pressure. The 
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sample was loaded into a Perkin Elmer Spectrum 400 spectrometer and the spectrum was 
collected in transmittance mode. 
8.  Brunauer, Emmett and Teller Surface Area (USP <846>) – a sample of approximately 3 
grams was weighed and loaded into a Micrometrics Gemini III 2375 surface area analyser. 
The sample was degassed under nitrogen at 40°C for 16 hours prior to testing using the 
multipoint measurement method.  
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Table 3.9: The C of A listing the test and specifications for each test for the current source, 
company A and alternate source, company B for metformin HCl USP 
Test Company A (Specifications) Company B (Specifications) 
Appearance White, Crystalline powder White, Crystalline powder 
Identification  IR Spectrum: Corresponds to standard  IR Spectrum: Corresponds to standard  
Identification  Positive for Chloride  Positive for Chloride  
Loss on Drying  NMT 0.5% NMT 0.5% 
Sulphated Ash NMT 0.1% NMT 0.1% 
Heavy Metals  NMT 10 ppm  NMT 10 ppm  
Polymorphic 
Identity  
N/A 
X-ray diffraction: Corresponds to 
metformin HCl Form A standard 
Appearance of 
solution  
Clarity of Solution: 
Solution is clear 
Color of solution:  
Solution is Colorless 
Clarity of Solution: 
Solution is clear 
Color of solution:  
Solution is Colorless 
Organic Volatile 
Impurities  
Methanol: NMT 1000 ppm 
Isopropanol: NMT 1000 ppm 
Methylene Chloride: NMT 600 ppm  
Chloroform: NMT 60 ppm 
Trichloroethylene: NMT 80 ppm 
N-Butanol – NMT 500 ppm 
1,4-Dioxane: NMT 380 ppm  
Methanol: NMT1000ppm   
Residual Solvent  Trimethylamine: NMT 50 ppm  N/A 
Related Compounds  
MO RC1: NMT 0.02% 
MO RC2: NMT 0.05% 
MO RC3: NMT 0.1% 
Unidentified Impurity: NMT 0.10% 
each 
Total Impurity: NMT 0.6% 
MT RC1: NMT 0.02% 
MT RC3: NMT 0.05% 
 
Unidentified Impurity: NMT 0.05% 
each 
Total Impurity (excluding MT RC3): 
NMT 0.2% 
Assay  98.5 to 101.0% (dried basis)  98.5 to 101.0% (dried basis)  
Bulk Density  0.6 to 0.9 g/cc N/A 
Particle Size (Sieve)  
% Spl through #20 mesh: NLT 90% 
% Spl through #40 mesh: NLT 20% 
% Spl through #60 mesh: NLT 5% 
N/A 
N/A – Criteria not included in C of A and therefore not tested  
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Table 3.10:  The C of A listing the test and specifications for each test for the current source, 
company X and alternate source, Company Y for gabapentin USP  
Test Company X (Specifications) Company Y (Specifications)  
Appearance White to off-white powder White to off-white powder 
Identification  
HPLC Retention Time: Corresponds to 
standard    
HPLC Retention Time: 
Corresponds to standard    
Identification  IR Spectrum: Corresponds to Standard  
IR Spectrum: Corresponds to 
Standard  
Identification  Polymorphic form III: NMT 5.0% N/A 
Assay  98.5 to 101.5% (Anhydrous basis)  98.0 to 102.0 % (Anhydrous basis) 
Bulk Density  0.4 to 0.6 g/cc 0.40 to 0.66 g/cc 
Tapped Density  0.6 to 1.0 g/cc N/A 
Heavy Metals  NMT 0.002% NMT 0.002% 
Limit of Chloride  NMT 0.01% NMT 0.01% 
Residual Solvent  
Methanol: NMT 250 ppm 
Isopropanol: NMT 1000 ppm Toluene: 
NMT 100 ppm  
Acetone: NMT 100 ppm 
Ethanol: NMT 0.2% 
Particle Size  
Percent smaller than 250 um: NLT 95%  
Percent smaller than 150 um: NLT 45% 
N/A 
pH 6.8 to 7.4 6.5 to 8.0 
Related Compounds  
GA RC2: NMT 0.05% 
Unidentified Impurity: NMT 0.05% 
each 
Total Impurities: NMT 0.30% 
GA RC2: NMT 0.05% 
Unidentified Impurity: NMT 0.05% 
each 
Related Compounds 
(Limit of late eluting 
impurities) 
Any impurity: NMT 0.10% each Any impurity: NMT 0.05% each 
Total related 
Compounds Total Impurities: NMT 0.5% Total Impurities: NMT 0.5% 
Residue on Ignition  NMT 0.1% NMT 0.1% 
Water  NMT 0.3% NMT 0.5% 
N/A – Criteria not included in C of A and therefore not tested  
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Table 3.11:  The C of A listing the test and specifications for each test for the current process, 
copovidone NF/EP 35 and alternate process, copovidone NF/EP 20 for copovidone NF/EP 
Test Copovidone NF/EP 35 (Specifications)     
Copovidone NF/EP 20 
(Specifications) 
Appearance White or lightly yellowish powder  White or lightly yellowish powder  
Identification  Corresponds to ID B (USP) Corresponds to ID B (USP) 
Identification  IR Spectrum: Corresponds to Standard  IR Spectrum: Corresponds to Standard  
Appearance of 
Solution  
Clarity: Sample solution is not more 
opalescent than reference suspension III 
Colour: Sample solution is not more 
intensely coloured than reference solution 
B5, R5, OR BY5 
Clarity: Sample solution is not more 
opalescent than reference suspension 
III 
Colour: Sample solution is not more 
intensely coloured than reference 
solution B5, R5, OR BY5 
Aldehydes  
NMT 500 PPM(as acetaldehyde) NMT 500 PPM(as acetaldehyde) 
Ethenyl Acetate  
35.3 to 41.4% (dried basis) 35.3 to 41.4% (dried basis) 
Heavy Metals  NMT 20 ppm NMT 20 ppm 
Hydrazine  
Any spot corresponding to 
salicylaldehydrazine in chromatogram 
obtained with the test solution is not more 
intense than the spot in the chromatogram 
obtained with the reference standard (1 
ppm) 
Any spot corresponding to 
salicylaldehydrazine in chromatogram 
obtained with the test solution is not 
more intense than the spot in the 
chromatogram obtained with the 
reference standard (1 ppm) 
Impurity A NMT 0.5% NMT 0.5% 
Loss on Drying  
NMT 5.0% NMT 5.0% 
Monomers  NMT 0.1% NMT 0.1% 
Limit of Monomers  
2-Pyrrolidone: NMT 0.5% 
Vinyl Acetate: NMT 0.001% 
1-Vinyl-2-2Pyrrolidone: NMT 0.001% 
2-Pyrrolidone: NMT 0.5% 
Vinyl Acetate: NMT 0.001% 
1-Vinyl-2-2Pyrrolidone: NMT 0.001% 
Nitrogen  
7.0 to 8.0% (dried basis)  7.0 to 8.0% (dried basis)  
Peroxides  NMT 0.35% (400PPM) NMT 0.35% (400PPM) 
Sulphated Ash  NMT 0.1% NMT 0.1% 
Viscosity (AS K-
VALUE) 25.2 to 30.8% (dried basis) 25.2 to 30.8% (dried basis) 
Particle Size  
D (v,0.1): NLT 18um 
D (v,0.5): NMT 135um 
D (v,0.9): NMT 290um 
D (v,0.1): NLT 18um 
D (v,0.5): NMT 135um 
D (v,0.9): NMT 290um 
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Table 3.12:  The C of A listing the test and specifications for each test for the current source, 
Company J, and alternate source, Company K, for Fenofibrate EP/BP: 
Test Company J (Specifications)  Company K (Specifications) 
Appearance White to off white powder  White to off white powder  
Identification  N/A 
UV Spectrum: Corresponds to 
Standard  
Identification  IR Spectrum: Corresponds to Standard  
IR Spectrum: Corresponds to 
Standard  
Melting Point  79 to 82 
o
C 79 to 82 
o
C 
Halides (Expressed 
as Chloride) NMT 100 ppm  NMT 100 ppm  
Sulphates  NMT 100 ppm NMT 100 ppm 
Acidity 
Volume of 0.1 M NaOH required NMT 
0.2 mL 
Volume of 0.1 M NaOH required 
NMT 0.2 mL 
Loss on Drying  NMT 0.5% NMT 0.5% 
Sulphated Ash NMT 0.1% NMT 0.1% 
Heavy Metals  0.002% 0.002% 
Residual Solvents  Isopropanol: NMT 2000 ppm  
  
Acetone: NMT 1000 ppm 
Isopropanol: NMT 2000 ppm  
Chloroform: NMT 60 ppm  
Toluene: NMT 890 ppm  
Butyl acetate: NMT 1000ppm  
Related Compounds  
FF RC1: NMT 0.1% 
FF RC2: NMT 0.1% 
FF RC4: NMT 0.2% 
FF RC5: NMT 0.10% 
FF RC6: NMT 0.10% 
FF RC7: NMT 0.10% 
FF RC8: NMT 0.10% 
Unidentified Impurity: NMT 0.10% 
each 
Total Impurities: NMT 0.5% 
FF RC2: NMT 0.1% 
FF RC1: NMT 0.1% 
EP Imp. C: NMT 0.10% 
EP Imp. D: NMT 0.10% 
EP Imp. E: NMT 0.10% 
EP Imp. F: NMT 0.10% 
FF RC4: NMT 0.2% 
Unidentified Impurity: NMT 0.10% 
each 
Total Impurities: NMT 0.5% 
Assay  98.0% to 102.0% (dried basis) 98.5% to 101.0% (dried basis) 
Appearance of 
Solution   
Solution is clear and not more intensely 
colored than reference solution BY6 
Solution is clear and not more 
intensely colored than reference 
solution BY6 
Bulk Density  0.50 to 0.70 g/cc 0.50 to 0.70 g/cc 
N/A – Criteria not included in C of A and therefore not tested  
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Table 3.13:  The C of A listing the test and specifications for each test for the current source, 
Company G, and alternate source, Company H, for croscarmellose sodium NF/EP: 
Test Company G (Specifications) Company H (Specifications)  
Appearance 
White or greyish-white, free-flowing 
powder  
White or greyish-white powder 
Identification  
Reaction with Methylene Blue: Sample 
absorbs methylene blue 
Appearance of solution after settling: A 
blue fibrous mass is formed  
The sample absorbs the methylene 
blue and settles as a blue, fibrous 
mass 
Identification  
Corresponds to ID B. A reddish-violet 
Colour develops at the interface upon 
reaction with 1-Napthol TS 
A reddish – violet Colour develops 
at the interface  
Identification  Positive test for sodium  Positive to tests for sodium  
Identification  Positive to flame test for sodium  N/A 
Heavy Metals  NMT 20 ppm NMT 10 ppm 
Sulphated Ash  14.0 to 28.0% (dried basis) 14.0 to 28.0% 
Microbial Limits   
E.Coli: Absent in 1g 
Total Aerobic Microbial Count: NMT 
1000 cfu/g 
Total Yeast and Mould Count: NMT 
100 cfu/g 
E.Coli: Absent in 1g 
Total Aerobic Microbial Count: 
NMT 1000 cfu/g 
Total Yeast and Mould Count: 
NMT 100 cfu/g 
Particle Size  
D (v,0.5): NM 60um 
D (v,0.9): NMT 155 UM 
N/A 
pH N/A 5.0 to 7.0 
Degree of 
Substitution  
N/A 0.60 to 0.85 (dried basis) 
Sodium Chloride & 
Sodium Glycolate   
N/A NMT 0.5% (dried basis) 
Water Soluble 
substances 
N/A NMT 10.0% 
Loss on Drying  N/A NMT 10.0% 
Settling Volume  10 – 30ml  
(From Manufacturer’s C of A)  
10.0 to 30.0 mL 
N/A – Criteria not included in C of A and therefore not tested  
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3.5 - The Tablet Manufacturing Process  
Metformin tablets (batches 1 and 2) were manufactured by direct compression 
manufacturing process. The process flow diagram is presented in figure 3.1. The tablets were 
stored in high density polyethylene bottles until testing. The required amount of metformin HCl 
USP, methylcellulose USP A15LV, microcrystalline cellulose NF M102, polyethylene glycol NF 
8000, colloidal silicon dioxide NF and magnesium stearate NF were accurately weighed (Mettler 
Toledo, model XS204 and XS32001L). The metformin HCl USP, methylcellulose USP A15LV, 
microcrystalline cellulose NF M102 and colloidal silicon dioxide NF were screened using a 
Quadro Comil (Quadro Engineering, model 196) fitted with a 0.075” screen. The screened 
powders were then transferred to a 2.2 cu. ft. tumbler bin (Inox Industries, model IN-2.2) and 
mixed using a bin mixer (Servo – Lift, model PBL-600-H-FC-GP-575) for 24.5 minutes. The 
polyethylene glycol NF 8000 and magnesium stearate NF were hand screened through a 0.032” 
screen, added to the 2.2 cu. ft. tumbler bin and then mixed for an additional 1.5 minutes. The 
powder mix was then compressed into tablets using the instrumented tablet press (Korsch AG, 
model PH300 single sided). The tablet punch was 0.3125” x 0.6145” capsule shaped and 
standard cup in dimensions. 
  Gabapentin USP tablets (batches 3 –6) were manufactured by a compaction process. The 
process flow diagram is presented in figure 3.2. The tablets were stored in high density 
polyethylene bottles until testing. The required amount of gabapentin USP, copovidone NF/EP 
and magnesium stearate NF were accurately weighed. The gabapentin USP and copovidone 
NF/EP were screened using a Quadro comil fitted with a 0.045” screen. The screened powders 
were then transferred to a 2.2 cu. ft. tumbler bin and mixed for 10 minutes. The powder mix was 
then compacted into granules using the instrumented Gerteis compactor (Gerteis Maschinen + 
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Process Engineering AG, model Macro-Pactor 250/100/3) at targeted settings. The compacted 
granules were then transferred to a 2.2 cu. ft. tumbler bin. The magnesium stearate NF was hand 
screened through a 0.024” screen, added to the 2.2 cu. ft. Tumbler bin containing the compacted 
granules and then mixed for 3 minutes. The compacted granule mix was then compressed into 
tablets using the instrumented tablet press. The tablet punch was 0.3440” x 0.6875” modified 
concave, oval shape in dimensions. 
Fenofibrate EP/BP tablets (batches 7 –10) were manufacture by a hot melt technology 
process. The process flow diagram is presented in figure 3.3. The tablets were stored in high 
density polyethylene bottles until testing. The required amount of Fenofibrate EP/BP and 
croscarmellose sodium NF/EP were accurately weighed. The Fenofibrate EP/BP was loaded into 
a 30 L stainless steel vessel and heated using a hot plate (Cimarec, model HP131535) to 100oC 
until melted. The croscarmellose sodium NF/EP was then slowly added while mixing (Lightnin, 
model XIP25/XJ43) until a smooth, lump free suspension was formed. The suspension was 
poured into high density polyethylene containers to cool and solidify for at least 12 hours. The 
solid material was pulverized using a granumil (Fluid Air Inc., model GUM) fitted with a 0.625” 
screen. The material that went through the 0.625” screen was again pulverized using a granumil 
fitted with a 0.109” screen. The screened powders were then transferred to a 2.2 cu. ft. tumbler 
bin and mixed for 5 minutes. The milled granule mix was then compressed into tablets using the 
instrumented tablet press. The tablet punch was 0.2620” x 0.5020” modified oval, concave shape 
in dimensions. 
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3.6 - Processing tests 
3.6.1 - Sieve Analysis  
The sieve profile was obtained by weighting five grams of material and placing it on the 
top, #20 mesh screen, of a Gilsonic Autosiever (Gilson Company Inc., model GA-6). In addition 
to the #20 mesh screen the #40, #60, #80, #100, #200 and a fines screen collector were used. The 
autosiever tapped the material for 5 minutes. The material retained on each screen was weighed 
and reported as a percentage of the total initial weight (five grams) of the material. This was 
completed once for all batches at the final blend stage, while two additional samples were tested 
for batches 3 –10, during either the granulation stage (batches 3 –6) or the milling stage (batches 
7 –10) at the beginning and end of their respective processes. 
3.6.2 - Flow Index 
In the pharmaceutical industry most powders are blended in bins and then flow through a 
discharge chute at the bottom of the bin to supply material to the tableting or capsule-filling 
machines. As a result, the ability of the material to flow through an orifice is of great value. This 
is also of value because of the need to deliver material to the die cavity of the tableting or 
capsule-filling machines to form a tablet or capsule, which is usually in the milligram range and 
rarely exceeds 1 gram. As a result a different approach is used to determine the flow of material 
to predict its ability to flow from the bin. This is done by using a Hanson Flodex Test Instrument, 
which utilizes a flow measurement disk at the bottom of a cylindrical container with an orifice at 
the centre of the disk ranging from 4 mm – 34 mm (figure 3.4)97. The materials ability to flow 
through a smaller orifices means that it has better flow properties. 
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Figure 3.4: The Hanson Flodex Test Instrument used in the determination of blend powder flow 
properties for the three formulations97. 
 
The flow index was determined by weighing 100 grams of material and placing it in the 
flodex (Hansen Research, model 21-101-050) containing a disk with different orifices ranging 
from 4 mm to 34 mm. The orifice at which the material flows freely through was reported as the 
flow index. This was completed once for all batches at the final blend stage, while two additional 
samples were tested for batches 3 –10, during either the granulation stage (batches 3 –6) or the 
milling stage (batches 7 –10) at the beginning and end of their respective processes. 
3.6.3 - Bulk Density  
The bulk density is measured by pouring 100 mL of powder into a 100 mL graduated 
cylinder. The net weight is then recorded and the density was determined by dividing the weight 
by the volume (100 mL). This was completed once for all batches at the final blend stage, while 
two additional samples were tested for batches 3 –10, during either the granulation stage (batches 
3 –6) or the milling stage (batches 7 –10) at the beginning and end of their respective processes. 
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3.6.4 - Tapped Density  
The tapped density is measured by taking the graduated cylinder filled with powder from 
the bulk density testing and tapping it 100 times using a tap density tester (Vankel, model 50-
12000). The final volume is recorded and the tapped density is determined by dividing the net 
weight from the bulk density testing by the final volume after the tapping. This was completed 
once for all batches at the final blend stage, while two additional samples were tested for batches 
3 –10, during either the granulation stage (batches 3 –6) or the milling stage (batches 7 –10) at 
the beginning and end of their respective processes. 
3.6.5 – Hausner ratio and Carr Index 
The Hausner ratio is a measure of the ratio of the tapped bulk density over the poured 
bulk density calculated according to Equation 3.1. The Hausner Ratio can vary from 
approximately 1.2 to 1.6 with the powder becoming more cohesive and therefore less free 
flowing as the number increases. The Carr Index or compressibility index is the percentage of the 
tapped bulk density minus the poured bulk density divided by the poured bulk density and 
calculated according to Equation 3.2. The Carr Index Classification and Powder Flowability are 
described in table 3.1453. 
 
𝐻𝑎𝑢𝑠𝑛𝑒𝑟 𝑅𝑎𝑡𝑖𝑜 =  
𝑡𝑎𝑝𝑝𝑒𝑑 𝑑𝑒𝑛𝑠𝑖𝑡𝑦
𝑝𝑜𝑢𝑟𝑒𝑑 𝑑𝑒𝑛𝑠𝑖𝑡𝑦
                    (Equation 3.1) 
 
 
𝐶𝑎𝑟𝑟 𝐼𝑛𝑑𝑒𝑥 =  
𝑡𝑎𝑝𝑝𝑒𝑑 𝑑𝑒𝑛𝑠𝑖𝑡𝑦 − 𝑝𝑜𝑢𝑟𝑒𝑑 𝑑𝑒𝑛𝑠𝑖𝑡𝑦
𝑝𝑜𝑢𝑟𝑒𝑑 𝑑𝑒𝑛𝑠𝑖𝑡𝑦
 X 100      (Equation 3.2) 
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Table 3.14: Carr Index Classification and Powder Flowability used to theoretically characterize 
the APIs, Excipients and the blends of the 10 batches executed  
Carr Index (%) Powder Flowability  
5 – 12 Free flowing  
12 – 16 Good 
18 - 21 Fair 
23 - 35 Poor 
33 - 38 Very poor  
40 Extremely poor  
 
3.7 - Critical Quality Attribute testing  
3.7.1 - Tablet Weight  
Ten (10) tablets from the start, 20%, 40%, 60%, 80% completion and end of each batch 
were individually weighed in milligrams (mg) on an analytical balance. The minimum weight, 
maximum weight, average weight, standard deviation (STDEV) and Coefficient of Variation 
(CV) was reported. Additional samples were tested for some of the batches at the start of the 
compression runs due to the fact that the CQAs were not met at the compression force that was 
initially targeted.  
3.7.2 - Tablet Thickness 
The thickness in inches (ins) were measured individually for 10 pre-weighed tablets from 
the start, 20%, 40%, 60%, 80% completion and end of each batches by using a hand held 
thickness gauge (Mitutoyo, model 547-300). The minimum thickness, maximum thickness, 
average thickness, STDEV and CV were reported.  
3.7.3 - Tablet Hardness 
The hardness in kilopound (kp)  were measured individually for 10 pre-weighed tablets 
from the start, 20%, 40%, 60%, 80% completion and end of each batch by using a hardness tester 
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(Pharmatron, model 6D). The minimum hardness, maximum hardness, average hardness, 
STDEV and CV were reported.  
3.7.4 - Tablet Friability  
The friability was measured from the start, 20%, 40%, 60%, 80 % completion and end of 
each batch by weighing 10 tablets or approximately 6.5 grams and rotating the tablets in a 
friabilator (Vankel, model Friabilator and Sotax, model F1) at 25 Revolutions Per Minute for 
four minutes and twenty minutes respectively. The loss of weight was recorded as a percentage 
of the total initial weight at four minutes and then at twenty minutes.  
3.7.5 - Tablet Disintegration 
The disintegration was measured from the start, 20%, 40%, 60%, 80% completion and 
end of each batch by placing six tablets in the disintegration apparatus (Vankel, model 
Disintegration). The minimum time was recorded as the first tablet to completely disintegrate 
into granules and pass through a disk with an aperture of 1.8mm – 2.2mm and the maximum 
time was when the last tablet completely disintegrated and passed through a disk with an 
aperture of 1.8mm – 2.2mm.  
3.8 – Drug product performance testing  
3.8.1 - Uniformity of dosage unit    
The dosage uniformity was assessed according to the USP requirements <USP 905> 
where the acceptable value for stage one testing is < 15.0%96. A composite sample was prepared 
by taking ten tablets from the start, 20%, 40%, 60%, 80% completion and end of each batch. The 
metformin HCl, gabapentin USP and fenofibrate EP/BP were tested by accurately weighing ten 
tablets randomly selected from the composite sample of each batch. The uniformity was then 
calculated using the following equation: 
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% 𝑜𝑓 𝑐𝑙𝑎𝑖𝑚 =  
𝑊𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑖𝑛𝑑𝑖𝑣𝑖𝑑𝑢𝑎𝑙 𝑡𝑎𝑏𝑙𝑒𝑡 𝑥 𝐴𝑠𝑠𝑎𝑦 𝑟𝑒𝑠𝑢𝑙𝑡𝑠 (%)
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 10 𝑡𝑎𝑏𝑙𝑒𝑡𝑠 
  (Equation 3.3) 
 
 
The Acceptable Value is calculated using the following equation:  
𝐴𝑐𝑐𝑒𝑝𝑡𝑎𝑏𝑙𝑒 𝑉𝑎𝑙𝑢𝑒 =   |𝑀 − ?̅?| + 𝑘𝑠                                     (Equation 3.4) 
Where; 
M = Target value (100%) 
?̅? = Mean of individual content  
k  = Acceptable constant (2.4)  
s  = Sample STDEV  
 
 The Acceptable Value is based on the sum of two components, the first being how much 
difference there is between the target value (M) and the process mean (?̅?) which is |𝑀 − ?̅?|.The 
second is the variability in the number of units tested which is calculated by multiplying the 
Acceptable constant k (2.4 for 10 tablets) with the STDEV of the 10 samples tested.    
3.8.2 - Assay of API content in tablets  
The assays of the API content in the tablets were assessed according to the USP 
requirements <USP 905> where the acceptance criterion for stage one testing is an average of 
90% - 110% for the API present in 20 tablets96. The metformin HCl, gabapentin USP and 
fenofibrate EP/BP tablets were tested using their respective High Pressure Liquid 
Chromatography (HPLC) methods for assay. A composite sample was prepared by taking ten 
tablets from the start, 20%, 40%, 60%, 80% completion and end of each batch, twenty tablets 
from the composite sample was randomly selected and tested for assay of the API content. 
Metformin Hydrochloride Tablets: 
The mobile phase was 95% of phosphate buffer with a pH of 3.00 ± 0.05 and 5% of 
acetonitrile. The chromatographic conditions are listed in table 3.15. Twenty tablets were 
accurately weighed to determine the average weight. The tablets were grounded into a fine 
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powder and 200mg was weighed and transferred to a volumetric flask containing the mobile 
phase, used as the sample solvent. The solution was diluted to 0.1 mg/mL of metformin HCl. The 
standard was prepared by accurately weighing out 50mg of metformin HCl reference standard, 
transferred to a volumetric flask containing the sample solvent and diluted to 0.1 mg/mL. Sample 
solvent was injected to ensure the system is stable, follow by five calibrated standard injections, 
sample injections and one standard injection at the end.  
Table 3.15: The chromatographic conditions for the HPLC equipment used to test for the assay 
of the API in the metformin HCl tablets 
Parameter  Specification  
Column type  Symmetry C 18 
Dimensions  4.6 x 50 mm 
Particle size  3.5 µm 
Column temperature  25°C 
Detector wavelength  218 nm  
Needle wash Acetonitrile/Water (1:1) 
Column wash Acetonitrile/Water (1:1) 
Filter  Pall Acrodisc nylon 0.45 µm 
Flow rate  1.0 mL/minute 
Injection volume  10 µL 
Total run time  5 minutes 
Post run time  Off 
Retention time  2.3 minutes  
Trailing factor  NMT: 2.0 
Column efficiency NLT: 1000 
 
Gabapentin USP Tablets: 
The mobile phase was 94% of Phosphate buffer with pH of 6.90 ± 0.1 and 6% of 
Acetonitrile. The chromatographic conditions are listed in table 3.16. 
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Table 3.16: The chromatographic conditions for the HPLC equipment used to test for the assay 
of the API in the gabapentin USP tablets  
Parameter  Specification  
Column type  Waters Xbridge C 18 
Dimensions  4.6mm x 25 cm 
Particle size  5 µm 
Column temperature  Ambient 
Detector wavelength  210 nm  
Needle wash Acetonitrile/Water (3:47) 
Column wash Acetonitrile/Water (3:47) 
Flow rate  1.2 mL/minute 
Filter  Pall Acrodisc nylon 0.45 µm 
Injection volume  10 µL 
Total run time  10 minutes 
Post run time  Off 
Retention time  7.0 minutes  
Trailing factor  NMT: 2.0 
Column efficiency NLT: 7000 
 
Twenty tablets were accurately weighed to determine the average weight. The tablets 
were grounded into a fine powder and 100mg was weighed and transferred to a volumetric flask 
containing the mobile phase, used as the sample solvent. The solution was diluted to 4 mg/mL of 
gabapentin USP. The standard was prepared by accurately weighing out 100mg of gabapentin 
USP reference standard, transferred to a volumetric flask containing the sample solvent and 
diluted to 4 mg/mL. Sample solvent was injected to ensure the system is stable, follow by five 
calibrated standard injections, sample injections and one standard injection at the end.  
Fenofibrate EP/BP Tablets: 
The mobile phase was 20% of phosphate buffer with a pH of 3.0 ± 0.5 and 80% of 
acetonitrile. The chromatographic conditions are listed in table 3.17 
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Table 3.17: The chromatographic conditions for the HPLC equipment used to test for the assay 
of the API in the fenofibrate EP/BP tablets 
Parameter  Specification  
Column type  Waters Delta Pak C 18 
Dimensions  3.9 x 150 mm 
Particle size  5 µm 
Column temperature  Ambient 
Detector wavelength  290 nm  
Needle wash Acetonitrile/Water (80:20) 
Column wash Acetonitrile/Water (80:20) 
Filter  Pall Acrodisc nylon 0.45 µm 
Flow rate  1.0 mL/minute 
Injection volume  10 µL 
Total run time  8 minutes 
Post run time  Off 
Retention time  2.5 minutes  
Trailing factor  NMT: 2 
Column efficiency NLT: 2000 
 
Twenty tablets were accurately weighed to determine the average weight. The tablets 
were grounded into a fine powder and 50mg was weighed and transferred to a volumetric flask 
containing the mobile phase, used as the sample solvent. The solution was diluted to 0.05 mg/mL 
of fenofibrate EP/BP. The standard was prepared by accurately weighing out 50mg of fenofibrate 
EP/BP reference standard, transferred to a volumetric flask containing the sample solvent and 
diluted to 0.05 mg/mL. Sample solvent was injected to ensure the system is stable, follow by five 
calibrated standard injections, sample injections and one standard injection at the end.  
3.8.3 - Dissolution   
The in-vitro drug release was performed for the manufactured tablets as per the drug 
product dissolution procedure using an automated dissolution system (Distek, model 
2100A/2100B/2100C). The metformin HCl tablets, gabapentin USP tablets and fenofibrate 
EP/BP tablets were analyzed using Ultraviolet spectrophotometer.  A composite sample was 
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prepared by taking ten tablets from the start, 20%, 40%, 60%, 80% completion and end of each 
batch. Six tablets were randomly selected from the composite sample of each batch and tested for 
dissolution. Any failure in the dissolution test will lead to a failure in the qualification of the 
alternate source of the material as it is the most critical test to determining equivalency of not 
only two sources of material but between any two drug product batches.  
Metformin Hydrochloride tablets: 
The dissolution medium was 1000 mL of 0.68% phosphate buffer prepared using 
potassium phosphate monobasic, pH was maintained using 1 N sodium hydroxide. The standard 
solution was prepared by accurately weighing 20mg of metformin HCl USP reference standard 
and diluting to a concentration of 0.01 mg/mL using the dissolution medium as the solvent. Each 
of the dissolution vessels were filled with 1000 mL of dissolution medium and allow to stand 
until the temperature stabilized, the operational parameters are listed in table 3.18. One tablet 
each was placed in each of the six dissolution vessels, the apparatus was immediately started 
with a stirring speed of 100 rpm. 10 mL was withdrawn at the specified time points for analysis. 
The sample solution was prepared by transferring 4.0 mL of filtered sample into a 200 mL 
volumetric flask and dilute to volume using the dissolution medium. The UV spectrophotometer 
was zeroed with dissolution medium, the absorbance of standard solution was read; follow by 
sample solution and by standard solution at the end. 
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Table 3.18: The operational parameters for the dissolution apparatus used for the metformin HCl 
tablets dissolution test   
Parameter  Specification  
pH 6.8 ± 0.05 
Apparatus   USP 1 with baskets  
Stirring speed  100 rpm 
Time points 10, 15, 20, 30, 45, 60 minutes  
Detector wavelength 234 nm  
Stationary Cell 1.0 cm 
Temperature  37.0 ± 0.5°C 
Filter  0.45 µm Nylon 
 
Gabapentin USP tablets: 
The dissolution medium was 900 mL of 0.06N Hydrochloric acid prepared by adding 30 
mL of hydrochloric acid to 6000 mL of purified water. Each of the dissolution vessels were filled 
with 900 mL of dissolution medium and allow to stand until the temperature stabilized, the 
operational parameters are listed in table 3.19. One tablet each was placed in each of the six 
dissolution vessels, the apparatus was immediately started with a stirring speed of 50 rpm. 3 mL 
was withdrawn at the specified time points for analysis. 
Table 3.19: The operational parameters for the dissolution apparatus used for the gabapentin 
USP tablets dissolution test   
Parameter  Specification  
Apparatus   USP II with paddles  
Stirring speed  50 rpm 
Time points 5, 10, 15, 30, 45, 60 minutes  
Stationary Cell 1.0 cm 
Temperature  37.0 ± 0.5°C 
Filter  0.45 µm Nylon 
 
The mobile phase was 94% of Phosphate buffer with pH of 6.90 ± 0.1 and 6% of 
Acetonitrile. The chromatographic conditions are listed in table 3.16. 
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The standard was prepared by accurately weighing out 110 mg of gabapentin USP 
reference standard, transferred to a volumetric flask containing the sample solvent and diluted to 
660 mg/mL. Dissolution medium was injected to ensure the system is stable, follow by five 
calibrated standard injections, sample injections and five standard injections at the end.  
Fenofibrate EP/BP tablets: 
The dissolution medium was 900 of 0.1N sodium lauryl sulphate prepared by dissolving 
173.0 grams of sodium lauryl sulphate in 6,000 mL of purified water. The standard solution was 
prepared by accurately weighing 55 mg of fenofibrate EP/BP reference standard and diluting to a 
concentration of 0.018 mg/mL using a dissolution medium as the solvent.  
Table 3.20: The operational parameters for the dissolution apparatus used for the fenofibrate 
EP/BP tablets dissolution test   
Parameter  Specification  
Apparatus   USP II with paddles 
Stirring speed  100 rpm 
Time points 5, 10, 15, 30, 45, 60 minutes  
Detector wavelength 290 nm  
Stationary Cell 1.0 cm 
Temperature  37.0 ± 0.5°C 
Filter  0.45 µm Nylon 
 
Each of the dissolution vessels were filled with 900 mL of dissolution medium and allow 
to stand until the temperature stabilized, the operational parameters are listed in table 3.20. One 
tablet each was placed in each of the six dissolution vessels, the apparatus was immediately 
started with a stirring speed of 100 rpm. 10 mL was withdrawn at the specified time points for 
analysis. The sample solution was prepared by transferring 2.0 mL of filtered sample into a 25 
mL volumetric flask and dilute to volume using the dissolution medium. The UV 
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spectrophotometer was zeroed with dissolution medium, the absorbance of standard solution was 
read; follow by sample solution and by standard solution at the end. 
3.9 – Statistical evaluation     
A two tailed t-test with a critical p (probability) value of 0.05 will be performed to evaluate if 
there is any significant difference with two different set of test results from two different sources 
of the API and Excipient (specific objective 2, section 2.4). The evaluation will be completed on 
the 5 pairs of materials listed in table 3.1 by comparing current source of material with the 
alternate source of material. For the purpose of this evaluation a minimum of three batches will 
be tested for each source of material and therefore at least three data point will be available for 
each test. The p value represents the probability that the two sets of results are from the same 
population (i.e. there is no actual difference between the means of the two sets). The probability 
p is derived based on the t value under the t distribution with the specific degree of freedom. The 
t value is the ratio of the difference in the average of the two sets of data and the combination of 
the STDEV and the sample size of the same two data sets.  The degree of freedom is the total 
number of samples from both sources minus two, which represents the two means from the two 
sets of test results.  
The significance level was set at 0.05, meaning that any p value less than 0.05 is indicative that 
probability that the two sets are from the same population is less than 5%; that is, the chance that 
there is no difference on their test results is 5% or less. This means the difference observed is 
true with a 95% confidence level. The two tailed t-test will be used to evaluate differences 
between the two sources of materials in the unit operations, CQAs, and drug product 
performance, if required (specific objectives 4 and 5).   
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3.10 – List of equipment used during the manufacturing and testing of the tablets   
A list of all equipment used in the execution and testing of these ten batches is listed in table 3.21 
and 3.21a.   
Table 3.21: List of the equipment used during the testing of the raw materials used, manufacture 
of the tablets and testing of the tablets; with the equipment manufacturer name and the 
equipment model number: 
DESCRIPTION MANUFACTURER MODEL NUMBER 
      
Quadro comil  Quadro Engineering  Model 196 
Tablet press  Korsch AG PH300 Single Sided 
Compactor Gerteis Maschinen + Process 
Engineering  AG 
MACRO-PACTOR 
250/100/3 
Granumil Fluid Air INC. GUM  
Mixer Lightnin    X1P25/XJ43 
Balance - LAB 200g Mettler Toledo XS204 
Balance - 32100 G. Mettler Toledo XS32001L 
Gauge-Thickness-Mitutoyo Mitutoyo 547-300 
Tester-Hardness-6D Pharmatron 6D 
Tester-Friability-Vankel Vankel FRIABILATOR 
Tester-Friability-Sotax Sotax F1 
Tester-Flowability-Flodex Hanson Research 21-101-050 
Sieve-Shaker-Gilsonic Gilson Company INC. GA-6 
Tester-Density-Tap-Vankel Vankel 50-1200 
Sieve-Shaker-Rotap Tyler RX-29 
Mini Bin-2.2 Cu Ft INOX Industries IN-2.2 
Tester-Disintegration-Vankel Vankel DISINTEGRATION 
Disintegration Apparatus Hanson Research 39-400-460 
Hot Plate-Cimarec Cimarec HP131535 
Blender-Mini Bin Servo-Lift PBL-600-H-FC-GP-575 
Kit-Test Weight Mettler Toledo CLASS F 
Particle Size Analyzer Malvern MASTERSIZER2000 
Surface Area Analyzer Micrometrics GEMINI III 2375 
Polarized Microscope Olympus BX60/BX61 
Stereomicroscope   Olympus SZX12 
Scanning Electron Microscope 
 
Hitachi 
 
TM3000 
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Table 3.21a: List of the equipment used during the testing of the raw materials used, 
manufacture of the tablets and testing of the tablets; with the equipment manufacturer name 
and the equipment model number: 
FT-IR Microscope Perkin Elmer 
PARAGON1000PC/ 
SPECTRUN 400 
Differential Scanning Calorimetry   TA Instruments Q2000 
Thermo Gravimetric  Analyzer  TA Instruments Q500 
X - Ray Diffraction  System PanAnalytical L INC. PW3040/60 
Balance – Lab Mettler Toledo  
AX205/AG285/ 
PB211D/XP603S/ 
MX5/XP2U/XP56 
Balance – Lab Sartorius BP211D 
 
 
HPLC system Agilent 
1200/1201/1202 
INFINITY SERIES 
Dissolution System Distek 2100A/2100B/2100C 
pH Meter – Lab Fisher Scientific AR20 
Purified Water System Millipore ADVANTAGE A10 
Purified Water System Thermo Scientific 7148 
Timer – Lab VWR 62344-641 
Rotameter – Lab Praxair MS4-LRB-1/4-D5 
Thermocouple - Lab  VWR 61220-601 
Oven – Lab Sheldon Manufacturing   Inc. 1410M 
IR Spectrophotometer  Perkin Elmer SPECTRUM TWO 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
76 
 
Chapter – 4: Results and Discussion 
 
All results for the API and Excipient in – process testing and analytical testing are summarized 
below, and tabulated (in detail) in the appendices of this thesis.  Results will be discussed in the 
same pairings and batch numbers introduced in Chapter 3.  
4.1 - Metformin HCl USP (batch 1, company A; and batch 2, company B)  
4.1.1 - Metformin HCl C of A testing  
The two APIs from the two sources were tested according to the requirements of the C of 
A for each source and the C of A requirements were met (see table 4.1 and 4.1a). As a result of 
meeting specifications, the materials from the two sources would be deemed equivalent. There 
were differences in the specifications for organic volatile impurities and related compounds. The 
C of As for four batches from each source of material was evaluated to determine if there were 
any differences within the sources of the material. There was no substantial variability in the 
results from the C of A within the four batches for each source of API (refer to table A1.1 in the 
appendices). A CV of 25% and 40% was seen with the loss on drying (LOD) results from 
company A and B respectively, however, with a limit of NMT 0.5% and results reported to one 
decimal figure this was predictable. A similarly high CV of 24% and 26% was seen with 
methanol from company A and B respectively.  
 A two tailed t-tests with a critical p (probability) value of 0.05 was performed to 
determine if there were any significant differences between the two sources of material. The 
LOD and methanol tests were shown to be significantly different between the two sources of 
material.  The mean LOD for Company A was 0.375 % with a STDEV of 0.096 %, the mean 
LOD for Company B was 0.125 % with a STDEV of 0.050 % and t-test: t(6) = -4.63, p-value = 
0.0036. The mean methanol for Company A was 48.500 ppm with a STDEV of 11.504 ppm, the 
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mean methanol for Company B was 276.000 ppm with a STDEV of 71.447 ppm and t-test: t(6) = 
6.287, p-value = 0.0008. 
Moisture is known to impact both the compaction and compression processes of powders 
and can also impact the flow properties and stability of the drug product98, 99. The significant 
difference observed in the moisture could be a contributing factor to the challenges observed 
with the compression of the blend using Company B material (as discussed in section 4.1.3 of 
this chapter). 
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Table 4.1: The C of A listing the tests, specifications and testing results for metformin HCl USP 
API from Company A and Company B used in batch 1 and batch 2 respectively.  
Test Specifications   
Results  
(Company A) 
Results 
(Company B) 
Appearance White, Crystalline powder Conforms  Conforms  
Identification  
IR Spectrum: Corresponds to 
standard  
Conforms  Conforms 
Identification  Positive for Chloride  Conforms  Conforms 
Loss on 
Drying  
NMT 0.5% 0.3% 0.2% 
Sulphated 
Ash 
NMT 0.1% 0.0% 0.0% 
Heavy 
Metals  
NMT 10 ppm  Less than 10 ppm  Less than 10  
Polymorphic 
Identity  
X-ray diffraction: Corresponds 
to metformin Form A standard 
N/A Conforms  
Appearance 
of solution  
Clarity of Solution: 
Solution is clear 
Color of solution:  
Solution is Colorless 
Conforms 
 
Conforms  
Conforms 
 
Conforms  
Organic 
Volatile 
Impurities  
Methanol: NMT 1000 ppm 
Isopropanol: NMT 1000 ppm 
Methylene Chloride: NMT 600 
ppm  
Chloroform: NMT 60 ppm 
Trichloroethylene: NMT 80 ppm 
N-Butanol – NMT 500 ppm 
1,4-Dioxane: NMT 380 ppm  
61 ppm 
ND 
 
ND 
ND 
ND 
ND 
ND 
238 ppm 
 
N/A 
N/A 
N/A 
N/A 
N/A 
N/A 
Residual 
Solvent  Trimethylamine: NMT 50 ppm  13 ppm N/A 
Related 
Compounds  
MO RC1: NMT 0.02% 
MO RC2: NMT 0.05% 
Unidentified Impurity: NMT 
0.10% each 
Total Impurity: NMT 0.5% 
MO RC3: NMT 0.1% 
Total Impurity: NMT 0.6% 
BRT 
BRT 
BRT 
 
BRT 
BRT 
BRT 
N/A 
N/A 
N/A 
 
N/A 
N/A 
N/A 
N/A – Criteria not included in C of A and therefore not tested  
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Table 4.1a: The C of A listing the tests, specifications and testing results for metformin HCl USP 
API from Company A and Company B used in batch 1 and batch 2 respectively.  
Test Specifications   
Results  
(Company A) 
Results  
(Company B) 
Related 
Compounds  
MT RC1: NMT 0.02% 
Unidentified Impurity: NMT 
0.05% each 
Total Impurity: NMT 0.2% 
MT RC3: NMT 0.05% 
N/A 
 
N/A 
N/A 
N/A 
BRT 
 
BRT 
BRT 
ND 
Assay of 
API 98.5 to 101.0% (dried basis)  99.9% 100.3% 
Bulk 
Density  0.6 to 0.9 g/cc 0.7 g/cc N/A 
Particle Size 
(Sieve)  
% through #20 mesh: NLT 90% 
% through #40 mesh: NLT 20% 
% through #60 mesh: NLT 5% 
100% 
85% 
54% 
N/A 
N/A – Criteria not included in C of A and therefore not tested  
 
Acronyms used in table 4.1 and 4.1a: 
BRT – Below reporting threshold  
IR – Infrared  
MO RC – Metformin HCl related compound  
MT RC – Metformin HCl related compound 
ND – None detected 
NLT – Not less than   
NMT – Not more than  
ppm – Parts per million  
 
 4.1.2 – Additional testing for metformin HCl  
The additional tests performed were particle size, specific surface area, surface weighted 
mean diameter, volume weighted mean, bulk density, tapped density, FT-IR (Microscope), DSC, 
TGA, image analysis and powder X-Ray diffraction.  
The C of A for material supplied by Company A has a requirement for bulk density and 
particle size while the C of A for material supplied by Company B does not; however both were 
tested for, bulk density, tapped density and particle size as a means of comparison. There were 
measurable differences in the results obtained for the bulk density, tapped density and the particle 
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size, with all of these properties being larger for the metformin HCl supplied by Company A (see 
table A1.2 in the appendices). The metformin HCl supplied by Company A also had higher 
specific surface area and volume weighted mean diameter while surfaced weighted mean 
diameter was substantially lower. The material supplied by Company A not only had a larger 
particle size, but also had a higher variation in sizes, ranging from 2 µm to 1000 µm, while 
material from Company B ranged in size from 10 µm to 900 µm, (see table A1.2 in the 
appendices). Image analysis was one of the tests completed that was not part of the C of A for 
either source; the images in figure 4.1 A and 4.1 B clearly indicate differences in the crystal 
shape and particle size of the two materials. The material supplied by Company A was more 
prismatic or bipyramid while material supplied by Company B was more acicular or needle like. 
While there was a significant difference in shape observed from the image analysis, the X-Ray 
diffraction pattern of the metformin HCl from Company A and Company B in figure 4.2, 
compare excellently to the reference profile for metformin HCl (crystal form A) and indicates 
that there were no other polymorphs present.  The DSC thermograms (see figures A1.2 and A1.3 
in the appendices) indicate that the phase transition for metformin HCl occurred at 
approximately the same temperature (232.7oC and 231.9oC for material from Company A or 
Company B, respectively) and over a similar temperature range (2.25°C and 1.4°C for material 
from Company A and Company B, respectively) indicting the similarities in the two materials. 
The TGA (see figures A1.4 and A1.5 in the appendices) indicates no difference in the physical 
and chemical properties of the material while the FT-IR (see figure A1.1 in the appendices) 
showed similar infrared absorption patterns.   
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Figure 4.1: Image analysis for metformin HCl USP from Company A (A) and Company B (B). 
The differences in both particle size and shape are clearly evident. 
 
 
Figure 4.2: The powder X-Ray Diffraction spectrum for metformin HCl USP (Company A, 
Company B, and Standard Form A) indicating identical 2Theta values for major peaks. This 
clearly demonstrates that the material form both Company A and Company B are the same 
crystalline From A.     
A B 
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The relative rate at which molecules deposit on the crystal faces ultimately determines 
the final shape of a crystal100. It was already discussed in the introduction that many factors such 
as the degree of supersaturation, crystallizing solvent, temperature, rate of cooling and others can 
all affect the rate of deposition on the faces and therefore have an impact on the properties of the 
crystals25, 26. A review of the manufacturing process for metformin HCl reveals two differences 
that could potentially explain the difference in particle size and morphology of the two materials. 
The first was the use of different solvents, with Company A using xylene and purified water 
during the reaction step, and methanol and purified water during the purification step. Company 
B uses isopropyl alcohol during the reaction step and ethanol during the purification step. The 
second and perhaps more substantial  difference in the synthesis of metformin HCl is the 
difference in process, with Company A using two solvents at each stage indicating a two phase 
system  using water as the solvent for the highly soluble metformin HCl and methanol for the 
impurities. These differences in the synthetic procedure for metformin HCl (shown in figure 
4.3A and 4.3B) 101, 102 were likely the source of the difference in the material properties observed. 
In particular, the final step in the synthetic procedure used by Company A could result in less 
impurities being present in the final API as the two phase system is more efficient at removing 
residual solvents and impurities. This being said, the residual solvent and impurity levels 
reported by each company were comparable, with the exception of methanol being higher in the 
metformin HCl supplied by Company B. 
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Figure 4.3:  Synthetic schemes for metformin HCl manufactured by (A) Company A101, and (B) 
Company B102 showing differences in both the process and the solvents used in the manufacture 
of the APIs.  
 
4.1.3 – Processing and critical quality attributes evaluation  
The manufacturing process for the complete drug product was direct compression, with 
the final tablets containing 83.9% ʷ/w metformin HCl. The same lot of excipients was used in 
both batches (i.e. Batch 1 – Company A, and Batch 2 – Company B) and as a result, the physical 
properties of the blend were expected to be very similar to those for the respective API’s. The 
resulting bulk density, tapped density and particle size of the blend prepared with metformin HCl 
from Company A was higher than the blend with API from Company B (see table A1.3 in the 
appendices).  
It has been shown that there can be lot to lot variability on flow during processing of metformin 
HCl API depending on the age of the API103. It was therefore possible that the flow properties of 
A 
B 
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the two blends from different sources will be different. The Hausner ratio and Carr Index both 
provide an indication of the flowability of the blend 53, and as such both were calculated for the 
metformin HCl formulations and APIs from both sources.   
The Hausner ratios were determined to be 1.24 and 1.31, respectively for the blends containing 
API from Company A and Company B respectively.  These values indicate that the material flow 
was fair for both blends. The Carr Index was 24% and 31% respectively for the blends 
containing API from Company A and Company B indicating that the material flow was poor for 
both. Both of these measures indicated that the blend containing API from Company A had 
slightly better flow properties than the blend containing API from Company B. The Hausner 
ratio was 1.23 and 1.47 while the Carr Index was 23 % and 47 % (shown in table 4.2) 
respectively for the API from Company A and Company B indicating poor flow for material 
supplied by Company A and extremely poor flow for material supplied by Company B. These 
results can be directly correlated to the particle shapes observed from the image analysis in 
figure 4.1. The Hausner ratio and Carr Index for both the API and blends were similar for 
material supplied by Company A however a similar correlation did not exist for material supplied 
by Company B. 
Table 4.2:  Bulk densities, tapped densities and flow indices for the metformin HCl blends 
prepared using metformin HCl from Company A and Company B.  Hausner ratios and Carr 
indices (calculated from the experimental density values) are also reported. 
Property Metformin HCl 
(Company A) 
Batch 1 
(Company A) 
Metformin HCl 
(Company B) 
Batch 2 
(Company B) 
Bulk density (g/mL) 0.69 0.66 0.45 0.55 
Tapped density (g/mL) 0.85 0.82 0.66 0.72 
Flow Index (mm) N/A 5 N/A  5 
Hausner Ratio 1.23 1.24  1.47 1.31 
Carr Index (%) 23 24 47 31 
N/A – Criteria not assessed  
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 The above values for the Hausner ratios and Carr indices indicate that the flow and 
compressibility properties for material supplied by Company B were enhanced by the additional 
excipients added to the blend. The Hausner Ratio decreased by 11% and the Carr Index dropping 
from 47% to 31% indicating the blend has poor flow as compared to extremely poor flow for the 
API. The powder flow result obtained from both blends using a flodex test instrument was 5 mm, 
indicating comparable flow properties, and indicative of very good flow; this was also the 
observation during the actual execution of the tableting process.   
            The blend using metformin HCl obtained from the current source (Company A, batch 1) 
was compressed first on a Korsch PH300 press. The target in-process quality attributes during 
the compression are described in table 3.3. The press was set up as close as possible to the target 
quality attribute for the tablets and all were within the target range from the start to the end of the 
compression run (approximately one hour duration). The mean compression force at which all of 
the CQAs were met was 34 kN for the blend using metformin HCl from Company A. The tablet 
weight and friability remained fairly constant throughout the run; however, the mean hardness 
increased from 6.7 kp at the beginning of the tablet manufacturing process to 9.1 kp at the end, 
along with a corresponding drop in thickness and increase in disintegration time (see tables A1.4 
and A1.5 in the appendices). There is no obvious cause for this change in the hardness 
(approximately 16%) over the course of the compression process as there was no change in the 
compression force used. It is known that the physical properties of metformin HCl can change 
over time103; although given the short compression run of one hour, it would be unlikely to be 
sufficient for such a change.  
A mean compression force range of 17 kN – 57 kN was evaluated for the blend 
containing metformin HCl obtained from the alternative source (Company B); however, tablets 
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having comparable CQAs (specifically tablets made using API from Company B had a lower 
hardness and higher friability) as those prepared using metformin HCl from Company A, could 
not be manufactured. Target mean compression forces of 17 kN, 24.7 kN, 34 kN, 47.3 kN and 57 
kN were evaluated, and a mean compression force of 34 kN was found to produce the best 
results, but again not with the same quality attributes as tablets prepared in batch 1.  A similar 
trend was seen for tablet hardness with a mean value of 4.9 kp observed for tablets formed at the 
start of the run, increasing to 5.7 kp for tablets formed at the end of the run.  Unlike for tablets 
formed in batch 1, no trend in tablet thickness or disintegration time was observed, as these 
attributes were more variable for batch 2.  
The friability tests for tablets prepared with the alternate source metformin HCl 
(Company B) did not meet specifications (see table A1.5 in the appendices) with several tablets 
“capping” during testing.  The occurrence of capping is where the top or cap of the tablet breaks 
off; usually during the ejection process however can also occur over a period of time (shown in 
figure 4.4).  
 
Figure 4.4: An example of capped metformin HCl tablets obtained from Company B’s API 
compare to un-capped tablets obtains from Company A’s API 
 
There are several factors that can cause capping including entrapment of air, short dwell 
time or the time that the tablet is held in between the punches to form a tablet, insufficient pre-
Company A Company B 
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compression, and  the presence of too many fines (very small particles), which do not adhere as 
well as larger particles80. The blend containing Company B’s metformin HCl contained 56.2% 
(see table A1.3 in the appendices) of material that was 200 mesh or finer, while the blend 
containing Company A’s API contained 33.8% of material that was 200 mesh or finer; a 
difference of 22.4% that was likely one of the causes of the lower hardness and the capping 
observed for tablets prepared using metformin HCl from Company B. The compression behavior 
is governed by the viscoelastic properties of the blend, which can also be responsible for 
capping. The particles in the die cavity rearrange and then experience fragmentation or 
deformation (shown in figure 1.4 from Chapter 1) or both depending on the brittleness of the 
particles forming a tablet53, 80. The tablet will then go through a relaxation process that is directly 
related to the elastic properties of the material. The tablet must be strong enough to withstand 
this force or the tablet will fall apart or can cap if the rate and extent of this process is too great80.  
Particle shape can impact the flow and packing properties of the blend and therefore can impact 
the tablet properties. The particle shapes (figure 4.1), which were different for the two sources of 
metformin HCl, was likely a contributing factor to the differences observed in the in-process 
quality attributes; given that particle shape is not typically evaluated, there would be no way of 
determining from a review of the C of A that these materials would in fact behave differently. 
4.1.4 – Drug product performance       
The assay, dosage uniformity and dissolution (shown in table 4.3) of tablets manufactured 
using metformin HCl from Company A  were consistently 2-3% higher than for those prepared 
using metformin HCl from Company B; however, the variability for both sets of tablets was less 
than 1% STDEV for the dissolution and dosage uniformity. The in – vitro performance was 
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similar regardless of the source of metformin HCl, with tablets fully dissolved within 10 minutes 
for both batches.  
 
Table 4.3: Drug product performance test of assay, dosage uniformity and dissolution results for 
batch 1 (Company A) and batch 2 (Company B) 
 Company A (%) Company B (%) 
Assay   100.9 98.8 
Dosage  Uniformity  
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
Min 
Max 
Mean 
SD 
AV 
 
 
100.5 
101.5 
100.4 
101.9 
99.9 
101.1 
101.8 
101.0 
100.7 
100.3 
99.9 
101.9 
100.91 
0.67 
  0.70 
 
98.6 
99.0 
98.0 
99.4 
98.6 
98.3 
99.8 
99.7 
98.9 
97.8 
97.8 
99.8 
98.81 
0.62 
          2.67 
Dissolution Time points  
10mins  
15mins  
20mins  
30mins  
45mins  
60mins  
 
Dissolution  
102 
102 
102 
102 
102 
102 
 
STDEV 
1 
1 
1 
1 
1 
1 
 
Dissolution  
99 
99 
99 
99 
99 
99 
 
STDEV 
1 
0 
0 
0 
0 
0 
 
 
In summary, there were substantial differences observed for tablets manufactured using 
metformin HCl obtained from Company B, and these differences subsequently lead to challenges 
in the compression process and ultimately to CQA failures for tablets manufactured using 
metformin HCl from Company B. These differences were both in properties reported on the C of 
A such as LOD and methanol as well as properties not reported on the C of A such as particle 
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size and particle shape. The differences in the two materials did not have an impact on the in 
vitro performance of the tablets, and therefore one can propose that these would also not have an 
impact on the in-vivo performance; however, the decreased hardness and increased friability 
would result in a failure of the batch based on the CQAs, which would have represented a 
significant loss for the generic manufacturer.    
4.2 - Gabapentin USP with copovidone NF/EP 35 (batch 3, Company X; and batch 4, 
Company Y) 
4.2.1 – Gabapentin USP C of A testing  
The gabapentin USP obtained from Company X and Company Y were each tested 
according to the requirements of the C of A for each source; all C of A requirements were met 
(see table 4.4). Contrary to the above case with metformin HCl, for the two sources of 
gabapentin USP there were differences in the specifications for assay, bulk density, residual 
solvents and related compounds. The C of A for material supplied by Company X has additional 
specification for tapped density, particle size and identification for Polymorphic form III, which 
the material from Company Y does not have. The only residual solvent present in material 
supplied by Company Y was ethanol, while material from Company X contains methanol, 
isopropanol, toluene and acetone. The C of As for four batches from each source of material was 
evaluated to determine if there were any differences within the sources of material. There was no 
substantial variability in the results from the C of A within the four batches for each source of 
API (refer to table A2.1 in the appendices).  
A two tailed t-tests with a critical p (probability) value of 0.05 was performed to 
determine if there were any significant differences between the two sources of material. The bulk 
density test was shown to be significantly different between the two sources of material.  The 
mean bulk density for Company X was 0.600 g/cc with a STDEV of 0.000 g/cc, the mean bulk 
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density for Company Y was 0.505 g/cc with a STDEV of 0.017 g/cc  and t-test: t(6) = -10.97, p-
value = 0.0001.  
This difference can have an impact on the manufacturing process and drug product due to 
the high concentration of API in the formulation. This will impact the bin fill volume, and 
therefore the mixing properties of the materials which can lead to segregation and potential 
dosage uniformity challenges with the drug product. The manufacturing process includes 
compaction and from the data it was determined that the difference in bulk density between the 
two sources of material did not impact on the CQAs of the process or the drug product (refer to 
section 4.2.3).  
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Table 4.4: The C of A listing the tests, specifications and testing results for gabapentin USP API 
from Company X and Company Y used in batches 3 and 5, and batches 4 and 6 respectively 
Test Specifications 
Results 
(Company X) 
Results 
(Company Y)  
Appearance White to off-white powder Conforms  Conforms  
Identification  
HPLC Retention Time: Corresponds to 
standard    
Conforms  Conforms  
Identification  IR Spectrum: Corresponds to Standard  conforms Conforms  
Identification  Polymorphic form III: NMT 5.0% Conforms  N/A 
Assay  98.5 to 101.5% (Anhydrous basis)  99.7% N/A 
Assay  98.0 to 102.0% (Anhydrous basis) N/A 99.2 
Bulk Density  0.4 to 0.6 g/cc 0.6 g/cc N/A 
Bulk Density  0.40 to 0.66 g/cc N/A 0.51 g/cc 
Tapped Density  0.6 to 1.0 g/cc 0.8 g/cc N/A 
Heavy Metals  NMT 0.002% Less than 0.002% Less than 0.002% 
Limit of Chloride  NMT 0.01% 0.00% 0.01% 
Residual Solvent  
Methanol: NMT 250 ppm 
Isopropanol: 
NMT 1000 ppm  
Toluene: NMT 100 ppm  
Acetone: NMT 100 ppm 
35 ppm 
 
64 ppm 
0 ppm 
2 ppm 
N/A 
Residual Solvent Ethanol: NMT 0.2% N/A 0.0% 
Particle Size  
Percent smaller than  
250 um: NLT 95%  
Percent smaller than  
150 um: NLT 45% 
99% 
 
82% 
N/A 
pH 6.8 to 7.4 7.2 N/A 
pH 6.5 to 8.0  N/A 7.2  
Related Compounds  
GA RC2: NMT 0.05% 
Unidentified Impurity: 
NMT 0.05% each 
Total Impurities:  
NMT 0.30% 
BRT 
 
BRT 
 
BRT 
BRT 
 
BRT 
 
N/A 
Related Compounds 
(Limit of late eluting 
impurities) 
Any Impurity: NMT 0.05% each  N/A ND  
Related  
Compounds (Limit of 
late eluting impurities) 
Any impurity: NMT 0.10% each ND N/A 
Total related 
Compounds 
Total Impurities: NMT 0.5% BRT BRT 
Residue on Ignition  NMT 0.1% 0.0% 0.0% 
Water  NMT 0.3% 0.0% N/A 
Water  NMT 0.5% N/A 0.0% 
N/A – Criteria not included in C of A and therefore not tested  
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Acronyms used in table 4.4:  
BRT – Below reporting threshold  
HPLC – High pressure liquid chromatography  
IR – Infrared  
GA RC – Gabapentin USP related compound  
ND – None detected 
NLT – Not less than   
NMT – Not more than  
ppm – Parts per million  
 
4.2.2 – Additional testing for gabapentin USP   
The additional tests performed were particle size, specific surface area, surface weighted 
mean diameter, volume weighted mean, tapped density, DSC, image analysis and powder X-Ray 
diffraction. 
From this work, the particle sizes obtained from laser diffraction for gabapentin USP 
supplied by Company Y were not only substantially larger than those obtained for gabapentin 
USP from Company X but also had a larger distribution, ranging from 12 µm to 900 µm for 
gabapentin USP from Company Y compared to a range of 1µm to 500 µm for that supplied by 
Company X. In addition material supplied by Company Y had higher surface weighted mean 
diameter and volume weighted mean diameter but a lower specific surface area (see table A2.2 in 
the appendices). Image analysis was one of the tests performed that were not part of the reported 
C of A. Images in figure 4.5 indicates a similar acicular or needle like structure for both 
materials.  The images also reflect the difference in the particle size observed, with material 
supplied by Company X being finer/smaller.  
There are four polymorphic forms for Gabapentin USP reported in the literature with 
polymorphic form II being supplied commercially104, 105. Company X includes a specification (on 
the C of A) for polymorphic form III of NMT (not more than) 5.0% and a claim to be supplying 
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the more stable polymorphic form II.  Company Y does not have this limit for polymorphic form 
III, but similarly claims to be supplying polymorphic Form II. 
 
Figure 4.5: Image analysis for gabapentin USP samples from (A) Company X, and (B) 
Company Y.  Both materials possess a needle-like or acicular crystal shape, also, the difference 
in particle size is clearly evident. 
 
The X-Ray diffraction spectrum in figure 4.6 indicates that both sources were producing 
the same polymorphic form, which we can safely conclude to be polymorphic form II. The 
intensity of the peaks were slightly different for the two materials, and while several factors such 
as the orientation, position and shape of the crystals can contribute to this, the most likely cause 
was the difference in the particle size. The DSC thermograms, (see figure A2.1 and A2.2 in the 
appendices), show the start of the phase transition for gabapentin USP at the same temperature of 
175.7°C for both sources of material, with temperature ranges for the transition of 1.72°C and 
2.47°C for material obtained from Company X and Company Y, respectively. This provides 
additional confirmation of the similarities in the two structures.  
A 
B A B 
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Figure 4.6: The powder X-Ray diffraction spectra for gabapentin USP obtained from Company 
X (blue) and Company Y (red) indicating identical 2Theta values for major peaks. This clearly 
demonstrates that the material from both Company X and Company Y is the same crystalline 
Form II. 
 
A review of the manufacturing process for gabapentin USP from each source reveals 
many differences, with Company X first synthesizing gabapentin USP lactam from cyclohexane 
1,1-diacetic acid as the starting material for the synthesis of gabapentin USP  , figure 4.7106. 
Company Y synthesizes gabapentin USP from 1,1-cyclohexane-diacetic acid-monoamide 
through a two-step reaction process, figure 4.8107. The other noticeable difference was that 
Company Y uses only one solvent, ethanol, while Company X uses acetone, methanol and 
isopropyl alcohol in the final recrystallization process. These differences in the process likely 
resulted in the variation observed in particle size between the two materials; however, the 
difference in particle size could also be as a result of mechanical stress introduced during the 
latter stages of the process such as drying and milling. It is known that many factors, such as 
manufacturing process and solvent use, can impact the crystal form and crystal habit and 
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therefore it is notable that the shape of the crystal for both materials was very similar although 
the manufacturing process and solvents used were different for the two materials. 
 
Figure 4.7: Synthetic route for gabapentin USP for material from Company X, showing a 
difference in both the process and the solvents used in the manufacture of the API compare to 
Company Y106.  
 
 
 
Figure 4.8: Synthetic route for gabapentin USP for material from Company Y, showing a 
difference in both the process and the solvents used in the manufacture of the API compare to 
Company X107. 
 
  
96 
 
4.2.3 - Processing and critical quality attributes evaluation 
The manufacturing process for the gabapentin USP tablets was via blending; compaction, 
followed by compression, with the formulation containing gabapentin USP, copovidone NF/EP 
and magnesium stearate NF (see table 3.4 in Chapter 3). As gabapentin USP  is a crystalline 
material (as compared to an amorphous material), which typically does not compress well, a 
compaction followed by compression process was developed for the manufacturing of the drug 
product108  instead of a direct compression process as was used for the metformin HCl tablets 
described above. The same lot of excipients was used in both blends (batch 3 and batch 4) and 
therefore the source of gabapentin USP  was expected to have an impact, if any, on the physical 
properties of the blend, compaction process, compression process and the resulting tablets.  
The Hausner ratios and Carr indices for both gabapentin USP from each source, along 
with those for the granulated blends prepared using gabapentin USP from each source are 
reported in table 4.5.  The Hausner ratio for gabapentin USP  supplied by Company X was 1.22 
while the Hausner ratio for gabapentin USP  from Company Y was 1.25 suggests free flowing 
properties for both material. Similar results were obtained for the Carr indices, which were 22% 
and 25% for gabapentin USP supplied by Company X and Company Y, respectively. The 
copovidone NF/EP 35 had a Hausner ration of 1.27 and a Carr Index of 27 %, suggesting poor to 
fair flow for the excipient (see table 4.8 for a comparison with copovidone NF/EP 20, in section 
4.3.3 below). The materials were blended and the blend was then compacted using a Gerteis 
compactor with target process parameters listed in table 3.5 and the resulting granulation was 
over blended with magnesium stearate NF prior to compression. The granulation for batch 3 was 
coarser with 10% more retained on the 20 mesh and 9% less on the fines for Company X API 
(see table A2.3 in the appendices). The Hausner ratio for the granulation blends was 1.24 and 
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1.26, while the Carr Index was 24% and 26% respectively for material supplied by Company X 
and Company Y. The Hausner ratio and Carr Index for the granulation with material from 
Company X and Company Y were comparable to their respective APIs; also, both results were 
very close to the excipient, copovidone NF/EP 35. The flow index, which was 18mm for both 
granulation blends, also shows the similarity of the two granulation blends.  
Table 4.5: Bulk densities, tapped densities and flow indices for the gabapentin USP blends 
prepared using gabapentin USP from Company X and Company Y and copovidone NF/EP 35.  
Hausner ratios and Carr indices (calculated from the experimental density values) are also 
reported. 
Property Gabapentin 
USP  
(Company X) 
Batch 3 
(Company X) 
Gabapentin 
USP  
(Company Y) 
Batch 4 
(Company y) 
 Results  Results  STDEV Results Results  STDEV 
Bulk density (g/mL) 0.60 0.54 0.00 0.51 0.57 0.04 
Tapped density (g/mL) 0.73 0.67 0.00 0.64 0.72 0.04 
Flow Index (mm) N/A 18 3.1 N/A 18 1.2 
Hausner Ratio 1.22 1.24  0.00 1.25 1.26 0.02 
Carr Index (%) 22 24 0.00 25 26 1.50 
N/A – Criteria not assessed  
The granulation blends were compressed on a Korsch PH300 press with the target in 
process quality attributes listed in table 3.6.The press was set up as close as possible to the target 
quality attribute for the tablets and all were within the target range from the start to the end of the 
compression run; approximately one hour in duration. The mean compression force at which all 
of the CQAs were achieved was 47.0 kN with granulation blend using Company X API.  The 
tablet weight, hardness, thickness, friability and disintegration all remain consistent throughout 
the run (see table A2.4 in the appendices).  
A mean compression force of 47.0 kN was targeted to achieve the same CQAs with 
granulation blend using Company Y’s API and all were within the range specified. The mean 
hardness, however, was 24 kp which was higher than the 22 kp achieved in batch 3; the 
disintegration time was also slightly higher. As a result the mean compression force was reduced 
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to 38.5 kN and all of the CQAs were achieved and were comparable to the Company X API at 
47.0 kN. The tablet weight, hardness, thickness, friability and disintegration all remain consistent 
throughout the compression run which was approximately one hour duration at 38.5 kN (see 
table A2.5 in the appendices). The gabapentin USP obtained from Company Y was measurably 
coarser than that from Company X; however, the resulting granulation was 9% finer.  
4.2.4 – Drug product performance  
The assay and dosage uniformity of tablets using Company Y gabapentin USP  was 2% higher 
than that for Company X; however, the in – vitro performance was similar for both formulations, 
with tablets fully dissolved at 100 % after 60 minutes (see table 4.6). With the exception of the 
compression force, the particle size and bulk density of the gabapentin USP API and the sieve 
results for the granulation, there was no other noticeable difference observed with the gabapentin 
USP itself, the manufacturing process, or the CQAs for both sources. The differences in the two 
sources of gabapentin USP did not have an impact on the in vitro performance and therefore one 
can propose that it will similarly not have an impact on the in-vivo performance of the tablets. 
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Table 4.6: Drug product performance test of assay, dosage uniformity and dissolution results for 
batch 3 (Company X (copovidone NF/EP 35)) and batch 4 (Company Y (copovidone NF/EP 35)) 
 Company X            
(copovidone NF/EP 35) (%) 
Company Y             
(copovidone NF/EP 35) (%) 
Assay   98.1 99.8 
Dosage  Uniformity  
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
Min 
Max 
Ave 
STDEV 
AV 
 
 
97.9 
98.4 
98.9 
97.9 
98.1 
98.5 
96.7 
98.4 
98.4 
98.0 
96.7 
98.9 
98.12 
0.62 
3.37 
 
101.1 
99.8 
98.8 
99.8 
99.9 
99.9 
100.2 
99.6 
99.5 
99.6 
98.8 
101.1 
99.82 
0.61 
        1.65 
Dissolution Time points  
5mins  
10mins  
15mins  
30mins  
45mins  
60mins  
 
Dissolution  
21 
35 
52 
84 
99 
100 
 
STDEV 
1 
1 
1 
1 
1 
1 
 
Dissolution  
22 
37 
54 
84 
98 
100 
 
STDEV 
1 
2 
2 
2 
1 
1 
 
 
4.3 - Gabapentin USP with copovidone NF/EP 20 (batch 5, Company X; and batch 6, 
Company Y) 
4.3.1 – Copovidone NF/EP C of A testing  
The supplier of copovidone EP/NF uses two different sizes of fluid bed processor to 
produce their commercial quantities of copovidone NF/EP. These two materials are supplied by 
Company D and were denoted as copovidone NF/EP 35 and copovidone NF/EP 20. The same 
sources of gabapentin USP  from batch 3 (Company X) and batch 4 (Company Y) were used for 
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batches 5 and 6 respectively, using  copovidone manufactured from the smaller fluid bed 
processor (copovidone NF/EP 20) in place of the copovidone NF/EP 35 used in batches 3 and 4. 
The copovidone from the two different fluid bed processors were tested according to the 
requirements of the C of A for each; the requirements were met for both samples (see table 4.7). 
The specifications were the same for both materials with the exception for Limit of Monomers 
which was required for copovidone NF/EP 35 and not for copovidone NF/EP 20. The ethenyl 
acetate and LOD was slightly higher for copovidone NF/EP 35 while the particle size was higher 
copovidone NF/EP 20. The C of As for four batches from each source of material was evaluated 
to determine if there were any differences within the two sources of material. There was no 
substantial variability in the results from the C of A within the four batches for each source of 
copovidone (refer to table A3.1in the appendices).  
A two tailed t-tests with a critical p (probability) value of 0.05 was performed to 
determine if there were any significant differences between the two sources of material. The 
particle size (d(90)) test was shown to be significantly different between the two sources of 
material.  The mean particle size (d(90))  for copovidone NF/EP 35 was 173.750 µm with a 
STDEV of 6.021 µm, the mean particle size (d(90))  for copovidone NF/EP 20 was 211.750 µm  
with a STDEV of 20.056 µm and t-test: t(6) = -3.63, p-value = 0.0110. The potential impact of 
particle size on the manufacturing process and drug product is discussed in detail in section 
1.6.4.     
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Table 4.7: The C of A listing the tests, specifications and testing results for copovidone NF/EP 
35 and copovidone NF/EP 20 excipient used in batches 3 and 4, and batches 5 and 6 respectively.  
Test Specifications  
Results 
(Copovidone 
NF/EP 35) 
Results 
(Copovidone 
NF/EP 20)  
Appearance White or lightly yellowish powder  Conforms  Conforms  
Identification  Corresponds to ID B (USP) Conforms  Conforms  
Identification  IR Spectrum: Corresponds to Standard  Conforms  Conforms  
Appearance of 
Solution  
Clarity: Sample solution is not more 
opalescent than reference suspension III 
Colour: Sample solution is not more 
intensely coloured than reference solution 
B5, R5, OR BY5 
Conforms  
 
 
Conforms  
Conforms  
 
 
Conforms  
Aldehydes  NMT 500 PPM(as acetaldehyde) 0 ppm 0 ppm  
Ethenyl Acetate  35.3 to 41.4% (dried basis) 38.2% 36.8% 
Heavy Metals  NMT 20 ppm 
Less than 20 
ppm 
Less than 20 
ppm  
Hydrazine  
Any spot corresponding to 
salicylaldehydrazine in chromatogram 
obtained with the test solution is not more 
intense than the spot in the chromatogram 
obtained with the reference standard (1 
ppm) 
ND ND 
Impurity A NMT 0.5% BRT 0.1% 
Loss on Drying  NMT 5.0% 3.2% 2.3% 
Monomers  NMT 0.1% 0.0% 0.0% 
Limit of 
Monomers  
2-Pyrrolidone: NMT 0.5% 
Vinyl Acetate: NMT 0.001% 
1-Vinyl-2-2Pyrrolidone: NMT 0.001% 
0.07% 
ND 
BQL 
 
N/A 
 
 
Nitrogen  7.0 to 8.0% (dried basis)  7.0% 7.2% 
Peroxides  NMT 0.35% (400PPM) 
Less than 400 
ppm 
Less than 400 
ppm  
Sulphated Ash  NMT 0.1% 0.0% 0.0% 
Viscosity (AS K-
VALUE) 
25.2 to 30.8% (dried basis) 26.0 25.4 
Particle Size  
D (v,0.1): NLT 18um 
D (v,0.5): NMT 135um 
D (v,0.9): NMT 290um 
34 
85 
179 
59 
128 
239 
N/A – Criteria not included in C of A and therefore not tested  
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Acronyms used in table 4.7: 
BQL – Below quantification limit   
ID – Identification 
IR – Infrared  
ND – None detected 
NLT – Not less than   
NMT – Not more than  
ppm – Parts per million 
  
4.3.2 – Additional testing for Copovidone NF/EP  
The additional tests performed were specific surface area, surface weighted mean 
diameter, volume weighted mean, bulk density, tapped density, DSC, TGA, image analysis and 
SEM. 
The surface weighted mean diameter and volume weighted mean diameter was higher for 
copovidone NF/EP 20 while the specific surface area was higher for copovidone NF/EP 35 (see 
table A3.2 in the appendices).  
Image analysis of the copovidone NF/EP samples presented in figure 4.9, along with 
scanning electron micrographs for each sample in figure 4.10, did not reveal any noticeable 
differences between the two materials (other than the difference in the particle size and specific 
surface area already noted). The DSC thermograms (figure 4.11 A and B) confirm that the 
material was amorphous in nature, while the TGA (see figure A3.1and A3.2 in the appendices) 
indicates no difference in the physical and chemical properties between the two materials. The 
loss of weight observed during the TGA correlates with the difference in the LOD results 
observed during the C of A testing with copovidone NF/EP 35 having a slightly larger LOD 
compared to copovidone NF/EP 20. 
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Figure 4.9:  Image Analysis for (A) copovidone NF/EP 20; and (B) copovidone NF/EP 35, 
clearly indicating the similarity in the morphology of the two materials but no clear indication of 
the difference in particle size  
 
 
Figure 4.10: Scanning electron micrographs for (A) copovidone NF/EP 35; and (B) copovidone 
NF/EP 20; with fractures clearly visible and supporting the 78% higher specific surface area 
obtained for material (A) copovidone NF/EP 35 
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Figure 4.11: The DSC thermograms for (A) copovidone NF/EP 20; and (B) copovidone NF/EP 
35 indicating comparable spectrums and confirming the amorphous nature of both materials.  
 
4.3.3 - Processing and critical quality attributes evaluation  
The manufacturing process for the granulation of batches 5 and 6 was the same as with 
batches 3 and 4, using the same process parameters as in table 3.5 Also, the same lots of 
gabapentin USP and magnesium stearate NF used in batches 3 and 4 were used for batches 5 and 
6. The Hausner ratio and Carr Index for copovidone NF/EP 20 were 1.19 and 19% respectively 
(shown in table 4.8), indicating fair to good flow for this material; recall from section 4.2 that the 
Hausner ratio and Carr Index for copovidone NF/EP 35 were 1.27 and 27%, respectively, 
indicating poor to fair flow properties. The resulting granulation blend was slightly finer (44% vs 
38%) for batch 5 using gabapentin USP from company X (see table A3.3 in the appendices).  
The Hausner ratios and Carr indices for the granulation blends prepared using 
copovidone NF/EP 20 are found in table 4.8. Generally the flow properties of the granulation 
blends prepared using copovidone NF/EP 20 are very similar to the properties for granulation 
blends using copovidone NF/EP 35 (see table 4.5 above vs table 4.8 below). The Hausner ration 
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and Carr Index for the granulation blend containing copovidone NF/EP 20 and gabapentin USP 
from company X was similar to the granulation blend containing copovidone NF/EP 20 and 
gabapentin USP from company Y (see table 4.5 vs table 4.8). The Hausner ratio and Carr Index 
was better for copovidone NF/EP 20; however, this did not translate into similar flow properties 
for the granulation blends. The flow index was 18mm for both granulation blends, which 
demonstrates the similarity of these two granulation blends and the two granulation blends from 
batches 3 and 4 (which also both had a flow index of 18 mm). 
Table 4.8:  Bulk densities, tapped densities and flow indices for the gabapentin USP blends 
prepared using gabapentin USP from Company X and Company Y and copovidone NF/EP 20.  
Hausner ratios and Carr indices (calculated from the experimental density values) are also 
reported. 
Property Copovidone 
NF/EP 20 
Batch 5 
(Company X) 
Copovidone 
NF/EP 35 
Batch 6 
(Company Y) 
 Results  Results  STDEV Results  Results  STDEV 
Bulk density (g/mL) 0.36 0.57 0.02 0.30 0.56 0.02 
Tapped density (g/mL) 0.43 0.72 0.02 0.38 0.71 0.02 
Flow Index  N/A 18 2.0 N/A 18 1.2 
Hausner Ratio 1.19 1.26 0.01 1.27  1.27 0.00 
Carr Index (%) 19 26 1.03 27 27 0.43 
N/A – Criteria not assessed  
The granulation blends were compressed on a Korsch PH300 press, with the blend 
containing gabapentin USP from company X and copovidone NF/EP 20 being compressed first, 
also targeting the same in process quality attributes used for batches 3 and 4, listed in table 3.6. 
The press was set up as close as possible to the target quality attribute using the same mean 
compression force of 47 kN used in batch 3 (which is the base line for the gabapentin USP  
batches), however, the mean hardness obtained (18 kp) was below the 22 kp obtained in batches 
3 and 4. A mean compression force of 37 kN, which was close to the force of 38.5 kN used in 
batch 4, was also evaluated, with the obtained hardness being 16 kp. The compression force was 
increased to 64 kN, at which point a hardness of 20 kp was achieved for batch 5 which was 
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below the 22 kp consistently achieved for batches 3 and 4. The compression force of 64 kN was 
used to run batch 5 which was approximately 1 hour in duration. A compression force above 64 
kN was not attempted to achieve 22 kp hardness due to the physical limitation of the 
compression tooling and compression machine.  
A compression force of 60 kN was targeted to achieve the CQAs for the granulation 
blend in batch 6; all attributes were found to be within the ranges specified. Compression forces 
of 38.5 kN and 47 kN were also evaluated, and the hardness achieved at 38.5 kN was 17 kp 
(again below target) while the hardness achieved 47 kN was 19 kp. While comparable hardness 
of 22 kp was achieved at 60 kN for batch 6, it was ran at 47 kN and 19kp hardness (see table 
4.9). This was done to prevent the possibility of any damage to the compression tooling and 
compression machine.  
Table 4.9:  Mean compression forces, mean hardness and hardness STDEV for the gabapentin 
USP tablets prepared using gabapentin USP from Company X and Company Y and copovidone 
NF/EP 35 and copovidone NF/EP 20, showing the higher compression force require for tablets 
using copovidone NF/EP 20 and gabapentin USP from Company X  
 Compression Force (kN) Hardness (kp) 
Results Results  STDEV  
Batch  3 
Company X and Copovidone NF/EP 35 
47  22 1.6 
Batch 4 
Company Y and Copovidone NF/EP 35 
47 24 1.3 
38.5 22 0.9 
Batch 5 
Company X and Copovidone NF/EP 20 
64 20 1.3 
47 18 1.8 
37 16 1.2 
Batch 6 
Company Y and Copovidone NF/EP 20 
47 19 1.1 
38.5 17 1.2 
60 22 0.8 
 
 In comparing batches 3 and 4 with batches 5 and 6, it can be seen that a lower 
compression force was required to achieve comparable CQAs for tablets prepared using 
gabapentin USP from company Y, regardless of which source of copovidone (i.e. copovidone 
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NF/EP 20 or copovidone NF/EP 35). This clearly indicates that while the copovidone NF/EP is 
the binder in the gabapentin USP  tablet formulation, the compression properties were also 
impacted by the source and physical properties of the gabapentin USP  itself. 
4.3.4 – Drug product performance evaluation  
 The assay and dosage uniformity of tablets prepared with copovidone NF/EP 20 were 
comparable, regardless of the source of gabapentin USP (batches 5 and 6). The in – vitro 
performance was also comparable for both batches 5 and 6, with tablets fully dissolved within 45 
minutes (see table 4.10). With the exception of the compression force, the particle size for 
copovidone NF/EP, and the sieve results for the granulation blends, there were no other 
noticeable differences for batches 5 and 6, regardless of the source of gabapentin USP.  As was 
the case for batches 3 and 4, the minor differences observed for the two sources of gabapentin 
USP did not have an impact on the in vitro performance of the resulting tablets, and again one 
can propose that there would be no impact on the in-vivo performance.  
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Table 4.10: Drug product performance test of assay, dosage uniformity and dissolution results 
for batch 5 (Company X (copovidone NF/EP 20)) and batch 6 (Company Y (copovidone NF/EP 
20)) 
 Company X                  
(copovidone NF/EP 20) (%) 
Company Y                   
(copovidone NF/EP 20) (%) 
Assay   98.6 99.3 
Dosage Uniformity  
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
Min 
Max 
Ave 
STDEV 
AV 
 
 
98.4 
98.1 
97.9 
99.0 
98.8 
98.7 
97.7 
99.4 
98.7 
99.2 
97.7 
99.4 
98.59 
0.55 
                       2.72 
 
100.3 
98.3 
99.1 
99.3 
100.2 
100.4 
98.5 
99.0 
98.6 
99.0 
98.3 
100.4 
99.27 
0.81 
                      2.68 
Dissolution Time points  
5mins  
10mins  
15mins  
30mins  
45mins  
60mins  
 
Dissolution  
21  
36   
51   
85   
99   
100   
 
STDEV 
2 
2  
2  
1  
1  
1  
 
Dissolution  
23  
38  
54  
86  
100  
101  
 
STDEV 
2 
1 
2  
1  
1  
1  
 
 
4.4 - Comparison of gabapentin USP formulations having the same source of 
gabapentin USP and different sources of copovidone NF/EP (batch 3 vs. batch 5 and 
batch 4 vs. batch 6)  
Gabapentin USP tablets manufactured using gabapentin USP obtained from Company X, 
and copovidone NF/EP 35 (batch 3) was used as the reference tablets for all the gabapentin USP 
formulations. In this section, we will examine a pair wise comparison of batches 3 and 5, and 
  
109 
 
batches 4 and 6, in order to evaluate the impact of the two different sources of copovidone 
NF/EP for tablets formulated with gabapentin USP obtained from company X and company Y, 
respectively.  For the reference tablets (batch 3) the granulation blend was coarser with 16% 
more material being retained on the 20 mesh screen and 23% less material retained on the 200 
mesh plus fines screen for the blend using copovidone NF/EP 35, as compared to the results 
obtained for the blend using copovidone NF/EP 20 (batch 5). The compression force at which all 
CQAs were achieved was 47 kN using copovidone NF/EP 35 (batch 3) while the compression 
force at which all physical properties was achieved using copovidone NF/EP 20 (batch 5) was 
much higher at 64 kN (see table 4.9).  Compression forces of 37 kN and 47 kN were also 
evaluated for the blend using copovidone NF/EP 20; however, higher friability and lower 
hardness were achieved (see tables A2.4 and A3.4 in the appendices). Interestingly, the Hausner 
ratios of 1.24 and 1.26, and Carr indices of 24% and 26% (shown in table 4.11), respectively for 
granulation blends using copovidone NF/EP 35 and copovidone NF/EP 20; however, the Hausner 
ratio and Carr Index for the two source copovidone NF/EP samples (see table 4.8) were quite 
different. Even with the higher compression forces used for copovidone NF/EP 20 the hardness 
was slightly lower, while the 4 and 20 minutes friability and the thickness were higher (batch 5). 
The weight, disintegration, flow, assay and CU results were comparable regardless of the source 
of copovidone, and the in – vitro performance was similar for both batches (3 and 5).  
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Table 4.11: Comparison of in process test results for gabapentin USP  formulations with 
gabapentin USP  tablets made with gabapentin USP  API from Company X and the two different 
sources of copovidone (batch 3 vs. batch 5), showing the higher compression force require for 
tablets using copovidone NF/EP 20 (batch 5) 
 Batch 3 Batch 5 
20 mesh (12+20 mesh) (%) 36.04 20.32 
80 mesh (40+60+80 mesh) (%) 36.64 35.55 
Fines (100+200+ Fines mesh) (%) 27.12 43.75 
Bulk density (g/mL) 0.54 0.57 
Tapped density (g/mL) 0.67 0.72 
Hausner Ratio 1.24 1.26 
Carr Index (%) 24 26 
Compression Force (kN) 47 64 47 37 
Hardness (kp) 22 20 18 16 
 
The comparison with the two different copovidone NF/EP materials was also made for 
tablets prepared using gabapentin USP obtained from Company Y (batches 4 and 6). The 
granulation blends had comparable sieve fractions and flow indices. The compression force at 
which all of the CQAs were achieved was 38.5 kN for tablets prepared in batch 4 (Company Y 
gabapentin USP with Copovidone NF/EP 35) while the compression force at which all physical 
properties were achieved for batch 6 (Company Y gabapentin USP with Copovidone NF/EP 20) 
was 56% higher at 60 kN. An attempted was made to use this same compression force (47 kN) 
for batch 4 (company Y gabapentin USP and copovidone NF/EP 35); however the hardness and 
disintegration time were higher, and the tablet thickness was lower. Similarly, compression 
forces of 38.5 kN and 47 kN were evaluated for batch 6 (company Y gabapentin USP with 
copovidone NF/EP 20), with a lower than target hardness achieved at 38.5 kn and a slightly 
higher hardness of 19 kp at 47 kN (shown in table 4.12). The Hausner ratio and Carr Indices 
were similar for the two granulation blends, and were also comparable to the granulation blends 
using Company X gabapentin USP; even with the differences in the Hausner ratios and Carr 
Indices for the two copovidone materials (see table 4.8). Despite the higher compression forces 
  
111 
 
used for Copovidone NF/EP 20 the hardness was slightly lower. The weight, thickness, friability, 
disintegration, flow, assay and CU results were comparable between the two copovidone, and the 
in – vitro performance was also similar (see tables 4.6 and 4.10). The above results clearly 
indicate that the copovidone materials produced using the two different fluid bed processors had 
different physical characteristics, not captured in the C of As; and the minor differences observed 
between the two materials were not sufficient to explain the difference in the performance. 
Table 4.12: Comparison of in process test results for gabapentin USP  formulations with 
gabapentin USP  tablets made with gabapentin USP  API from Company Y and the two different 
sources of copovidone (batch 4 vs. batch 6), showing the higher compression force require for 
tablets using copovidone NF/EP 20 (batch 6) 
 Batch 4 Batch 6 
20 mesh (12+20 mesh) (%) 26.4 23.87 
80 mesh (40+60+80 mesh) (%) 37.2 36.68 
Fines (100+200+ Fines mesh) (%) 35.6 38.46 
Bulk density (g/mL) 0.57 0.56 
Tapped density (g/mL) 0.72 0.71 
Hausner Ratio 1.26 1.27 
Carr Index (%) 26 27 
Compression Force (kN) 38.5 47 47 38.5 60 
Hardness (kp) 22 24 19 17 22 
 
These results also support the need to perform additional characterizations prior to the 
introduction of a new source of excipients as this work clearly demonstrates that equivalency 
cannot be determined by a simple comparison of C of As. In these batches several tests beyond 
the C of A were completed; one of which was specific surface area. There was a clear difference 
in the specific surface area, 0.124 square meters per gram for copovidone NF/EP 35 compare to 
0.0697 square meters per gram for copovidone NF/EP 20, between the two materials and the 
difference in particle size observed does not compensate for the greater than 75% difference in 
specific surface area. Copovidone NF/EP generally is spherical in shape and the difference in 
surface area was more likely due to fractures in the spheres. This will also lead to more effective 
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bonding when the materials are compressed resulting in lower compression force require to 
produce the same physical properties of the tablet.  
4.5 - Comparison of gabapentin USP formulations having different sources of 
gabapentin USP and different sources of copovidone (batch 3 vs. batch 6 and batch 4 
vs. batch 5) 
This pair wise comparison evaluates the two different copovidone NF/EP with the two 
different gabapentin USP sources.  
Table 4.13: Comparison of in process test results for gabapentin USP formulations with 
gabapentin USP tablets made with gabapentin USP API from Company X and copovidone 
NF/EP 35 and gabapentin USP API from Company Y and copovidone NF/EP 20 (batch 3 vs. 
batch 6), showing the higher compression force require for tablets using copovidone NF/EP 20 
(batch 6) 
 Batch 3 Batch 6 
20 mesh (12+20 mesh) (%) 36.04 23.87 
80 mesh (40+60+80 mesh) (%) 36.64 36.68 
Fines (100+200+ Fines mesh) (%) 27.12 38.46 
Bulk density (g/mL) 0.54 0.56 
Tapped density (g/mL) 0.67 0.71 
Hausner Ratio 1.24 1.27 
Carr Index (%) 24 27 
Compression Force (kN) 47 47 38.5 60 
Hardness (kp) 22 19 17 22 
 
The compression force at which all of the CQAs were achieved was 47 kN for Company X 
gabapentin USP with copovidone NF/EP 35, which was the baseline batch in batch 3. The 
compression force at which all physical properties was achieved for Company Y gabapentin USP 
with copovidone NF/EP 20 was 60 kN. Compression forces of 38.5 kN and 47 kN were also 
evaluated for Company Y gabapentin USP with copovidone NF/EP 20 with lower than target 
hardness achieved at 38.5 kN and slightly higher hardness of 19kp at 47 kN. The Hausner ratio 
and Carr Index were similar for the two granulation blends with the Hausner ratio of 1.24 and 
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1.27 and Carr Index of 24% and 27% respectively was obtained for granulation blends from 
Company X gabapentin USP with copovidone NF/EP 35 and Company Y gabapentin USP with 
copovidone NF/EP 20. It was concluded earlier that the copovidone NF/EP 35 had better 
compressibility properties and as a result produce comparable CQAs at a lower compression 
force when compare to ccopovidone NF/EP 20, the same was also true for the gabapentin USP 
where Company Y require a lower compression force to achieve comparable CQAs when 
compare to Company X gabapentin USP. A change in the source of the API and the excipient 
yielded equivalent results; however, when tested individually there was variability in the results.  
This equivalent result was achieved despite the fact that the granulation was coarser with 12% 
more on 20 mesh and 10% less on 100 mesh plus 200 mesh plus fines for Company X 
gabapentin USP with copovidone NF/EP 35 (see table 4.13). The weight, thickness, friability, 
disintegration, flow, assay and CU results were comparable between the two batches also, the in 
– vitro performance was similar (see tables 4.6 and 4.10).  
Table 4.14: Comparison of in test process results for gabapentin USP formulations with 
gabapentin USP tablets made with gabapentin USP API from Company Y and copovidone 
NF/EP 35 and gabapentin USP API from Company X and copovidone NF/EP 20 (batch 4 vs. 
batch 5), showing the higher compression force require for tablets using copovidone NF/EP 20 
and gabapentin USP from Company X (batch 5) 
 Batch 4 Batch 5 
20 mesh (12+20 mesh) (%) 26.4 20.32 
80 mesh (40+60+80 mesh) (%) 37.2 35.55 
Fines (100+200+ Fines mesh) (%) 35.6 43.75 
Bulk density (g/mL) 0.57 0.57 
Tapped density (g/mL) 0.72 0.72 
Hausner Ratio 1.26 1.26 
Carr Index (%) 26 26 
Compression Force (kN) 38.5 47 64 47 37 
Hardness (kp) 22 24 20 18 16 
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This pair wise comparison also evaluates the different copovidone NF/EP with the 
different API sources. This pair wise comparison evaluate the two batches at the extreme end of 
their physical characteristics with the compression force at which all CQAs were achieved was 
38.5 kN for Company Y gabapentin USP with copovidone NF/EP 35 while 66% more 
compression force, 64 kN, was require by Company X gabapentin USP with copovidone NF/EP 
20 to achieve comparable CQAs (see table 4.14).  A compression force of 47 kN was also 
evaluated for Company Y gabapentin USP with copovidone NF/EP 35 and both the hardness and 
disintegration time were higher when compared to the results at 38.5 Kn (see table A2.5).  The 
friability at both 4 minutes and 20 minutes were approximately 10% higher for Company Y 
gabapentin USP with copovidone NF/EP 35. While the granulation was slightly finer (36% vs 
44%) for 100 mesh plus 200 mesh plus fines for Company X gabapentin USP with copovidone 
NF/EP 20, it was unlikely the root cause for the much higher force require to create tablets of 
comparable physical properties. A change in the gabapentin USP source produced the best 
results, batch 4, a change in excipient source produce the worse result, batch 5. Even with the 
extended testing it was difficult to predict the performance of the change in source of gabapentin 
USP and copovidone NF/EP, and after the experiments it was difficult to pin point the exact 
properties that resulted in the difference in performance. What was clear is that any change to the 
source of any material can impact the manufacturing process and CQAs, however, the in-vitro 
performance of the drug product was not impacted and therefore one can conclude that the in 
vivo performance will also not be impacted.     
4.6 - Pair wise evaluation of granulation, weight, hardness and thickness for batches 
3, 4, 5, and 6 (gabapentin USP tablets) 
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In addition to the pair wise comparisons described above, an evaluation was carried using 
the six distinct pairings of data to determine if there was any difference between the change in a 
particular material and the in process critical quality attributes measured during the 
manufacturing of the drug product (weight, hardness and thickness).  The six pairings are (X 
(35m3) - Y (35m3)), batches 3 and 4, (X (20m3) - Y (20m3)) batches 5 and 6, (Y (35m3) – Y 
(20m3)) batches 4 and 6, (X (35m3) - Y (20m3)) batches 3 and 6, (Y (35m3) – X (20m3)) batches 
4 and 5 and (X (35m3) - X (20m3)) batches 3 and 5.  The granulation blends were also examined 
in order to determine any trend between the materials and the percentage difference of each pair 
retained on each sieve fraction.   
The beginnings, figure 4.12, of the granulation process were analyzed and all showed the 
same trends, with noticeable differences within each pair was observed as the particle size gets 
smaller/finer specifically at the 100 mesh fraction. Company X gabapentin USP with copovidone 
NF/EP 35 (batch 3) produced the largest particle size granulation while the Company X 
gabapentin USP with copovidone NF/EP 20 (batch 5) produced the finest particle size 
granulation; however, the granulations for Company Y gabapentin USP and the two sources of 
copovidone NF/EP did not show the same correlation and were similar (see table 4.12).  
The same evaluation was also completed for the compression process, where the weight, 
hardness, and thickness of the tablets were evaluated for the 6 comparison pairs described above. 
The percentage differences for each of the 6 pairs are presented in figure 4.13 for differences in 
the weight (figure 4.13A), hardness (figure 4.13B), and thickness (figure 4.13C), are presented as 
a function of time during the manufacture process with samples taken at the start and at 20% 
intervals during the compression run and at the end (total time for the manufacture of each batch 
was approximately one hour).   
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Figure 4.12: The pairwise percentage differences in the amount of each granulation blend 
retained on each sieve fraction for gabapentin USP batches with the largest difference observed 
at the 100 mesh fraction. 
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Figure 4.13: The percentage difference for each comparison pair of gabapentin USP  tablets for 
the differences in the: A) weight; B) hardness; and C) thickness with less than ± 2 % difference 
observed with weight and thickness and a ± 10 % difference with hardness. 
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There was no trend observed over time for weight, hardness, or thickness, and generally 
if the difference was positive at the start of the compression process it remained positive, and if it 
was negative it remained negative throughout the compression run. This observation was more 
likely a function of the setup of the critical quality attributes at the beginning of the compression 
run, as the start closely compares to the end of the compression run.  
4.7 – Fenofibrate EP/BP tablets (Batch 7 Company J, Batch 8 Company K; 
croscarmellose sodium NF/EP supplied by Company G)  
4.7.1 – Fenofibrate EP/BP C of A testing  
Fenofibrate EP/BP samples from each source were tested according to the requirements 
of the C of A for each source, and in both cases the C of A requirements were met (see tables 
4.15 and 4.15a). There was a minor difference in the specification for assay with fenofibrate 
EP/BP supplied by Company J having a limit of 98.0% to 102.0% and fenofibrate EP/BP 
supplied by Company K having a limit of 98.5% to 101.0%. The fenofibrate EP/BP supplied by 
Company J contains one residual solvent, isopropanol, while fenofibrate EP/BP supplied by 
Company K also contains isopropanol in addition to four additional solvents: acetone; 
chloroform; toluene; and butyl acetate. The bulk density specification was the same for both 
sources; however, material supplied by Company K was 30% denser at 0.61 g/cc compare to 
0.47 g/cc for Company J. The tapped density was almost the same at 0.72 g/cc and 0.71 g/cc 
respectively (see table A4.2 in the appendices). The C of As for four batches from Company J 
and three batches from Company K was evaluated to determine if there were any differences 
within the two sources of material. There was no substantial variability in the results from the C 
of A within the batches for each source of API (refer to table A4.1).  
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A two tailed t-tests with a critical p (probability) value of 0.05 was performed to 
determine if there were any significant differences between the two sources of material. The 
Isopropanol, total impurities and bulk density tests were shown to be significantly different 
between the two sources of material.  The mean Isopropanol  for Company J was 331.750 ppm 
with a STDEV of 15.629 ppm, the mean Isopropanol for Company K was 1075.000 ppm with a 
STDEV of 24.245 ppm and t-test: t(5) = 49.81, p-value = < 0.0001. The mean total impurities for 
Company J was 0.128 % with a STDEV of 0.013 %, the mean total impurities  for Company K 
was 0.000 % with a STDEV of 0.000 % and t-test: t(5) = -17.13, p-value = < 0.0001. The mean 
bulk density for Company J was 0.530 g/cc with a STDEV of 0.012 g/cc, the mean bulk density 
for Company K was 0.647 g/cc with a STDEV of 0.012 g/cc and t-test: t(5) = 13.23, p-value = < 
0.0001. These differences, specifically the bulk density, can have an impact on the manufacturing 
process and drug product, however, this was not observed (refer to section 4.7.3) 
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Table 4.15: The C of A listing the tests, specifications and testing results for fenofibrate EP/BP 
API from Company J and Company K used in batches 7 and 9, and batches 8 and 10 respectively 
Test Specifications   Results (Company J) Results (Company K) 
Appearance White to off white powder  Conforms   Conforms  
Identification  
UV Spectrum: Corresponds to 
Standard 
 N/A Conforms  
Identification 
  
IR Spectrum: Corresponds to 
Standard  
 
Conforms  
 
Conforms  
 
Melting Point  79 to 82 oC  82 
°
C 82 °C 
Halides 
(Expressed as 
Chloride) 
NMT 100 ppm  Less than 100 ppm Less than 100 ppm  
Sulphates  NMT 100 ppm Less than 10 ppm Less than 100 ppm 
Acidity 
Volume of 0.1 M NaOH 
required: NMT 0.2 mL 
 0.1 mL 0.1 mL 
Loss on Drying  NMT 0.5% 0.1% 0.4% 
Sulphated Ash NMT 0.1% 0.1% 0.0% 
Heavy Metals  0.002% Less than 0.002% Less than 0.002% 
Residual Solvent  
 
Acetone: NMT 1000 ppm 
Isopropanol:  
NMT 2000 ppm  
Chloroform: NMT 60 ppm  
Toluene: NMT 890 ppm  
Butyl acetate:  
NMT 1000ppm 
 
N/A 
 
342 ppm 
N/A 
N/A 
 
N/A 
 
7 ppm 
 
1103 ppm 
7 ppm 
71 ppm 
 
ND 
 
N/A – Criteria not included in C of A and therefore not tested   
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Table 4.15a: : The C of A listing the tests, specifications and testing results for fenofibrate 
EP/BP API from Company J and Company K used in batches 7 and 9, and batches 8 and 10 
respectively 
Test Specifications   Results (Company J) 
Results (Company 
K) 
 
Related 
Compounds  
 
 
FF RC1: NMT 0.1% 
FF RC2: NMT 0.1% 
FF RC4: NMT 0.2% 
FF RC5: NMT 0.10% 
FF RC6: NMT 0.10% 
FF RC7: NMT 0.10% 
FF RC8: NMT 0.10% 
Unidentified Impurity:  
NMT 0.10% each 
Total Impurities: NMT 0.5% 
BRT 
 ND 
0.13% 
BRT 
ND 
BRT 
BRT 
 
BRT 
0.13% 
 
N/A 
Related 
Compounds  
FF RC2: NMT 0.1% 
FF RC1: NMT 0.1% 
EP Imp. C: NMT 0.10% 
EP Imp. D: NMT 0.10% 
EP Imp. E: NMT 0.10% 
EP Imp. F: NMT 0.10% 
FF RC4: NMT 0.2% 
Unidentified Impurity:  
NMT 0.10% each 
Total Impurities: NMT 0.5% 
N/A 
N/D 
BRT 
ND 
BRT 
BRT 
BRT 
BRT 
 
BRT 
BRT 
Assay  98.0% to 102.0% (dried 
basis) 
99.6% N/A 
Assay 98.5% to 101.0% (dried 
basis) 
N/A 100.1% 
Appearance of 
Solution   
Solution is clear and not 
more intensely coloured than 
reference solution BY6 
Conforms  Conforms  
Bulk Density  0.50 to 0.70 g/cc 0.54 g/cc 0.66 g/cc 
N/A – Criteria not included in C of A and therefore not tested  
 
Acronyms used in table 4.15 and 4.15a: 
BRT – Below reporting threshold  
EP Imp. – European Pharmacopeia impurity standard  
FF RC – Fenofibrate EP/BP related compound  
IR – Infrared 
M – Molar  
ND – None detected 
NMT – Not more than  
ppm – Parts per million  
UV – Ultraviolet  
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4.7.2 - Additional testing for fenofibrate EP/BP 
 
The additional tests performed were particle size, specific surface area, surface weighted 
mean diameter, volume weighted mean, tapped density, DSC, image analysis and powder X-Ray 
diffraction. 
There was no specification for particle size but the test results indicates that fenofibrate 
EP/BP supplied by Company K was much coarser with a D(v,0.1) of 97µm, D(v,0.5) of 229µm 
and D(v,0.9) of 509µm; compared to values of D(v,0.1) of 22µm, D(v,0.5) of 78µm and D(v,0.9) 
of 250µm for fenofibrate EP/BP supplied by Company J. In addition fenofibrate EP/BP supplied 
by Company J had a lower surface weighted mean diameter and volume weighted mean diameter 
but a considerable higher (3.3x) surface area. The image analysis (see figure 4.14) indicates 
different crystal structures for the two materials with fenofibrate EP/BP supplied by Company J 
being platy (figure 4.14A), while fenofibrate EP/BP supplied by Company K was more prismatic 
in shape (figure 4.14B). The image analysis also reflects the noticeable differences in the particle 
size observed, with fenofibrate EP/BP supplied by Company K been coarser.      
 
Figure 4.14: Image Analysis for fenofibrate EP/BP from: (A) Company J; (B) Company K. The 
differences in both particle size and particle shape are clearly evident. 
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There are two polymorphic forms and an amorphous solid of fenofibrate reported by the 
literature with polymorphic form I being supplied commercially109. There is a metastable Form 
II, which is formed by crystallizing amorphous fenofibrate, grinding, or exposure to high 
humidity; Form II converts back to Form I within a few days. Company J claims to be supplying 
Form I, and while Company K does not make this claim, their materials have a specification for 
melting point, 79°c to 82°c, which is characteristic of Form I. This was confirmed by DSC 
(thermograms are provided as figures A4.1 and A4.2 in the appendices), which indicates the start 
of the phase transition at a temperature of 79.6 °C for both materials; the temperature range over 
which the transition occurred was 0.6 °C and 0.9 °C, respectively, for fenofibrate EP/BP supplied 
by Company J and fenofibrate EP/BP supplied by Company K, again indicating the similarities 
in the two materials. The X-Ray diffraction spectrum (see figure 4.15) clearly indicates that both 
sources were producing polymorphic form I when compare to the reference standard (Exhibit A 
in figure 4.15). 
 
 
Figure 4.15: The powder X-Ray Diffraction for fenofibrate EP/BP; Company J (purple, 
KC3112), Company K (light blue, KK3524), and reference material (dark blue, Exhibit A) 
indicating identical 2Theta values for major peaks. This clearly demonstrates that the material 
from both Company J and Company K are the same crystalline Form I.     
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A review of the manufacturing process reveals many differences between fenofibrate 
EP/BP manufactured by each company; however, both use 4-chloro-4-hydroxybenzophenone as 
a starting material. Company J describes 4-chloro-4-hydroxybenzophenone as a starting material 
(see figure 4.16)110 using a condensation process to produce crude fenofibrate I which then goes 
through a two - step purification process. Company K describes the formation of pure fenofibrate 
in four steps (see figure 4.17)111; step one was formation of 4-chloro-4-hydroxybenzophenone, 
step two was formation of fenofibrate acid, step three was formation of crude fenofibrate and 
step four was purification. Each of the four steps require an additional nine processes to 
complete, for a total of thirty six steps from start to end,  that includes agitation, reflux, cooling, 
distillation, centrifuge, filtration, extraction, washing, separation, crystallization, drying, milling 
and blending. While it was not described in detail, it is expected that each of these nine processes 
at each step will have defined critical processing parameters and CQAs, highlighting the 
difficulty and complexity of making APIs.  These differences in the process can result in the 
variation observed in particle size between the two materials; however, the differences could also 
be as a result of mechanical stress introduced during the latter stages of the process such as 
drying and milling. It is know that many factors such as the manufacturing process and solvent 
use can impact the crystal form and crystal habit and can therefore the differences in shape and 
particle size of the crystal for both materials can be supported. 
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Figure 4.16: Synthetic route for fenofibrate EP/BP for material from by Company J, showing the 
similarity in both the process and the solvents used in the manufacture of the API compare to 
Company K110 
 
 
 
Figure 4.17: Synthetic route for fenofibrate EP/BP for material from Company K showing the 
similarity in both the process and the solvents used in the manufacture of the API compare to 
Company J111 
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4.7.3 – Processing and critical quality attributes evaluation  
The manufacturing process for the fenofibrate EP/BP was a hot melt extrusion, followed 
by pulverization of the cooled solids, and then compression of the pulverized blend.  The 
formulation contained fenofibrate BP/EP and croscarmellose sodium NF/EP. Fenofibrate EP/BP 
is a BCS class II drug, with low solubility and high permeability; the hot melt technology was 
used to enhance the solubility and dissolution rate of the drug product112. The process involves 
crystallization of the drug substance in an excipient matrix to enhance its physiochemical 
properties and any change to material or processing conditions can impact the resulting 
mixture113. The Hausner ratio and Carr Index for the pure fenofibrate EP/BP supplied by 
Company K were 1.18 and 18% respectively, indicating that the material had much better flow 
and compressibility properties compared to fenofibrate EP/BP supplied by Company J which 
Hausner ratio and Carr Index of 1.51 and 51% respectively (see table 4.16 below).  
Table 4.16:  Bulk densities, tapped densities and flow indices for pulverized fenofibrate EP/BP 
blends prepared using fenofibrate EP/BP from Company J and Company K, and croscarmellose 
sodium NF/EP from Company G. Hausner ratios and Carr indices (calculated from the 
experimental density values) are also reported. 
Property Fenofibrate 
EP/BP 
(Company J) 
Batch 7 
(Company J) 
Fenofibrate 
EP/BP 
(Company K) 
Batch 8 
(Company K) 
 Results  Results  STDEV  Results  STDEV 
Bulk density 
(g/mL) 
0.47 0.59 0.03 0.61 0.57 0.05 
Tapped density 
(g/mL) 
0.71 0.81 0.03 0.72 0.81 0.05 
Flow Index  N/A 30 1.15 N/A 32 1.15 
Hausner Ratio 1.51 1.37  0.04 1.18 1.42 0.05 
Carr Index (%) 51 37 3.88 18 42 5.33 
N/A – Criteria not assessed  
Due to the hot melt process, this property was not expected to influence the physical 
properties of the final blend. The API and excipient were heated to approximately 100°C until a 
uniform, molten mass was achieved. The material was then poured into high density 
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polyethylene container to solidify for at least twelve hours, after which it was pulverized twice 
using a Granumil fitted with 0.625” screen follow by a 0.109” screen. The resulting material was 
blended with itself prior to compression. The resulting in process granulation blend sieve range 
targets and results are indicated in table 4.17 and shows that they are very similar for both 
blends. The results for the sieve analysis, bulk density, tapped density, flow index as well as the 
resulting Hausner ratio, Carr index were all very similar. The Hausner ratios of 1.37 and 1.42, 
Carr indices of 37% and 42%, and flow indices of 30 and 32, respectively for fenofibrate EP/BP 
from Company J and Company K, were obtain for the granulation blends (see table 4.16). All 
three measures are indicative of a poor flowing and poorly compressible material, which was the 
observation during the compression process.  
Table 4.17: The target sieve analysis range and results for the granulation blend for batches 7 
and 8, showing the similarity of the sieve analysis, but with higher variability for batch 8 using 
fenofibrate EP/BP form Company K. 
 
The granulation blends were compressed on a Korsch PH300 press with the target in 
process quality attributes listed in table 3.8. The press was set up as close as possible to the target 
quality attribute for the tablets and all attributes were within the target range from the start to the 
end of the compression run which was approximately one hour in duration (see tables A4.4 and 
A4.5 in the appendices). The mean compression force at which all of the CQAs were achieved 
was 5.3 kN for the granulation blend using fenofibrate EP/BP from Company J.  The tablet 
hardness, thickness, friability and disintegration values all remained consistent throughout the 
Sieve Analysis Limits 
(%) 
Batch 7 Batch 8 
Results (%) STDEV Results (%) STDEV 
20 + 40 mesh 18 - 53 42.8 4.41 45.9 9.18 
60 + 80 mesh 0 - 34 12.2 0.90 10.9 0.70 
100 + 200 + Fines 22 - 74 45.0 3.23 43.5 8.69  
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run. The weight was variable throughout the compression run with a STDEV range of 3.3 mg to 
11.2 mg. A mean compression force of 5.3 kN was also targeted to achieve the same CQAs for 
the granulation blend using fenofibrate EP/BP from Company K, and all attributes were found to 
be well within the range specified. The weight was slightly more consistent than for the run 
using fenofibrate EP/BP from Company J; however it was still variable with a STDEV range of 
6.7 mg to 9.4 mg. The tablet hardness, thickness, friability and disintegration again all remained 
consistent throughout the run. 
The mean compression force at which all physical properties was achieved was the same 
for both sources of API at 5.3 kN. This was achieved despite the differences observed in the 
fenofibrate EP/BP obtained from Company K, having a bulk density approximately 30% higher 
than that for Company J, a particle size that was much higher with a visibly shape  difference . In 
addition the Company K fenofibrate EP/BP had a higher volume weighted mean diameter, 
surface weighted mean diameter, and 300% less specific surface area. The resulting physical 
characteristics of the granulation blend and finished tablets were independent of the physical 
properties of the fenofibrate EP/BP API, and suggests that the hot melt process may be 
particularly useful in the formulation of tablets using materials from alternate sources as this 
method nullifies any difference observed in the physical properties of the API.  
4.7.4 – Drug product performance evaluation  
The assay, dosage uniformity and dissolution of tablets manufactured using fenofibrate 
EP/BP supplied by Company J were consistently higher than those for tablets manufactured 
using fenofibrate EP/BP supplied by Company K; however, the variability for both was less than 
4% STDEV (for the dissolution and dosage uniformity). The in – vitro performance was similar 
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regardless of fenofibrate EP/BP source with > 85% dissolved within 15 minutes for both (see 
table 4.18).  
In summary, there were measurable differences observed in the material from the two 
fenofibrate EP/BP sources; however, these differences did not carry over to the manufacturing 
process or the drug product. The differences in the two materials ultimately did not have an 
impact on the in vitro performance and therefore one can propose that there would similarly be 
no impact on the in-vivo performance. 
Table 4.18: Drug product performance test of assay, dosage uniformity and dissolution results 
for batch 7 (Company J (croscarmellose sodium NF/EP G)) and batch 8 (Company K 
(croscarmellose sodium NF/EP G)) 
 Company J (croscarmellose sodium 
NF/EP G) (%) 
Company K (croscarmellose 
sodium NF/EP G) (%) 
Assay   97.7 96.0 
Dosage  Uniformity  
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
Min 
Max 
Ave 
SD 
AV 
 
 
97.1 
93.1 
96.7 
102.5 
102.2 
98.3 
100.0 
91.9 
96.0 
99.0 
91.9 
102.5 
97.68 
3.49 
10.70 
 
97.7 
94.9 
93.2 
97.2 
96.9 
94.1 
97.5 
100.0 
91.2 
96.9 
91.2 
100.0 
95.96 
2.58 
                    10.23 
Dissolution Time points  
5mins  
10mins  
15mins  
30mins  
45mins  
60mins  
 
Dissolution  
76  
97   
103  
104  
105  
105   
 
STDEV 
5
4
4
4
3
4
 
Dissolution  
67  
87  
93  
96  
96  
96  
 
STDEV 
4 
2 
2  
2  
2  
2  
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4.8 - Fenofibrate EP/BP tablets (Batch 9 Company J, Batch 10 Company K; 
croscarmellose sodium NF/EP supplied by Company H) 
4.8.1 – Croscarmellose sodium NF/EP C of A testing  
The same two sources and lots of fenofibrate EP/BP used in the manufacture of batches 7 and 
8 were also used in the manufacture of batches 9 and 10, which differed in the source of 
croscarmellose sodium NF/EP, now supplied by Company H. The croscarmellose sodium NF/EP 
from the two different sources was tested according to the requirements of the C of A for each 
and these requirements were met (see table 4.19). The specifications were similar for 
croscarmellose sodium NF/EP supplied from both sources with one clear exception; material 
supplied by Company G has a specification for particle size while material supplied by Company 
H does not. The results obtained on the C of A were also comparable with two exceptions, 
settling volume and sulphated ash.  The specification for settling volume was 10 – 30 milliliters 
for both sources, with a settling volume of 15 milliliters determined in this work for 
croscarmellose sodium NF/EP supplied by Company G (batch 7 and 8), and 25 milliliters 
obtained for croscarmellose sodium NF/EP supplied by Company H (batch 9 and 10). 
Croscarmellose sodium NF/EP is a super disintegrant and the ability of the disintegrant to absorb 
water and break the tablet apart is measured by the settling volume. The higher the milliliter of 
water absorb the faster the disintegration time is expected to be. However, despite the 10 
milliliter difference in the settling volume the disintegration times were comparable for the two 
sets of tablets. The disintegration time for batch for batches 7 and 8 range from 3 minutes 35 
seconds to 7 minutes 18 seconds, while the disintegration time for batches 9 and 10 range from 4 
minutes 48 seconds to 8 minutes 42 seconds. The results obtained are likely due to the higher 
compression force of 7.4 kN and 7.5 kN used in batch 9 and 10 compare to the 5.3 kN used in 
batch 7 and 8. 
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Table 4.19: : The C of A listing the tests, specifications and testing results for croscarmellose 
sodium NF/EP excipient from Company G and Company H used in batches 7 and 8, and batches 
9 and 10 respectively 
Test Specifications  
Results 
(Croscarmellose 
Sodium NF/EP G)  
Results 
(Croscarmellose 
Sodium NF/EP H) 
Appearance 
White or greyish-white, free-flowing 
powder  
Conforms  
N/A 
 
Appearance  White or greyish-white powder N/A Conforms  
Identification 
Reaction with Methylene Blue: 
Sample absorbs methylene blue 
Appearance of solution after settling: 
A blue fibrous mass is formed  
Conforms  
 
 
Conforms  
Conforms  
 
 
Conforms  
Identification  
Corresponds to ID B. A reddish-
violet colour develops at the 
interface upon reaction with 1-
Napthol TS 
Conforms  Conforms  
Identification  Positive to test for Sodium  Conforms  Conforms  
Identification  Positive to flame test for sodium  Conforms  N/A 
Heavy Metals NMT 20 ppm Less than 20 ppm  N/A 
Heavy Metals NMT 10ppm  N/A Less than 10 ppm  
Sulphated Ash  14.0 to 28.0% (dried basis) 16.5% 19.9% 
Microbial Limits   
E.Coli: Absent in 1g 
Total Aerobic Microbial Count: 
NMT 1000 cfu/g 
Total Yeast and Mould Count:  
NMT 100 cfu/g 
Absent  
 
Less than 100 cfu/g 
 
Less than 100 cfu/g 
Absent  
 
Less than 100 cfu/g 
 
Less than 100 cfu/g 
Particle Size  
D (v,0.5): NM 60um 
D (v,0.9): NMT 155 um 
37 um 
85 um 
N/A 
pH 
5.0 to 7.0 (From Manufacturer’s      
C of A) 
6.7 6.7 
Degree of 
Substitution  
0.60 to 0.85 (dried basis) (From 
Manufacturer’s C of A) 
0.77 0.73 
Sodium Chloride 
& Sodium 
Glycolate   
NMT 0.5% (dried basis) (From 
Manufacturer’s C of A) 
0.15% 0.4% 
Water Soluble 
substances 
NMT 10.0% (From Manufacturer’s 
C of A) 
4.2 4.6% 
Loss on Drying  
NMT 10.0% (From Manufacturer’s 
C of A) 
2.4 1.9% 
Settling Volume  10 – 30ml  
(From Manufacturer’s C of A)  
15 mL 25.0 mL 
N/A – Criteria not included in C of A and therefore not tested  
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Acronyms used in table 4.19: 
Cfu/g – Colony forming unit in 1 gram  
ID – Identification 
NMT – Not more than  
ppm – Parts per million 
 
The specification for sulphated ash was 14.0% to 28.0% (dried basis) and the result obtained was 
16.5% for croscarmellose sodium NF/EP supplied by Company G and 19.9% obtain for 
croscarmellose sodium NF/EP supplied by Company H. The C of As for three batches from 
Company G and four batches from Company H were evaluated to determine if there were any 
differences within the two sources of material. There was no substantial variability, other than 
that mentioned above, in the results from the C of A within the batches for each source of API 
(refer to table A5.1).  
A two tailed t-tests with a critical p (probability) value of 0.05 was performed to determine if 
there were any significant differences between the two sources of material. The settling volume 
test was shown to be significantly different between the two sources of material.  The mean 
settling volume for Company G was 15.333 mL with a STDEV of 0.577 mL, the mean settling 
volume for Company H was 23.000 mL with a STDEV of 1.414 mL and t-test: t(5) = 8.69, p-
value = 0.0003. 
4.8.2 - Additional testing for croscarmellose sodium NF/EP 
The additional tests performed were particle size, specific surface area, surface weighted 
mean diameter, volume weighted mean, bulk density, tapped density, DSC, TGA, image analysis 
and SEM. 
The particle size was also tested for croscarmellose sodium NF/EP supplied by Company H 
and the results were comparable to the results obtained for material supplied by Company G. The 
surface weighted mean diameter, volume weighted mean diameter, and specific surface area 
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were similar for both sources of material, with the surface weighted mean diameter and volume 
weighted mean diameter being slightly higher and the specific surface area was slightly lower for 
material supplied by Company H (see table A5.2 in the appendices) . The image analysis of the 
two different sources of material (see figure 4.18) shows that the particles were similar in shape 
and size, while SEM (see figure 4.19) of the two sources of material shows that the morphology 
was slightly different, with material supplied by Company G been more globular while material 
supplied by Company H was more fibrous. The DSC thermograms (figures A5.1 and A5.2 in the 
appendices) confirm that the materials were amorphous in nature, while the thermogravimetric 
analysis (figures A5.3 and A5.4 in the appendices) correlates to the difference observed in the 
LOD results between the two materials during the C of A testing.  
 
 
Figure 4.18: Image Analysis for croscarmellose sodium NF/EP supplied by: (A) Company G; 
(B) Company H, clearly indicating the similarity in the morphology of the two materials but no 
clear indication of the difference in specific surface area  
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Figure 4.19: Scanning Electron Micrographs for croscarmellose sodium NF/EP supplied by: (A) 
Company G; (B) Company H, with fractures clearly visible and supporting the 76% higher 
specific surface area obtained for Company G croscarmellose sodium NF/EP(A).  
 
4.8.3 - Processing and critical quality attributes evaluation 
The hot melt manufacturing process used for batches 9 and 10 were the same as for batches 7 
and 8 and targets the same in process granulation blend sieve range (as indicated in table 4.17). 
The Hausner ratios and Carr Indices for croscarmellose sodium NF/EP from both sources are 
reported in table 4.21, and the values both indicate poor to fair flow for this excipient. The sieve 
analysis results (table 4.20) for the two granulation blends were almost identical, with less than 
one percentage difference in the sieve fractions between batches 9 and 10, which was similar to 
the difference observed in batches 7 and 8. The two granulations blends were, however, slightly 
finer than that of the previous two batches.  The particle size for material from Company H was 
coarser and the other material properties of the croscarmellose sodium NF/EP could not explain 
the difference in granulation. The result is likely a function of the manufacturing process that 
includes a very aggressive milling step using a hammer mill. The bulk density and the tapped 
density were the same for both batches 9 and 10, and as a result the Hausner ratio and Carr index 
  
135 
 
were the same at 1.46 and 46% respectively. The flow index of 32mm was the same for both 
granulation blends confirming the similarity and poor flow characteristics of the two granulation 
blends.  
Table 4.20: The target sieve analysis range and results for the granulation blends for batches 9 
and 10, showing the similarity in both the sieve analysis and variability using croscarmellose 
sodium NF/EP from Company H. 
 
 
Table 4.21:  Bulk densities, tapped densities and flow indices for pulverized fenofibrate EP/BP 
blends prepared using fenofibrate EP/BP from Company J and Company K, and croscarmellose 
sodium NF/EP from Company H. Hausner ratios and Carr indices (calculated from the 
experimental density values) are also reported. 
Property Croscarmellose 
sodium NF/EP  
(Company G) 
Batch 9 
(Company J) 
Croscarmellose 
sodium NF/EP 
(Company H) 
Batch 10 
(Company K) 
 Results  Results  STDEV  Results  STDEV 
Bulk density 
(g/mL) 
0.54 0.52 0.03 0.51 0.52 0.05 
Tapped density 
(g/mL) 
0.68 0.76   0.07 0.65 0.76 0.06 
Flow Index  N/A 32 0.00 N/A 32 1.41 
Hausner Ratio 1.26 1.46 0.07 1.27 1.46 0.04 
Carr Index (%) 26 46 7.12 27 46 4.39 
N/A - Criteria not assessed   
As for batches 7 and 8, granulation blends for batches 9 and 10 were compressed on a 
Korsch PH300 press with the target in process quality attributes listed in table 3.8. The press was 
again set up as close as possible to the target quality attribute for the tablets and all attributes 
were within the target range from the start to the end of the compression run, which was 
approximately one hour duration. The mean compression force at which all of the CQAs were 
Sieve Analysis Limits 
(%) 
Batch 9 Batch 10 
Results (%) STDEV Results (%) STDEV 
20 + 40 mesh 18 - 53 40.0 6.91 39.8 6.86 
60 + 80 mesh 0 - 34 8.9 1.68 8.6 1.40 
100 + 200 + Fines 22 - 74 50.9 5.86 51.3  5.52  
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achieved was 7.4 kN for batch 9 (fenofibrate EP/BP) from Company J and croscarmellose 
sodium NF/EP from Company H).  The tablet hardness, thickness, friability and disintegration all 
remain consistent throughout the run, the weight, however, was variable throughout with a 
STDEV range of 6.0 mg to 10.3 mg. A mean compression force of 7.4 kN was also targeted to 
achieve the same CQAs for batch 10 (fenofibrate EP/BP) from Company K and croscarmellose 
sodium NF/EP from Company H) and all were well within the range specified at a slightly higher 
mean compression force of 7.5 kN (see tables A5.4 and A5.5 in the appendices). This difference 
of 0.1 kN was not significant and was a function of the variability in the compression machine. 
The weight was as variable in batch 10 as that observed in batch 9 with a STDEV range of 6.8 
mg to 10.1 mg while the tablet hardness, thickness, friability and disintegration all remain 
consistent throughout the run. The compression force at which all physical properties were 
achieved was approximately 40 % higher in batches 9 and 10 using croscarmellose sodium 
NF/EP from Company H; as compared to the 5.3 kN use in batches 7 and 8 using croscarmellose 
sodium NF/EP from Company G. These results further supports the conclusion that the resulting 
physical characteristics of the granulation blends and tablets were independent of the physical 
properties of the fenofibrate EP/BP API from the two different sources and that the 
manufacturing process was more strongly influenced by the croscarmellose sodium NF/EP 
excipient source. The slightly higher disintegration time observed for batches manufactured 
using croscarmellose sodium NF/EP supplied by Company H was likely due to the relatively 
higher compression force used during the compression. The higher compression force used 
during tablet manufacture also impacted the 20 minutes friability testing, with broken tablets 
obtained using croscarmellose sodium NF/EP supplied by Company G but not when 
croscarmellose sodium NF/EP supplied by Company H was used. While the 20 minutes friability 
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is not an official specification or in process control, it is usually carried out in the drug product 
development process during the compression run to evaluate the potential for issues during the 
coating process.  
4.8.4 – Drug product performance evaluation  
The assay, dosage uniformity and dissolution of tablets manufactured using fenofibrate 
EP/BP from either source were similar, with the variability for dosage uniformity less than 1.5% 
and dissolution less than 6%. The in – vitro performance was similar for both sources of 
fenofibrate EP/BP with a different source of croscarmellose sodium NF/EP and was > 85% 
dissolved within 15 minutes for both (see table 4.22). While there were measureable differences 
observed between the two fenofibrate EP/BP sources, with the exception of the compression 
force, the manufacturing process and drug product performance was similar to that observed in 
batches 7 and 8. The different source of croscarmellose sodium NF/EP did not have an impact on 
the in vitro performance and therefore one can propose that it will also not have an impact on the 
in-vivo performance of the drug product.  
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Table 4.22: Drug product performance test of assay, dosage uniformity and dissolution results 
for batch 9 (Company J (croscarmellose sodium NF/EP H)) and batch 10 (Company K 
(croscarmellose sodium NF/EP H)) 
 Company J (croscarmellose 
sodium NF/EP H) (%) 
Company K (croscarmellose 
sodium NF/EP H) (%) 
Assay   99.9 99.2 
Dosage  Uniformity  
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
Min 
Max 
Ave  
SD 
AV 
 
 
100.5 
99.7 
99.9 
100.0 
98.3 
102.4 
98.8 
101.3 
99.6 
99.0 
98.3 
102.4 
99.95 
1.24 
                     3.02 
 
101.5 
99.1 
98.3 
98.8 
99.3 
96.5 
98.6 
99.2 
99.5 
101.7 
96.5 
101.7 
99.25 
1.30 
         3.88 
Dissolution Time points 
5mins  
10mins  
15mins  
30mins  
45mins  
60mins  
 
Dissolution 
52 
83 
97 
101 
102 
101 
 
STDEV 
5 
2 
4  
5  
5  
5  
 
Dissolution  
54 
87 
97 
102 
103 
103 
 
STDEV 
2 
2 
1  
3  
2  
2  
 
 
4.9 - Comparison of fenofibrate EP/BP formulations having the same source of 
fenofibrate EP/BP and different sources of croscarmellose sodium NF/EP (batch 7 
vs. batch 9 and batch 8 vs. batch 10) 
Fenofibrate EP/BP tablets manufactured using fenofibrate EP/BP obtained from 
Company J, and croscarmellose sodium NF/EP from Company G (batch 7) were used as the 
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reference tablets for all the fenofibrate EP/BP formulations. In this section, we will examine a 
pair wise comparison of batches 7 and 9, and batches 8 and 10, in order to evaluate the impact of 
the two different sources of croscarmellose sodium NF/EP for tablets formulated with fenofibrate 
EP/BP obtained from company J and company K, respectively.  For the reference tablets (batch 
7) the granulation blend was slightly coarser as compared to the results obtained for the blend 
using croscarmellose sodium NF/EP from company G (batch 9). The compression force at which 
all CQAs was achieved was 5.3 kN using croscarmellose sodium NF/EP from company G (batch 
7) while the compression force at which all physical properties was achieved using 
croscarmellose sodium NF/EP from company H (batch 9) was higher at 7.4 kN.  Interestingly, 
the Hausner ratios of 1.37 and 1.46, and Carr indices of 37% and 46% (shown in table 4.23), 
respectively for granulation blends using croscarmellose sodium NF/EP from company G and 
company H were similar; while, the Hausner ratio and Carr Index for the two sources of 
croscarmellose sodium NF/EP samples were almost identical (see table 4.21). Even with the 
much higher compression forces used for croscarmellose sodium NF/EP from company H the 
weight, hardness, thickness, 4 minutes friability,  disintegration, flow, assay and CU results were 
comparable regardless of the source of croscarmellose sodium NF/EP, and the in – vitro 
performance was similar for both batches (7 and 9). The only exception is that the 20 minute 
friability for batch 7 (croscarmellose sodium NF/EP from company G) had broken tablets while 
batch 9 (croscarmellose sodium NF/EP from company H) did not.  
The comparison with the two different croscarmellose sodium NF/EP materials was also 
made for tablets prepared using fenofibrate EP/BP obtained from Company K (batches 8 and 10). 
The same observation made for the comparison between batches 7 and 9 can be made for the 
comparison between batches 8 and 10 with one exception, and that is the hardness is slightly 
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lower for batch 8 using croscarmellose sodium NF/EP supplied by company G (see table 4.24). 
There are two other pair wise comparisons, batches 7 and 10 and batches 8 and 9; however, the 
conclusion is the same as above.  
 
Table 4.23: Comparison of the in process test results for fenofibrate EP/BP formulations with 
fenofibrate EP/BP tablets made with fenofibrate EP/BP API from Company J and the two 
different sources of croscarmellose sodium NF/EP (batch 7 vs. batch 9), with the main difference 
of the compression force with the use of croscarmellose sodium NF/EP from Company H (batch 
9) 
 Batch 7 Batch 9 
12+20 mesh (%) 42.8 40.0 
60+80 mesh (%) 12.2 8.9 
100+200+ Fines mesh (%) 45.0 50.9 
Bulk density (g/mL) 0.59 0.52 
Tapped density (g/mL) 0.81 0.76 
Hausner Ratio 1.37 1.46 
Carr Index (%) 37 46 
Compression Force (kN) 5.3 7.4 
Hardness (kp) 6 6 
 
Table 4.24: Comparison of the in process test results fenofibrate EP/BP formulations with 
fenofibrate EP/BP tablets with fenofibrate EP/BP API from Company K and the two different 
sources of croscarmellose sodium NF/EP (batch 8 vs. batch 10), with the main difference of the 
compression force with the use of croscarmellose sodium NF/EP from Company H (batch 10) 
 Batch 8 Batch 10 
12+20 mesh (%) 45.9 39.8 
60+80 mesh (%) 10.9 8.6 
100+200+ Fines mesh (%) 43.5 51.3 
Bulk density (g/mL) 0.57 0.52 
Tapped density (g/mL) 0.81 0.76 
Hausner Ratio 1.42 1.46 
Carr Index (%) 42 46 
Compression Force (kN) 5.3 7.5 
Hardness (kp) 5  6 
 
 
  
141 
 
Chapter – 5: Summary and Future direction    
 
The materials from the current and alternate sources used for the execution of the ten 
batches of tablets manufactured in this thesis demonstrate significant differences in the 
performance of materials, depending upon the source of the materials.  These differences in 
materials supplied from alternate sources generally arise from differences in the synthetic 
procedures used to manufacture the various APIs and/or excipients, and can include different 
manufacturing processes, equipment, solvent and batch sizes, etc.  These differences in processes 
then translate into differences in the physicochemical properties for each material. 
Physicochemical properties, identified in this thesis, that appear to be sensitive to differences in 
process include particle size, particle shape, densities, residual solvents; in most instances these 
differences were observed to impact the manufacturing process and the CQAs  of the resulting 
drug product. It is clear that the evaluation of the C of A must be more in depth, and go beyond 
the alternate source material simply meeting the C of A specifications for the reference material.  
Specifically relating to the comparisons in this thesis, the two sources of metformin HCl 
each met the specifications as outlined in the C of A; however, there were substantial differences 
in the particle size and bulk density of the two materials. The differences in the metformin HCl 
material were not overcome by the direct compression process resulting in processing challenges 
and CQA failures.  
The two sources of gabapentin USP and copovidone also met specifications; however, 
measureable differences were observed in bulk density results between the two sources of 
gabapentin USP, and in particle size results between the two sources of copovidone. The 
gabapentin USP material from company X had smaller particle size but the resulting granulation 
was coarser and required much higher compression force to produce equivalent tablets when 
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compared to the alternate source from company Y. The copovidone NF/EP 35 was finer and had 
a different morphology than the copovidone NF/EP 20 and the resulting granulation was finer but 
required 36 % less compression force to produce equivalent tablets with gabapentin USP from 
company X. 
The two sources of fenofibrate EP/BP and croscarmellose sodium NF/EP again met 
specification, but measureable differences were observed in bulk density results for fenofibrate 
EP/BP and settling volume and sulphated ash results for croscarmellose sodium NF/EP. The 
fenofibrate EP/BP from company J was finer but the resulting granulation, compression process 
and drug product were almost identical. The croscarmellose sodium NF/EP from company G was 
finer and had a different morphology and required relatively less compression force to produce 
equivalent tablets. Also, there was an obvious difference in the settling volume that did not 
impact the disintegration time.  
As can be seen from the combined results in this study, the impact on the manufacturing 
unit operation varies from no impact for the fenofibrate EP/BP materials, to not meeting the 
CQAs for metformin HCl tablets with the new source of the active pharmaceutical ingredients. 
The impact of the material attributes such as particle size on the finished drug product can vary, 
depending on the drug product formulation and the manufacturing process. It is important to 
identify these differences earlier in the evaluation stage and to assess the impact, if any, on the 
manufacturing process and the drug product. The tests performed beyond the C of A for the 
various materials indicates that there were measureable  differences in the particle shape, specific 
surface area, particle size, and densities while comparable results were obtained for the other 
tests. Importantly, these differences are not captured in the current C of A, and in most cases 
could not be captured using the existing C of A methods.  
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The ultimate test of any difference in the performance the drug product will be the 
performance of the drug product in-vivo; however, this is generally quite expensive to evaluate 
and therefore a surrogate test (i.e. the in – vitro performance), was evaluated in this work. There 
was very little, if any, difference between the two sets of active pharmaceutical ingredients and 
excipients used during this study. While this is most likely to be the case with respect to in – vivo 
performance, the failure of certain tablet CQAs introduces a level of uncertainty with respect to 
product performance.  The requirement to deliver a robust drug product meeting all of the CQAs 
is as important as the in vitro performance, and is a prerequisite by the regulatory bodies to 
having a consistently performing drug product. The additional testing requirement, as discussed 
previously, will be dependent on the formulation and process, however, as a minimum test such 
as particle size, particle shape, bulk density and tapped density should be performed during the 
evaluation.  
Countries around the world, especially the developed ones, are looking at ways to reduce 
their overall health care costs. With an aging population there will be continued and even 
increasing pressure to reduce these costs; however, there needs to be a balance between the cost 
and the quality of the drug product. The need to reduce the cost of prescription medication is 
currently driven by reducing the cost of the active pharmaceutical ingredients and the excipients 
use in the formulation of the drug product. Generic companies will launch the equivalent of a 
brand product at patent expiry and will pay a premium so that they can either be the first on the 
market or to get a significant market share. As part of the lifecycle management of the product, 
additional reduction in costs will be required to remain competitive in the market place. The 
process to qualify an alternate source is a long and costly one and it is an integral part of the 
strategy to reducing the overall cost of the drug product. If the assessment on the alternate source 
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material is not comprehensive and effective with respect to the identification of any potential 
impact on the process and/or quality attribute of the drug product, then the potential cost benefits 
of making the change may be lost or worse could result in a lost market opportunity. This can be 
due to several factors such as challenges in the manufacturing process, meeting CQAs and even 
potential failures of the manufacturing process and drug product. The cost difference between 
current an alternate source is mainly driven by the use of more efficient manufacturing processes 
and different raw (starting) material likely from a different sources. “Variability of Product 
Quality and manufacturability generally arise from two sources: raw material and processes”95. 
There is inherent variability in the manufacturing process and resulting material from batch to 
batch, and the quality of the final drug product is dependent on the understanding of the 
complexity of the interactions between the variables and the manufacturing process. This 
complexity increases significantly if a source of material is changed, and either the change or the 
material itself is not fully characterized; however, it is unrealistic to run every test on the new 
source of material to look for differences. The understanding of the material and impact on the 
manufacturing process and drug product should be known before the change is proposed. As a 
result, the critical material attributes should be identified during the development of the specific 
drug product. Monographs are set up to ensure safety and efficacy of the material; but these 
monographs cannot cover the individual requirement of every manufacturing process, 
formulation and corresponding drug product. The FDA guidance on Quality by Design, ICH Q7, 
good manufacturing practise guide for Active Pharmaceutical Ingredients,  ICH Q8, 
pharmaceutical development and ICH Q11, development and manufacture of drug substance 
guidelines provide the framework under which products should now be developed, and thereby 
identifying the design space at the time of launching the product. This approach should 
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ultimately lead to drug product manufacturers defining the requirement of an alternate source 
upfront rather than looking for differences after, and trying to understand the impact, or worse, 
introduces the new source which results in a failure in the drug product. Understanding the 
impact of changes to the API and excipient, and having the ability to correlate these to potential 
issues with the manufacturing process and drug product CQAs prior to introducing an alternate 
source of material is critical. This will ensure that there is no disruption to the supply of the drug 
product and realisation of the cost benefits. This will lead to the ultimate goal of having the best 
quality product at the best possible price to the patient.   
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Table A1.1: Additional C of A testing results for metformin HCl USP API from Company A and 
Company B used to evaluate variability within each source and between the two sources of material in 
chapter 4.  
 
N/A – Criteria not included in C of A and therefore not tested  
Test Specifications Batch  1 Batch  2 Batch  3 Batch  4 Batch  1 Batch  2 Batch  3 Batch  4
Appearance White, crystalline powder Conforms Conforms Conforms Conforms Conforms Conforms Conforms Conforms 
Identification IR Spectrum:  
Corresponds to standard Conforms Conforms Conforms Conforms Conforms Conforms Conforms Conforms 
Identification Positive for Chloride Conforms Conforms Conforms Conforms Conforms Conforms Conforms Conforms 
 Loss on drying NMT 0.5 % 0.4 0.3 0.5 0.3 0.2 0.1 0.1 0.1
Sulphated Ash NMT 0.1% 0 0 0.1 0 0 0 0.1 0
Heavy Metals NMT 10 ppm LT 10 LT 10 LT 10 LT 10 LT 10 LT 10 LT 10  LT 10 
Organic Volatile 
Impurities 
Methanol:                  
NMT 1000ppm 42 55 36 61 238 311 198 357
Organic Volatile 
Impurities 
Isopropanol:              
NMT 1000ppm ND ND ND ND N/A N/A N/A N/A 
Organic Volatile 
Impurities 
Methylene Chloride:   
NMT 600ppm ND ND ND ND N/A N/A N/A N/A 
Organic Volatile 
Impurities 
Chloroform:               
NMT 60ppm ND ND ND ND N/A N/A N/A N/A 
Organic Volatile 
Impurities 
Trichloroethylene:      
NMT 80ppm ND ND ND ND N/A N/A N/A N/A 
Organic Volatile 
Impurities 
N-Butanol:                
NMT 500ppm ND ND ND ND N/A N/A N/A N/A 
Organic Volatile 
Impurities
1,4-Dioxane:             
NMT 380ppm ND ND ND ND N/A N/A N/A N/A 
Residual Solvents Trimethylamine:          
NMT 50 ppm 16 12 12 13 N/A N/A N/A N/A 
Related 
Compounds MO RC1: NMT 0.02% BRT BRT BRT BRT BRT BRT BRT BRT
Related 
Compounds  MO RC2: NMT 0.05% BRT BRT BRT BRT N/A N/A N/A N/A 
Related 
Compounds
Unidentified Impurity: 
NMT 0.10% Each (A) 
NMT 0.05 % Each (B) 0.03 BRT BRT BRT BRT BRT BRT BRT
Related 
Compounds
Total Impurity:           
NMT 0.5% Each (A)       
NMT 0.2 % Each (B) 0.03 BRT BRT BRT BRT BRT BRT BRT
Related 
Compounds
MO RC3: NMT 0.1% (A) 
EP Impurity F (MT RC 3): 
NMT 0.05 % (B) BRT BRT BRT BRT BRT BRT BRT BRT
Related 
Compounds-
Total Impurities: 
NMT0.6% 0 BRT BRT BRT N/A N/A N/A N/A 
Assay 98.5 - 101.0%          
(dried basis) 99.7 100.4 100.3 99.9 100.0 100.0 100.0 100.1
 Bulk Density  0.6 - 0.9 g/cc 0.7 0.7 0.7 0.7 N/A N/A N/A N/A 
Particle Size % through # 20 mesh: 
NLT 90 % 100 100 100 100 N/A N/A N/A N/A 
Particle Size % through # 40 mesh: 
NLT 20 % 86 85 84 85 N/A N/A N/A N/A 
Particle Size % through # 60 mesh: 
NLT 5 % 52 52 51 54 N/A N/A N/A N/A 
Company A Company B
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Table A1.2: Results of physical properties test beyond the C of A for metformin HCl USP (Company 
A and Company B) 
 Company A Company B 
Specific Surface Area 0.06 Square Meter per Gram 0.0382 Square Meter per Gram 
Surface Weighted Mean Diameter  99.981 um 157.187 um 
Volume Weighted Mean Diameter 292.294 um 248.519 um 
Particle Size laser Diffraction (um)  
D 10 
D 50 
D 90 
Minimum 
Maximum  
 
 
 
62 
243 
600 
2 
1000 
 
 
 
91 
209 
470 
10 
900 
 
Bulk Density (g/cc) 0.69 0.45 
Tapped Density (g/cc) 0.85 0.66 
 
In process test results:  
Table A1.3: In – Process Blend results for batches 1 and 2 (Company A and Company B) 
 Company A Company B 
Flow Index (mm) 5 5 
Bulk Density (g/cc) 0.66 0.55 
Tapped Density (g/cc) 0.82 0.72 
 Sieve Analysis (%) 
40 mesh  
60 mesh  
80 mesh 
100 mesh  
200 mesh 
Fines  
 
 
14.4  
28.0  
14.6  
8.6  
19.4  
14.4 
 
0.6  
4.2  
20.6  
17.4  
39.6  
16.6 
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Table A1.4: Individual CQAs results of weight, hardness, thickness, friability, disintegration and 
compression force for batch 1 (Company A) 
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Table A1.5: Individual CQAs results of weight, hardness, thickness, friability, disintegration and 
compression force for batch 2 (Company B)    
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Figure A1.1: FT-IR (Microscope) Spectroscopic characterization for metformin HCl USP (Company 
A and Company B) clearly indicating similar profile for both sources of material  
 
 
                                                                                 Temperature °C 
Figure A1.2: Differential Scanning Calorimetric Analysis for metformin HCl USP  (Company A) 
showing the initiation of the phase transition at approximately the same temperature as material from 
Company B and confirming the crystalline nature of the material with a defined melting point  
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                                                         Temperature °C 
Figure A1.3: Differential Scanning Calorimetric Analysis for metformin HCl USP (Company B) 
showing the initiation of the phase transition at approximately the same temperature as material from 
Company A and confirming the crystalline nature of the material with a defined melting point  
  
Figure A1.4: Thermo Gravimetric Analysis metformin HCl USP (Company A) clearly indicating a 
similar weight loss as material from Company B at the same temperature range  
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Figure A1.5: Thermo Gravimetric Analysis metformin HCl USP (Company B) clearly indicating a 
similar weight loss as material from Company A at the same temperature range  
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Gabapentin USP testing 
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Table A2.1: Additional C of A testing results for gabapentin USP API from Company X and Company 
Y used to evaluate variability within each source and between the two sources of material in chapter 4.  
 
N/A – Criteria not included in C of A and therefore not tested  
 
 
 
 
Test Specifications Batch 1 Batch 2 Batch 3 Batch 4 Batch 1 Batch 2 Batch 3 Batch 4
Appearance White to off-white powder Conforms Conforms Conforms Conforms Conforms Conforms Conforms Conforms 
Identification 
HPLC Retention Time: 
Corresponds to standard   Conforms Conforms Conforms Conforms Conforms Conforms Conforms Conforms 
Identification 
IR Spectrum: Corresponds to 
Standard Conforms Conforms Conforms Conforms Conforms Conforms Conforms Conforms 
Identification 
Polymorphic form III: NMT 
5.0%
Conforms Conforms Conforms Conforms 
N/A N/A N/A N/A
pH 6.8 - 7.4 (X)                     
6.5 - 8.0 (Y) 7.2 7.1 7.1 7.1 7.2 7.2 7.2 7.2
Residue on 
Ignition NMT0.1% 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Heavy Metals NMT0.002% LT0.002 LT0.002 LT0.002 LT0.002 LT0.002 LT0.002 LT0.002 LT0.002
Water 
 0.3% (X)
NMT 0.5% (Y) 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Chloride NMT 0.01% 0.00 0.00 0.00 0.01 0.00 0.01 0.01 0.01
Related Compounds GA RC2: NMT0.05% BRT BRT BRT 0.03 BRT BRT BRT BRT
Related Compounds Unidentified impurity: 
NMT0.05% each BRT BRT BRT BRT BRT BRT ND BRT
Related Compounds  
(Limit of late Eluting 
impurities)
Any impurity:
NMT0.10% each (X) 
NMT0.05% each (Y) ND ND ND ND ND ND ND ND
Total Related 
Compounds Total Impurities: NMT0.5% BRT BRT BRT 0.03 BRT BRT BRT BRT
Assay
98.5 -101.5% (Anahydrous 
basis) (X)                         
98.0 - 102.0% (Anahydrous 
basis) (Y) 99.7 99.4 99.6 99.7 100.4 99.2 100.8 99.7
Bulk density 0.4 - 0.6 g/cc (X)            
0.40 - 0.66 g/cc (Y) 0.6 0.6 0.6 0.6 0.51 0.51 0.52 0.48
Tapped density 0.6 - 1.0 g/cc 0.8 0.8 0.8 0.8 N/A N/A N/A N/A
Residual Solvents Ethanol: NMT0.2% N/A N/A N/A N/A 0 0 0 0
Residual Solvents Methanol: NMT250 ppm 35 20 33 38 N/A N/A N/A N/A
Residual Solvents Isopropanol: NMT1000 ppm 64 37 61 66 N/A N/A N/A N/A
Residual Solvents Toluene: NMT100 ppm 0 ND 0 0 N/A N/A N/A N/A
Residual Solvents Acetone: NMT100 ppm 2 1 2 2 N/A N/A N/A N/A
Partical Size Percent smaller than 250 µm: 
NLT 95% 99 99 99 100 N/A N/A N/A N/A
Partical Size Percent smaller than150µm: 
NLT 45% 82 76 86 81 N/A N/A N/A N/A
Company X Company Y
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Table A2.2: Results of physical properties test beyond the C of A for gabapentin USP (Company X 
and Company Y) 
 Company X Company Y  
Specific Surface Area 0.158 Square Meter per Gram 0.0384 Square Meter per Gram 
Surface Weighted Mean Diameter  37.879 um 156.352 um 
Volume Weighted Mean Diameter  114.124 um 254.367 um 
Particle Size laser Diffraction (um)  
D 10 
D 50 
D 90 
Minimum  
Maximum  
 
 
25 
93 
233 
1 
500 
 
 
 
93 
206 
495 
12 
900 
 
Bulk Density (g/cc) 0.6 0.51 
Tapped Density (g/cc) 0.73 0.64 
 
Table A2.3: In – Process Granulation Blend results for batch 3 (Company X (copovidone NF/EP 35)) 
and batch 4 (Company Y (copovidone NF/EP 35)) 
 Company X            
(copovidone NF/EP 
35) 
 
STDEV 
Company Y             
(copovidone NF/EP 
35) 
 
STDEV 
Flow Index (mm) 18 3.1 18 1.2 
Bulk Density (g/cc) 0.54 0.00 0.57 0.04 
Tapped Density (g/cc) 0.67 0.00 0.72 0.04 
Particle Size by Sieve (%)  
 20 mesh  
40 mesh  
60 mesh  
80 mesh 
100 mesh  
200 mesh 
Fines  
 
 
 
36.0  
23.2  
8.1  
5.4  
12.9  
6.5 
7.7 
 
 
0.15 
0.09 
0.03 
0.03 
0.05 
0.03 
0.03 
 
 
26.4  
22.4    
9.2  
5.6  
5.4  
15.8  
14.4 
 
 
2.59 
0.75 
0.45 
0.14 
0.33 
0.42 
1.91 
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Table A2.4: Individual CQAs results of weight, hardness, thickness, friability, disintegration and 
compression force for batch 3 (Company X (copovidone NF/EP 35)) 
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Table A2.5: Individual CQAs results of weight, hardness, thickness, friability, disintegration and 
compression force for batch 4 (Company Y (copovidone NF/EP 35)) 
 
  
168 
 
Figure A2.1: Differential Scanning Calorimetric Analysis for gabapentin USP (Company X) showing 
the initiation of the phase transition at the same temperature as material from Company Y and 
confirming the crystalline nature of the material with a defined melting point. 
Figure A2.2: Differential Scanning Calorimetric Analysis for gabapentin USP (Company Y) showing 
the initiation of the phase transition at the same temperature as material from Company X and 
confirming the crystalline nature of the material with a defined melting point.   
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170 
 
Table A3.1: Additional C of A testing results for copovidone NF/EP 35 and copovidone NF/EP 20 
used to evaluate variability within each source and between the two sources of material in chapter 4.  
 
 
 
 
 
 
 
 
 
 
Test Specification Batch 1 Batch 2 Batch 3 Batch 4 Batch 1 Batch 2 Batch 3 Batch 4
Appearance
white or slightly yellowish 
powder Conforms Conforms Conforms Conforms Conforms Conforms Conforms Conforms
Identification Corresponds to ID B (USP) Conforms Conforms Conforms Conforms Conforms Conforms Conforms Conforms
Identification 
IR Spectrum: Corresponds to 
Standard Conforms Conforms Conforms Conforms Conforms Conforms Conforms Conforms
Appearance of 
Solution 
Clarity: Sample solution is not 
more opalescent than reference 
suspension III                 
Colour: Sample solution is not 
more intensely coloured than 
reference solution B5, R5, OR Conforms Conforms Conforms Conforms Conforms Conforms Conforms Conforms
Aldehydes NMT 500 ppm 0 245 135 0 0 219 0 18
Ethenyl Acetate 35.3 to 41.4 % (dried basis) 38.2 37.5 38.4 38 36.8 37.3 37.8 38.4
Heavy Metals NMT 20 ppm LT 20 LT 20 LT 20 LT 20 LT 20 LT 20 LT 20 LT 20
Hydrazine 1ppm ND ND ND ND ND ND ND ND
Impurities A NMT 0.5% BRT BRT BRT BRT 0.1 0.1 0.1 0.1
Loss on drying NMT 5.0 3.2 3 2.7 2.1 2.3 2.2 1.9 2.7
Monomers NMT 0.1 % 0.1 0.1 0.1 0.1 0 0 0 0
Nitrogen  7.0-8.0 % (dried basis) 7.0 7.1 7.2 7.1 7.2 7.7 7.2 7.3
Peroxides NMT 0.35 (400 ppm) LT 400 LT 400 LT 400 LT 400 LT 400 LT400 LT 400 LT400
Sulphated Ash NMT 0.1% 0 0 0 0 0 0 0 0.1
Viscosity (As 
K-value)  25.2-30.8 (dried basis) 26.0 27.8 25.7 25.7 25.4 27.0 25.7 26.3
Particle Size D(v,0.1):NLT 18µm 34 38 35 35 59 31 32 28
Particle Size D(v,0.5):NMT 135µm 85 85 85 83 128 93 96 88
Particle Size) D(v,0.9):NMT 290µm 179 172 178 166 239 206 211 191
Copovidone NF/EP 35 Copovidone NF/EP 20
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Table A3.2: Results of physical properties test beyond the C of A for copovidone NF/EP 35 and 
copovidone NF/EP 20 
 Copovidone NF/EP 35 Copovidone NF/EP 20  
Specific Surface Area 0.124 Square Meter per Gram 0.0697 Square Meter per Gram 
Surface Weighted Mean Diameter 48.569 um 86.128 um 
Volume Weighted Mean Diameter  91.938 um 136.905 um 
Particle Size laser Diffraction (um)  
D 10 
D 50 
D 90 
Minimum  
Maximum  
 
 
  32 
 80 
167 
2 
400 
 
 
48 
125 
245  
7 
300 
 
Bulk Density g/cc 0.36 0.30 
Tapped Density g/cc 0.43 0.38 
 
Table A3.3: In – Process Granulation Blend results for batch 5 (Company X (copovidone NF/EP 20)) 
and batch 6 (Company Y (copovidone NF/EP 20)) 
 Company X            
(copovidone NF/EP 
20) 
 
STDEV 
Company Y             
(copovidone NF/EP 
20) 
 
STDEV 
Flow Index (mm) 18 2.0 18 1.2 
Bulk Density (g/cc) 0.57 0.02 0.56 0.02 
Tapped Density (g/cc) 0.72 0.02 0.71 0.02 
Particle Size by Sieve (%)  
  20 mesh  
40 mesh  
60 mesh  
80 mesh 
100 mesh  
200 mesh 
Fines  
 
 
 
20.3  
18.0  
10.2  
7.4  
6.5  
21.1 
16.2 
 
 
1.92 
0.82 
0.27 
0.32 
1.96 
2.03 
2.38 
 
 
23.9  
19.7    
10.1  
6.9  
6.7  
17.6 
14.2 
 
 
3.80 
0.71 
0.42 
0.54 
0.36 
0.92 
2.11 
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Table A3.4: Individual CQAs results of weight, hardness, thickness, friability, disintegration and 
compression force for batch 5 Company X (copovidone NF/EP 20) 
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Table A3.5: Individual CQAs results of weight, hardness, thickness, friability, disintegration and 
compression force for batch 6 Company Y (copovidone NF/EP 20) 
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Figure A3.1: Thermo gravimetric Analysis for copovidone NF/EP 20 clearly indicating a similar 
weight loss as copovidone NF/EP 35 material at the same temperature  range  
 
Figure A3.2: Thermo gravimetric Analysis for Copovidone NF/EP 35 clearly indicating a similar 
weight loss as copovidone NF/EP 20 material at the same temperature range  
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Table A4.1: Additional C of A testing results for fenofibrate EP/BP API from Company J and 
Company K used to evaluate variability within each source and between the two sources of material in 
chapter 4.  
N/A – Criteria not included in C of A and therefore not tested  
 
 
Test Specifications Batch 1 Batch 2 Batch 3 Batch 4 Batch 1 Batch 2 Batch 3
Appearance White to off white powder Conforms Conforms Conforms Conforms Conforms Conforms Conforms 
Identification UV Spectrum: Corresponds to 
Standard N/A N/A N/A N/A Conforms Conforms Conforms 
Identification IR Spectrum: Corresponds to 
Standard Conforms Conforms Conforms Conforms Conforms Conforms Conforms 
Melting Point 79-82 °C 82 82 82 82 82 82 82
Halides (Expressed 
as Chlorides) NMT 100 ppm LT 100 LT 100 LT 100 LT 100 LT 100 LT 100 LT 100
Sulphates NMT 100 ppm LT 100 LT 100 LT 100 LT 100 LT 100 LT 100 LT 100
Acidity Volume of 0.1 M NaOH 
Requiredd: NMT 0.2 mL 0.1 0.1 0.1 0.1 0.1 0 0
Loss on drying NMT 0.5% 0.1 0.3 0.4 0.4 0.4 0.1 0.2
Sulphated Ash NMT 0.1% 0.1 0.0 0.0 0.0 0.0 0.0 0.0
Heavy Metals NMT 0.002 % LT 0.002 LT 0.002 LT 0.002 LT 0.002 LT 0.002 LT 0.002 LT 0.002
Organic Volatile 
Impurities 
Isopropanol: NMT 2000ppm
342 309 334 342 1103 1061 1061
Residual Solvents Acetone: NMT 1000ppm N/A N/A N/A N/A 7 7 7
Residual Solvents Chloroform: NMT 60ppm N/A N/A N/A N/A 7 8 8
Residual Solvents Toluene: NMT 890 ppm N/A N/A N/A N/A 71 72 72
Residual Solvents Butyl Acetate: NMT 1000 ppm N/A N/A N/A N/A ND ND ND
Related Compounds FF RC1: NMT 0.1% BRT BRT BRT BRT BRT BRT BRT
Related Compounds FF RC2: NMT 0.1% ND BRT BRT BRT ND ND ND
Related Compounds EP Imp. C: NMT 0.10% N/A N/A N/A N/A ND ND ND
Related Compounds EP Imp. D: NMT 0.10% N/A N/A N/A N/A BRT BRT BRT
Related Compounds EP Imp. E: NMT 0.10% N/A N/A N/A N/A BRT BRT BRT
Related Compounds EP Imp. F: NMT 0.10% N/A N/A N/A N/A BRT BRT BRT
Related Compounds FF RC4: NMT 0.2% 0.13 0.14 0.11 0.13 BRT BRT BRT
Related Compounds FF RC5: NMT 0.10% BRT BRT BRT BRT N/A N/A N/A
Related Compounds FF RC6: NMT 0.10% ND ND ND ND N/A N/A N/A
Related Compounds FF RC7: NMT 0.10% BRT BRT BRT BRT N/A N/A N/A
Related Compounds FF RC8: NMT 0.10% BRT BRT BRT BRT N/A N/A N/A
Related Compounds Unidentified Impurity:          
NMT 0.10% each BRT BRT BRT BRT BRT BRT BRT
Related Compounds Total Impurity: NMT 0.5% 0.13 0.14 0.11 0.13 BRT BRT BRT
Assay 98.0 - 102.0 % (dried basis) (J)                   
98.5-101.0 % (dried basis) (K) 99.6 99.7 99.9 99.7 100.1 100.2 100.4
Bulk Density  0.5 - 0.7 g/cc 0.54 0.52 0.52 0.54 0.66 0.64 0.64
Appearance of 
Solution  
Solution is clear and not more 
intensely coloured than reference 
solution BY6
Conforms Conforms Conforms Conforms Conforms Conforms Conforms 
Company J Company K
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Table A4.2: Results of physical properties test beyond the C of A for fenofibrate EP/BP (Company J 
and Company K) 
 Company J  Company K 
Specific Surface Area 0.158 Square Meter per 
Gram 
0.0365 Square Meter per 
Gram 
Surface Weighted Mean Diameter  37.970 um 164.227 um 
Volume Weighted Mean Diameter  114.270 um 269.791 um 
Particle Size laser Diffraction (um) 
D 10 
D 50 
D 90 
Minimum  
Maximum  
 
 
 22 
78 
250 
0.8 
700 
 
            
97 
229 
509 
10 
900 
 
Bulk Density g/cc 0.47 0.61 
Tapped Density g/cc 0.71 0.72 
 
Table A4.3: In – Process Granulation Blend results for batch 7 (Company J (croscarmellose sodium 
NF/EP G)) and batch 8 (Company K (croscarmellose sodium NF/EP H)) 
 Company J 
(croscarmellose 
sodium NF/EP G) 
 
STDEV 
Company K 
(croscarmellose 
sodium NF/EP G) 
 
STDEV 
Flow Index (mm) 30 1.2 32 1.2 
Bulk Density (g/cc) 0.59 0.03 0.57 0.05 
Tapped Density (g/cc) 0.81 0.03 0.81 0.05 
Particle Size by Sieve (%)  
  20 mesh  
40 mesh  
60 mesh  
80 mesh 
100 mesh  
200 mesh 
Fines  
 
 
 
24.3  
18.5  
8.4  
3.8  
2.0  
9.6  
33.4 
 
 
4.74 
2.49 
0.67 
0.42 
0.35 
4.82 
2.00 
 
 
27.9  
18.0  
7.7  
3.2  
1.8  
19.0  
22.7 
 
 
8.02 
1.45 
0.40 
0.30 
0.15 
4.96 
4.00 
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Table A4.4: Individual CQAs results of weight, hardness, thickness, friability, disintegration and 
compression force for batch 7 Company J (croscarmellose sodium NF/EP G) 
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Table A4.5: Individual CQAs results of weight, hardness, thickness, friability, disintegration and 
compression force for batch 8 Company K (croscarmellose sodium NF/EP G) 
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Figure A4.1: Differential Scanning Calorimetric Analysis for fenofibrate EP/BP (Company J) showing 
the initiation of the phase transition at the same temperature as material from Company K and 
confirming the crystalline nature of the material with a clearly defined melting point. 
 
Figure A4.2: Differential Scanning Calorimetric Analysis for fenofibrate EP/BP (Company K) 
showing the initiation of the phase transition at the same temperature as material from Company J and 
confirming the crystalline nature of the material with a clearly defined melting point. 
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Appendix E 
Croscarmellose Sodium NF/EP testing 
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Table A5.1: Additional C of A testing results for croscarmellose sodium NF/EP excipient from 
Company G and Company H used to evaluate variability within each source and between the two 
sources of material in chapter 4.  
 
 N/A – Criteria not included in C of A and therefore not tested  
 
 
 
 
 
 
Test Specifications Batch 1 Batch 2 Batch 3 Batch 1 Batch 2 Batch 3 Batch 4
Apperance A white orgreyish-white Conforms Conforms Conforms Conforms Conforms Conforms Conforms 
Identification 
Reaction with Methylene 
Blue: Sample absorbs 
methylene blue Conforms Conforms Conforms Conforms Conforms Conforms Conforms 
Identification 
A reddish-violet colour 
develops at the interface Conforms Conforms Conforms Conforms Conforms Conforms Conforms 
Identification Positive to test for Sodium Conforms Conforms Conforms Conforms Conforms Conforms Conforms 
Identification 
Positive to flame test for 
sodium Conforms Conforms Conforms N/A N/A N/A N/A
 pH  5.0 - 7.0 6.7 6.7 6.7 6.7 6.6 6.6 6.3
Load on drying NMT 10.0 % 2.4 2.5 2.4 1.9 2.6 2.3 1.7
Sodium Chloride & 
Sodium Glycolate NMT 0.5 % 0.15 0.2 0.21 0.4 0.2 0.2 0.1
Heavy Metals NMT 20 ppm (G)                
NMT 10 ppm (H) LT 20 LT 20 LT 20 LT 10 LT 10 LT 10 LT 10
Degree of 
Substitution  0.6 - 0.85 (dried basis) 0.77 0.75 0.75 0.73 0.74 0.74 0.83
Water - Soluble 
material NMT 10.0 % (dried basis) 4.2 3.8 3.6 4.6 3.8 3.9 3.9
Settling Volume 10.0 - 30.0 mL 15 15 16 25 22 22 23
Sulphated Ash 
(EP)
14.0 - 28.0 % (dried basis)
16.5 16.8 16.7 19.8 19.5 19.1 21.6
Microbial Limits Total Aerobic Microbial 
Count: NMT 1000 cfu/g LT 100 LT 100 LT 100 LT 100 LT 100 LT 100 LT 100
Microbial Limits Total Yeast and Mould  
Count: NMT 100 cfu/g LT 100 LT 100 LT 100 LT 100 LT 100 LT 100 LT 100
Microbial Limits E.Coli: Absent in 1g Absent Absent Absent Absent Absent Absent Absent 
Residual on ignition 
(NF)  14.0 - 28.0 % (dried basis) 19.3 19.7 19.7 N/A N/A N/A N/A
Particle size  D(v,0.5): NMT 60µm 37 39 38 N/A N/A N/A N/A
Particle size  D(v,0.9): NMT 155µm 85 89 85 N/A N/A N/A N/A
Company G Company H 
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Table A5.2: Results of physical properties test beyond the C of A for croscarmellose sodium NF/EP 
(Company G  and Company H) 
 Croscarmellose sodium 
NF/EP G 
Croscarmellose sodium NF/EP 
H 
Specific Surface Area 0.297Square Meter per Gram 0.169 Square Meter per Gram 
Surface Weighted Mean Diameter  20.185 um 35.573 um 
Volume Weighted Mean Diameter  47.163 um 54.363 um 
Particle Size laser Diffraction (um)  
D 10 
D 50 
D 90 
Minimum  
Maximum  
 
 
15 
38 
86 
0.7 
500 
 
 
 
18 
43 
108 
10 
200 
 
Bulk Density g/cc              0.54 0.51 
Tapped Density g/cc              0.68 0.65 
 
Table A5.3: In – Process Granulation Blend results for batch 9 (Company J (croscarmellose sodium 
NF/EP H)) and batch 10 (Company K (croscarmellose sodium NF/EP H)) 
 Company J 
(croscarmellose 
sodium NF/EP H) 
 
STDEV 
Company K 
(croscarmellose 
sodium NF/EP H) 
 
STDEV 
Flow Index (mm) 32 0.0 32 1.4 
Bulk Density (g/cc) 0.52 0.03 0.52 0.05 
Tapped Density (g/cc) 0.76 0.07 0.76 0.06 
Particle Size by Sieve (%)  
  20 mesh  
40 mesh  
60 mesh  
80 mesh 
100 mesh  
200 mesh 
Fines  
 
 
 
24.9  
15.1  
6.4  
2.5  
1.3  
9.4  
40.2 
 
 
6.50 
0.81 
1.00 
0.70 
0.40 
2.63 
2.89 
 
 
25.0  
14.8  
6.0  
2.6  
1.7  
11.8  
37.8 
 
 
6.73 
0.83 
1.01 
0.44 
0.20 
17.80 
12.79  
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Table A5.4: Individual CQAs results of weight, hardness, thickness, friability, disintegration and 
compression force for batch 9 (Company J (croscarmellose sodium NF/EP H)) 
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Table A5.5 Individual CQAs results of weight, hardness, thickness, friability, disintegration and 
compression force for batch 10 (Company K (croscarmellose sodium NF/EP H)) 
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Figure A5.1: The DSC thermogram for croscarmellose sodium NF/EP (Company G) indicating 
comparable spectrum to that of croscarmellose sodium NF/EP (Company H) and confirming the 
amorphous nature of the material.  
 
Figure A5.2: The DSC thermogram for croscarmellose sodium NF/EP (Company H) indicating 
comparable spectrum to that of croscarmellose sodium NF/EP (Company G) and confirming the 
amorphous nature of the material.  
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Figure A5.3: Thermo gravimetric Analysis for croscarmellose sodium NF/EP (Company G) 
indicating a similar weight loss as material from Company H at the same temperature range   
 
 
Figure A5.4: Thermo gravimetric Analysis for croscarmellose sodium NF/EP (company H) indicating 
a similar weight loss as material from Company G at the same temperature range 
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Appendix F 
Release form from Hanson Research      
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